Science.gov

Sample records for differential generic galois

  1. Splitting fields and general differential Galois theory

    SciTech Connect

    Trushin, Dmitry V

    2010-11-11

    An algebraic technique is presented that does not use results of model theory and makes it possible to construct a general Galois theory of arbitrary nonlinear systems of partial differential equations. The algebraic technique is based on the search for prime differential ideals of special form in tensor products of differential rings. The main results demonstrating the work of the technique obtained are the theorem on the constructedness of the differential closure and the general theorem on the Galois correspondence for normal extensions. Bibliography: 14 titles.

  2. Differential Galois theory and Darboux transformations for Integrable Systems

    NASA Astrophysics Data System (ADS)

    Jiménez, Sonia; Morales-Ruiz, Juan J.; Sánchez-Cauce, Raquel; Zurro, María-Angeles

    2017-05-01

    We apply the Differential Galois Theory of linear partial differential systems to the Bäcklund-Darboux transformations of the AKNS solitonic partial differential equations. We prove that the Galois group of the transformed system is isomorphic to a subgroup of the Galois group of the initial system. As an example, we study the integrability in closed form of the linear systems corresponding to the solitonic solutions of KdV equation.

  3. A Topology for Galois Types in AECs

    NASA Astrophysics Data System (ADS)

    Lieberman, Michael

    2009-06-01

    We present a way of topologizing sets of Galois types over structures in abstract elementary classes with amalgamation. In the elementary case, the topologies thus produced refine the syntactic topologies familiar from first order logic. We exhibit a number of natural correspondences between the model-theoretic properties of classes and their constituent models and the topological properties of the associated spaces. Tameness of Galois types, in particular, emerges as a topological separation principle.

  4. Construction of Logarithm Tables for Galois Fields

    ERIC Educational Resources Information Center

    Torres-Jimenez, Jose; Rangel-Valdez, Nelson; Gonzalez-Hernandez, Ana Loreto; Avila-George, Himer

    2011-01-01

    A branch of mathematics commonly used in cryptography is Galois Fields GF(p[superscript n]). Two basic operations performed in GF(p[superscript n]) are the addition and the multiplication. While the addition is generally easy to compute, the multiplication requires a special treatment. A well-known method to compute the multiplication is based on…

  5. Construction of Logarithm Tables for Galois Fields

    ERIC Educational Resources Information Center

    Torres-Jimenez, Jose; Rangel-Valdez, Nelson; Gonzalez-Hernandez, Ana Loreto; Avila-George, Himer

    2011-01-01

    A branch of mathematics commonly used in cryptography is Galois Fields GF(p[superscript n]). Two basic operations performed in GF(p[superscript n]) are the addition and the multiplication. While the addition is generally easy to compute, the multiplication requires a special treatment. A well-known method to compute the multiplication is based on…

  6. Differentiation of generic enoxaparins marketed in the United States by employing NMR and multivariate analysis.

    PubMed

    Guerrini, Marco; Rudd, Timothy R; Mauri, Lucio; Macchi, Eleonora; Fareed, Jawed; Yates, Edwin A; Naggi, Annamaria; Torri, Giangiacomo

    2015-08-18

    The U.S. Food and Drug Administration defines criteria for the equivalence of Enoxaparin with Lovenox, comprising the equivalence of physiochemical properties, heparin source material and mode of depolymerization, disaccharide building blocks, fragment mapping and sequence of oligosaccharide species, biological and biochemical assays, and in vivo pharmacodynamic profile. Chemometric analysis of the NMR spectra, utilizing both (1)H and (1)H-(13)C HSQC NMR experiments, of Lovenox and Enoxaparin, the latter being the generic version of the former, revealed that Lovenox and the four Enoxaparin compounds produced by Sandoz (Enoxaparin and Fibrinox), Winthrop, and Amphastar exhibit dissimilarities in terms of their composition. All of the collected samples had expiry dates between 2012 and 2015. These studies, in addition to chromatographic analysis, highlighted signatures that differentiated the branded material from the generic products.

  7. Detection of Salmonella spp. using a generic and differential FRET-PCR.

    PubMed

    Zhang, Jilei; Wei, Lanjing; Kelly, Patrick; Freeman, Mark; Jaegerson, Kirsten; Gong, Jiansen; Xu, Bu; Pan, Zhiming; Xu, Chuanling; Wang, Chengming

    2013-01-01

    To facilitate the detection of Salmonella and to be able to rapidly and conveniently determine the species/subspecies present, we developed and tested a generic and differential FRET-PCR targeting their tetrathionate reductase response regulator gene. The differential pan-Salmonella FRET-PCR we developed successfully detected seven plasmids that contained partial sequences of S. bongori and the six S. enterica subspecies. The detection limit varied from ~5 copies of target gene/per PCR reaction for S. enterica enterica to ~200 for S. bongori. Melting curve analysis demonstrated a T m of ~68 °C for S. enterica enterica, ~62.5 °C for S. enterica houtenae and S. enterica diarizonae, ~57 °C for S. enterica indica, and ~54 °C for S. bongori, S. enterica salamae and S. enterica arizonae. The differential pan-Salmonella FRET-PCR also detected and determined the subspecies of 4 reference strains and 47 Salmonella isolated from clinically ill birds or pigs. Finally, we found it could directly detect and differentiate Salmonella in feline (5/50 positive; 10%; one S. enterica salamae and 4 S. enterica enterica) and canine feces (15/114 positive; 13.2%; all S. enterica enterica). The differential pan-Salmonella FRET-PCR failed to react with 96 non-Salmonella bacterial strains. Our experiments show the differential pan-Salmonella FRET-PCR we developed is a rapid, sensitive and specific method to detect and differentiate Salmonella.

  8. Comment on "Nonlinear differential algorithm to compute all the zeros of a generic polynomial" [J. Math. Phys. 57, 083508 (2016)

    NASA Astrophysics Data System (ADS)

    Calogero, Francesco

    2016-10-01

    Recently a simple differential algorithm to compute all the zeros of a generic polynomial was introduced. In this paper an analogous, but finite-difference, algorithm is introduced and discussed. At the end of the paper a minor generalization of the differential algorithm is also mentioned.

  9. Discovering Binomial Identities with PascGaloisJE

    ERIC Educational Resources Information Center

    Evans, Tyler J.

    2008-01-01

    We describe exercises in which students use PascGaloisJE to formulate conjectures about certain binomial identities which hold when the binomial coefficients are interpreted as elements in the cyclic group Z[subscript p] of integers modulo a prime integer "p". In addition to having an appealing visual component, these exercises are open-ended and…

  10. Galois-unitary operators that cycle mutually-unbiased bases

    NASA Astrophysics Data System (ADS)

    Dang, Hoan; Appleby, Marcus; Bengtsson, Ingemar

    2015-03-01

    Wigner's theorem states that probability-preserving transformations of quantum states must be either unitary or anti-unitary. However, if we restrict ourselves to a subspace of a Hilbert space, it is possible to generalize the notion of anti-unitaries. Such transformations were recently constructed in search of Symmetric Informationally-Complete (SIC) states. They are called Galois-unitaries (g-unitaries for short), as they are unitaries composed with Galois automorphisms of a chosen number field extension. Despite certain bizarre behaviors of theirs, we show that g-unitaries are indeed useful in the theory of Mutually-Unbiased Bases (MUBs), as they help solve the MUB-cycling problem and provide a construction of MUB-balanced states. HD was supported by the Natural Sciences and Engineering Research Council of Canada and the Vanier Canada Graduate Scholarship

  11. Crystallographic interpretation of Galois symmetries for magnetic pentagonal ring

    NASA Astrophysics Data System (ADS)

    Milewski, J.; Lulek, T.; Łabuz, M.

    2017-03-01

    Galois symmetry of exact Bethe Ansatz eigenstates for the magnetic pentagonal ring within the XXX model are investigated by a comparison with crystallographic constructions of space groups. It follows that the arithmetic symmetry of Bethe parameters for the interior of the Brillouin zone admits crystallographic interpretation, in terms of the periodic square Z2 ×Z2 , that is the two-dimensional crystal lattice with Born-Karman period two in both directions.

  12. Quantum systems with positions and momenta on a Galois field

    NASA Astrophysics Data System (ADS)

    Vourdas, A.

    2008-03-01

    Quantum systems with positions and momenta in the Galois field GF(pe), are considered. The Heisenberg-Weyl group of displacements and the Sp(2,GF(pe)) group of symplectic transformations, are studied. Frobenius symmetries, are a unique feature of these systems and lead to constants of motion. The engineering of such systems from l spins with j = (p - 1)/2, which are coupled in a particular way, is discussed.

  13. Phylogenetic position and generic differentiation of Epithemateae (Gesneriaceae) inferred from plastid DNA sequence data.

    PubMed

    Mayer, Veronika; Möller, Michael; Perret, Mathieu; Weber, Anton

    2003-02-01

    The systematic position and generic differentiation of the morphologically and geographically outstanding tribe Epithemateae (Gesneriaceae) was analyzed using the rbcL/atpB-spacer and trnL-F intron-spacer regions of chloroplast DNA. In our analysis Epithemateae forms a strongly supported monophyletic clade (bootstrap [BS] = 100%; jackknife [JK] = 100%; decay index [DI] = 12) and appears as sister to the rest of the paleotropical Gesneriaceae (= subfamily Cyrtandroideae). The paleotropical Gesneriaceae form a monophyletic group (BS = 88%; JK = 85%; DI = 3) that is sister to the neotropical Gesneriaceae (subfamily Gesnerioideae) plus Austral Gesneriaceae (subfamily Coronantheroideae) (BS = 99%; JK = 98%; DI = 10). Within Epithemateae Rhynchoglossum is sister to the remaining Epithemateae (BS = 97%; JK = 96%; DI = 12), in which Epithema is sister to a clade of two genera: Loxonia/Stauranthera (BS = 68%; JK = 64%; DI = 1), which form, together with Epithema, a sister clade (BS = 85%; JK = 83%; DI = 2) to Whytockia and Monophyllaea. While the support for Loxonia and Stauranthera is moderate, the relationship of Whytockia and Monophyllaea is very strongly supported (BS = 100%; JK = 100%; DI = 13). Apart from the somewhat surprising (but well-substantiated) isolated position of Rhynchoglossum, the results are in perfect accordance with the relationships worked out earlier on grounds of architectural and floral characters. Especially remarkable is the predicted coherence between the morphologically and geographically different genera Whytockia and Monophyllaea.

  14. Generic polyhedron grid generation for solving partial differential equations on spherical surfaces

    NASA Astrophysics Data System (ADS)

    Oldham, D.; Davies, J. H.; Phillips, T. N.

    2012-02-01

    A new method for generating a numerical grid on a spherical surface is presented. This method allows the grid to be based on several different regular polyhedrons (including octahedron, cube, icosahedron, and rhombic dodecahedron). The type of polyhedron on which the grid is based can be changed by altering only a few input parameters. Each polygon face can then be subdivided using a mapping technique that is described. An advantage of this new grid is that it gives increased flexibility in terms of the total number of nodes in the system. It also makes comparison between different numerical grids easier and simplifies the transfer of code/data between numerical simulators with different grids. This generic grid is then used to solve Poisson's equation on a spherical surface using a spectral element implementation for a range of actual grids. The generic grid allows us to quickly compare the actual grids and illustrates its utility.

  15. [The posthumous birth of Évariste Galois (1811-1832)].

    PubMed

    Ehrhardt, Caroline

    2010-01-01

    The publication of Galois' works in the Journal de Liouville (1846) was announced during a debate between academicians Libri and Liouville as early as 1843. Rather than limiting this publication to a study of controversy, we would like to show that it is inscribed in a larger context of the redefinition of algebra, which this debate illuminates. In order to understand the rediscovery of Galois, it must be inscribed in the median time of mathematical practices and usages.

  16. A novel, efficient CNTFET Galois design as a basic ternary-valued logic field.

    PubMed

    Keshavarzian, Peiman; Mirzaee, Mahla Mohammad

    2012-01-01

    This paper presents arithmetic operations, including addition and multiplication, in the ternary Galois field through carbon nanotube field-effect transistors (CNTFETs). Ternary logics have received considerable attention among all the multiple-valued logics. Multiple-valued logics are an alternative to common-practice binary logic, which mostly has been expanded from ternary (three-valued) logic. CNTFETs are used to improve Galois field circuit performance. In this study, a novel design technique for ternary logic gates based on CNTFETs was used to design novel, efficient Galois field circuits that will be compared with the existing resistive-load CNTFET circuit designs. In this paper, by using carbon nanotube technology and avoiding the use of resistors, we will reduce power consumption and delay, and will also achieve a better product. Simulation results using HSPICE illustrate substantial improvement in speed and power consumption.

  17. A novel, efficient CNTFET Galois design as a basic ternary-valued logic field

    PubMed Central

    Keshavarzian, Peiman; Mirzaee, Mahla Mohammad

    2012-01-01

    This paper presents arithmetic operations, including addition and multiplication, in the ternary Galois field through carbon nanotube field-effect transistors (CNTFETs). Ternary logics have received considerable attention among all the multiple-valued logics. Multiple-valued logics are an alternative to common-practice binary logic, which mostly has been expanded from ternary (three-valued) logic. CNTFETs are used to improve Galois field circuit performance. In this study, a novel design technique for ternary logic gates based on CNTFETs was used to design novel, efficient Galois field circuits that will be compared with the existing resistive-load CNTFET circuit designs. In this paper, by using carbon nanotube technology and avoiding the use of resistors, we will reduce power consumption and delay, and will also achieve a better product. Simulation results using HSPICE illustrate substantial improvement in speed and power consumption. PMID:24198492

  18. A New Adaptive Structural Signature for Symbol Recognition by Using a Galois Lattice as a Classifier.

    PubMed

    Coustaty, M; Bertet, K; Visani, M; Ogier, J

    2011-08-01

    In this paper, we propose a new approach for symbol recognition using structural signatures and a Galois lattice as a classifier. The structural signatures are based on topological graphs computed from segments which are extracted from the symbol images by using an adapted Hough transform. These structural signatures-that can be seen as dynamic paths which carry high-level information-are robust toward various transformations. They are classified by using a Galois lattice as a classifier. The performance of the proposed approach is evaluated based on the GREC'03 symbol database, and the experimental results we obtain are encouraging.

  19. Detection of generic differential RNA processing events from RNA-seq data

    PubMed Central

    Tran, Van Du T; Souiai, Oussema; Romero-Barrios, Natali; Crespi, Martin; Gautheret, Daniel

    2016-01-01

    ABSTRACT RNA-seq data analysis has revealed abundant alternative splicing in eukaryotic mRNAs. However, splicing is only one of many processing events that transcripts may undergo during their lifetime. We present here RNAprof (RNA profile analysis), a program for the detection of differential processing events from the comparison of RNA-seq experiments. RNAprof implements a specific gene-level normalization procedure and compares RNA-seq coverage profiles at nucleotide resolution to detect regions of significant coverage differences, independently of splice sites or other gene features. We used RNAprof to analyze the effect of alternative-splicing regulators NSRa and NSRb on the Arabidopsis thaliana transcriptome. A number of intron retention events and alternative transcript structures were specifically detected by RNAprof and confirmed by qRT-PCR. Further tests using a public Mus musculus RNA-seq dataset and comparisons with other RNA isoform predictors showed that RNAprof uniquely identified sets of highly significant processing events as well as other relevant library-specific differences in RNA-seq profiles. This highlights an important layer of variation that remains undetected by current protocols for RNA-seq analysis. PMID:26849165

  20. Detection of generic differential RNA processing events from RNA-seq data.

    PubMed

    Tran, Van Du T; Souiai, Oussema; Romero-Barrios, Natali; Crespi, Martin; Gautheret, Daniel

    2016-01-01

    RNA-seq data analysis has revealed abundant alternative splicing in eukaryotic mRNAs. However, splicing is only one of many processing events that transcripts may undergo during their lifetime. We present here RNAprof (RNA profile analysis), a program for the detection of differential processing events from the comparison of RNA-seq experiments. RNAprof implements a specific gene-level normalization procedure and compares RNA-seq coverage profiles at nucleotide resolution to detect regions of significant coverage differences, independently of splice sites or other gene features. We used RNAprof to analyze the effect of alternative-splicing regulators NSRa and NSRb on the Arabidopsis thaliana transcriptome. A number of intron retention events and alternative transcript structures were specifically detected by RNAprof and confirmed by qRT-PCR. Further tests using a public Mus musculus RNA-seq dataset and comparisons with other RNA isoform predictors showed that RNAprof uniquely identified sets of highly significant processing events as well as other relevant library-specific differences in RNA-seq profiles. This highlights an important layer of variation that remains undetected by current protocols for RNA-seq analysis.

  1. Generic Drugs

    MedlinePlus

    Generic Drugs: The Same Medicine for Less Money What is a generic drug? A generic is a copy of a brand-name drug. A brand- name drug has a patent. When ... benefit to your health, and you will save money. 7KH IHGHUDO )RRG DQG 'UXJ $GPLQLVWUDWLRQ )'$ UHJXODWHV ERWK ...

  2. Advertising and generic market entry.

    PubMed

    Königbauer, Ingrid

    2007-03-01

    The effect of purely persuasive advertising on generic market entry and social welfare is analysed. An incumbent has the possibility to invest in advertising which affects the prescribing physician's perceived relative qualities of the brand-name and the generic version of the drug. Advertising creates product differentiation and can induce generic market entry which is deterred without differentiation due to strong Bertrand competition. However, over-investment in advertising can deter generic market entry under certain conditions and reduces welfare as compared to accommodated market entry.

  3. Learning generics.

    PubMed

    Shulkin, D J

    1992-01-01

    The growing use of generic drug substitution may have important implications on quality of care. This study was conducted to determine resident physicians' knowledge of restrictive prescribing policies at the hospitals where they primarily practice.

  4. Quaternary Galois field adder based all-optical multivalued logic circuits.

    PubMed

    Chattopadhyay, Tanay; Taraphdar, Chinmoy; Roy, Jitendra Nath

    2009-08-01

    Galois field (GF) algebraic expressions have been found to be promising choices for reversible and quantum implementation of multivalued logic. For the first time to our knowledge, we developed GF(4) adder multivalued (four valued) logic circuits in an all-optical domain. The principle and possibilities of an all-optical GF(4) adder circuit are described. The theoretical model is presented and verified through numerical simulation. The quaternary inverter, successor, clockwise cycle, and counterclockwise cycle gates are proposed with the help of the all-optical GF(4) adder circuit. In this scheme different quaternary logical states are represented by different polarized light. A terahertz optical asymmetric demultiplexer interferometric switch plays an important role in this scheme.

  5. A novel Lie algebra of the genetic code over the Galois field of four DNA bases.

    PubMed

    Sánchez, Robersy; Grau, Ricardo; Morgado, Eberto

    2006-07-01

    Starting from the four DNA bases order in the Boolean lattice, a novel Lie Algebra of the genetic code is proposed. Here, the main partitions of the genetic code table were obtained as equivalent classes of quotient spaces of the genetic code vector space over the Galois field of the four DNA bases. The new algebraic structure shows strong connections among algebraic relationships, codon assignments and physicochemical properties of amino acids. Moreover, a distance defined between codons expresses a physicochemical meaning. It was also noticed that the distance between wild type and mutant codons tends to be small in mutational variants of four genes: human phenylalanine hydroxylase, human beta-globin, HIV-1 protease and HIV-1 reverse transcriptase. These results strongly suggest that deterministic rules in genetic code origin must be involved.

  6. Typical kernel size and number of sparse random matrices over Galois fields: a statistical physics approach.

    PubMed

    Alamino, R C; Saad, D

    2008-06-01

    Using methods of statistical physics, we study the average number and kernel size of general sparse random matrices over Galois fields GF(q) , with a given connectivity profile, in the thermodynamical limit of large matrices. We introduce a mapping of GF(q) matrices onto spin systems using the representation of the cyclic group of order q as the q th complex roots of unity. This representation facilitates the derivation of the average kernel size of random matrices using the replica approach, under the replica-symmetric ansatz, resulting in saddle point equations for general connectivity distributions. Numerical solutions are then obtained for particular cases by population dynamics. Similar techniques also allow us to obtain an expression for the exact and average numbers of random matrices for any general connectivity profile. We present numerical results for particular distributions.

  7. Conceptual Distinctions amongst Generics

    ERIC Educational Resources Information Center

    Prasada, Sandeep; Khemlani, Sangeet; Leslie, Sarah-Jane; Glucksberg, Sam

    2013-01-01

    Generic sentences (e.g., bare plural sentences such as "dogs have four legs" and "mosquitoes carry malaria") are used to talk about "kinds" of things. Three experiments investigated the conceptual foundations of generics as well as claims within the formal semantic approaches to generics concerning the roles of prevalence, cue validity and…

  8. Conceptual Distinctions amongst Generics

    ERIC Educational Resources Information Center

    Prasada, Sandeep; Khemlani, Sangeet; Leslie, Sarah-Jane; Glucksberg, Sam

    2013-01-01

    Generic sentences (e.g., bare plural sentences such as "dogs have four legs" and "mosquitoes carry malaria") are used to talk about "kinds" of things. Three experiments investigated the conceptual foundations of generics as well as claims within the formal semantic approaches to generics concerning the roles of prevalence, cue validity and…

  9. Generic antiepileptic drugs.

    PubMed

    Shaw, Susan J; Krauss, Gregory L

    2008-07-01

    Generic antiepileptic drugs (AEDs) generally provide safe, effective, lower-cost alternatives to brand-name drugs. To be approved by the US Food and Drug Administration (FDA), manufacturers must show that generic drugs are comparable to brand-name formulations, meeting bioequivalence, dissolution, and manufacturing quality standards. Bioequivalence for most generic formulations is evaluated by measuring blood pharmacokinetic values in a small, crossover study of adult volunteers taking single doses of brand-name and generic AEDs. Bioequivalence standards require that ratios of average peak drug concentrations (C(max)) and total extent of absorption (area under the curve, AUC) for a test drug be within 80% to 125% of the reference brand-name drug, with a confidence interval of 90%. Bioequivalence of most generic AEDs, however, has not been evaluated in patients with epilepsy or in other special populations such as elderly patients or patients taking multiple AEDs and prodrugs. Moreover, evidence is limited regarding the adequacy of FDA generic standards for AEDs, particularly for "narrow therapeutic ratio" medications such as oxcarbazepine, although two carbamazepine studies are supportive. Most patients can successfully initiate therapy with generic AEDs and can safely switch from brand-name to generic AEDs (and sometimes back again). The FDA, however, has not shown safety in generic-to-generic switches, which could potentially cause drug concentration changes of up to 40%. Less expensive generic formulations will soon be available for most of the "second generation" AEDs--onisamide, for example, recently had 17 generic formulations approved in the United States--providing substantial savings in health care costs. In summary, although generic AEDs are generally safe and effective for most patients, the current bioequivalence standards may not be sufficient for certain patient populations and for certain drugs, requiring vulnerable patients to be monitored very

  10. What makes a generic medication generic?

    PubMed

    Howland, Robert H

    2009-12-01

    By law, the U.S. Food and Drug Administration (FDA) can approve generic versions of brand-name drugs without requiring that research be conducted to prove them safe and effective. However, compared with a brand-name drug, a generic drug must demonstrate that it (a) contains the same active ingredients; (b) is identical in strength, dosage form, and route of administration; (c) is bioequivalent; (d) has the same clinical use indications; (e) meets the same batch requirements for identity, strength, purity, and quality; and (f) is manufactured according to the same FDA regulations. The most important aspect of generic drug development are the concepts of bioavailability and bioequivalence. According to the concept of bioequivalence, if a drug product contains an active ingredient that is chemically identical and is delivered to the site of action at the same rate and extent as another drug product, then it is considered to be clinically equivalent and can be substituted for that drug product.

  11. On decoding of Reed-Solomon codes over GF/32/ and GF/64/ using the transform techniques of Winograd. [based on cyclic convolution of Galois Field elements

    NASA Technical Reports Server (NTRS)

    Reed, I. S.; Truong, T. K.; Benjauthrit, B.

    1978-01-01

    An algorithm based on the Winograd (1976) method is developed to compute a Fourier-like transform over Galois field GF(2 exp n) for n equal to 5 and 6. It is shown that this transform algorithm requires fewer multiplications than the more conventional fast transform algorithm described by Gentleman (1968). Such a transform can be used to encode and decode Reed-Solomon codes of length (2 exp n) -1.

  12. Patients’ Perceptions Of Generic Medications

    PubMed Central

    Shrank, William H.; Cox, Emily R.; Fischer, Michael A.; Mehta, Jyotsna; Choudhry, Niteesh K.

    2009-01-01

    Insurers and policymakers encourage the use of generic drugs to reduce costs, but generics remain underused. We conducted a national survey of commercially insured adults to evaluate their perceptions about generic drugs. Patients agreed that generics are less expensive and a better value than brand-name drugs, and are just as safe. However, although 56 percent reported that Americans should use more generics, only 37.6 percent prefer to take generics. We discuss perceptions about communicating with practitioners about generics, generic substitution, and policymakers’ role in influencing generic use. These findings underscore the challenge that providers, insurers, and policymakers face in stimulating the cost-effective use of medications. PMID:19276015

  13. Generic Fortran Containers (GFC)

    SciTech Connect

    Liakh, Dmitry

    2016-09-01

    The Fortran language does not provide a standard library that implements generic containers, like linked lists, trees, dictionaries, etc. The GFC software provides an implementation of generic Fortran containers natively written in Fortran 2003/2008 language. The following containers are either already implemented or planned: Stack (done), Linked list (done), Tree (done), Dictionary (done), Queue (planned), Priority queue (planned).

  14. Generic phytosanitary irradiation treatments

    USDA-ARS?s Scientific Manuscript database

    The history of the development of generic phytosanitary irradiation (PI) treatments is discussed beginning with its initial proposal in 1986. Generic PI treatments in use today are 150 Gy for all hosts of Tephritidae, 250 Gy for all arthropods on mango and papaya shipped from Australia to New Zeala...

  15. INL Generic Robot Architecture

    SciTech Connect

    2005-03-30

    The INL Generic Robot Architecture is a generic, extensible software framework that can be applied across a variety of different robot geometries, sensor suites and low-level proprietary control application programming interfaces (e.g. mobility, aria, aware, player, etc.).

  16. Bioequivalence of generic drugs.

    PubMed

    Andrade, Chittaranjan

    2015-09-01

    Generic drugs are bioequivalent to the original brand; this is a prerequisite for marketing approval. It is theoretically possible that one generic drug may overestimate the pharmacokinetic (PK) parameters of the original and another generic may underestimate these PK parameters; in consequence, these 2 generics may not be bioequivalent between themselves. The result could be loss of efficacy or development of drug-related adverse effects if these generics are interchanged in stable patients. In a recent study involving 292 indirect comparisons of generic formulations of 9 different drugs, mathematical modeling showed that in most cases (87.0% for maximum concentration, 90.1% for area under the curve, and 80.5% for both) generic drugs are bioequivalent to each other. These reassuring findings notwithstanding, prudence dictates that, in stable patients, generic drugs should be interchanged only if there is a good reason for it. This is because bioequivalent brands of drugs may differ in their excipient content, and this can result in variations in safety profiles. © Copyright 2015 Physicians Postgraduate Press, Inc.

  17. Price regulation and relative delays in generic drug adoption.

    PubMed

    Costa-Font, Joan; McGuire, Alistair; Varol, Nebibe

    2014-12-01

    Increasing the adoption of generic drugs has the potential to improve static efficiency in a health system without harming pharmaceutical innovation. However, very little is known about the timing of generic adoption and diffusion. No prior study has empirically examined the differential launch times of generics across a comprehensive set of markets, or more specifically the delays in country specific adoption of generics relative to the first country of (generic) adoption. Drawing on data containing significant country and product variation across a lengthy time period (1999-2008), we use duration analysis to examine relative delays, across countries, in the adoption of generic drugs. Our results suggest that price regulation has a significant effect on reducing the time to launch of generics, with faster adoption in higher priced markets. The latter result is dependent on the degree of competition and the expected market size.

  18. Generic antibiotics in Japan.

    PubMed

    Fujimura, Shigeru; Watanabe, Akira

    2012-08-01

    Generic drugs have been used extensively in many developed countries, although their use in Japan has been limited. Generic drugs reduce drug expenses and thereby national medical expenditure. Because generic drugs provide advantages for both public administration and consumers, it is expected that they will be more widely used in the future. However, the diffusion rate of generic drugs in Japan is quite low compared with that of other developed countries. An investigation on generic drugs conducted by the Ministry of Health, Labour and Welfare in Japan revealed that 17.2 % of doctors and 37.2 % of patients had not used generic drugs. The major reasons for this low use rate included distrust of off-patent products and lower drug price margin compared with the brand name drug. The generic drugs available in the market include external drugs such as wet packs, antihypertensive agents, analgesics, anticancer drugs, and antibiotics. Among them, antibiotics are frequently used in cases of acute infectious diseases. When the treatment of these infections is delayed, the infection might be aggravated rapidly. The pharmacokinetics-pharmacodynamics (PK-PD) theory has been adopted in recent chemotherapy, and in many cases, the most appropriate dosage and administration of antibiotics are determined for individual patients considering renal function; high-dosage antibiotics are used preferably for a short duration. Therefore, a highly detailed antimicrobial agent is necessary. However, some of the generic antibiotics have less antibacterial potency or solubility than the brand name products. We showed that the potency of the generic products of vancomycin and teicoplanin is lower than that of the branded drugs by 14.6 % and 17.3 %, respectively. Furthermore, we confirmed that a generic meropenem drug for injection required about 82 s to solubilize in saline, whereas the brand product required only about 21 s. It was thought that the cause may be the difference in size of bulk

  19. Product, generic, and random generic quantum satisfiability

    SciTech Connect

    Laumann, C. R.; Sondhi, S. L.; Laeuchli, A. M.; Moessner, R.; Scardicchio, A.

    2010-06-15

    We report a cluster of results on k-QSAT, the problem of quantum satisfiability for k-qubit projectors which generalizes classical satisfiability with k-bit clauses to the quantum setting. First we define the NP-complete problem of product satisfiability and give a geometrical criterion for deciding when a QSAT interaction graph is product satisfiable with positive probability. We show that the same criterion suffices to establish quantum satisfiability for all projectors. Second, we apply these results to the random graph ensemble with generic projectors and obtain improved lower bounds on the location of the SAT-unSAT transition. Third, we present numerical results on random, generic satisfiability which provide estimates for the location of the transition for k=3 and k=4 and mild evidence for the existence of a phase which is satisfiable by entangled states alone.

  20. Generic POCC architectures

    NASA Technical Reports Server (NTRS)

    1989-01-01

    This document describes a generic POCC (Payload Operations Control Center) architecture based upon current POCC software practice, and several refinements to the architecture based upon object-oriented design principles and expected developments in teleoperations. The current-technology generic architecture is an abstraction based upon close analysis of the ERBS, COBE, and GRO POCC's. A series of three refinements is presented: these may be viewed as an approach to a phased transition to the recommended architecture. The third refinement constitutes the recommended architecture, which, together with associated rationales, will form the basis of the rapid synthesis environment to be developed in the remainder of this task. The document is organized into two parts. The first part describes the current generic architecture using several graphical as well as tabular representations or 'views.' The second part presents an analysis of the generic architecture in terms of object-oriented principles. On the basis of this discussion, refinements to the generic architecture are presented, again using a combination of graphical and tabular representations.

  1. Generic Airspace Survey

    NASA Technical Reports Server (NTRS)

    Mogford, Richard H.; Bridges, Wayne; Gujarl, Vimmy; Lee, Paul U.; Preston, William

    2013-01-01

    This paper reports on an extension of generic airspace research to explore the amount of memorization and specialized skills required to manage sectors with specific characteristics or factors. Fifty-five retired controllers were given an electronic survey where they rated the amount of memorization or specialized skills needed for sixteen generic airspace factors. The results suggested similarities in the pattern of ratings between different areas of the US (East, Central, and West). The average of the ratings for each area also showed some differences between regions, with ratings being generally higher in the East area. All sixteen factors were rated as moderately to highly important and may be useful for future research on generic airspace, air traffic controller workload, etc.

  2. Generic robot architecture

    DOEpatents

    Bruemmer, David J [Idaho Falls, ID; Few, Douglas A [Idaho Falls, ID

    2010-09-21

    The present invention provides methods, computer readable media, and apparatuses for a generic robot architecture providing a framework that is easily portable to a variety of robot platforms and is configured to provide hardware abstractions, abstractions for generic robot attributes, environment abstractions, and robot behaviors. The generic robot architecture includes a hardware abstraction level and a robot abstraction level. The hardware abstraction level is configured for developing hardware abstractions that define, monitor, and control hardware modules available on a robot platform. The robot abstraction level is configured for defining robot attributes and provides a software framework for building robot behaviors from the robot attributes. Each of the robot attributes includes hardware information from at least one hardware abstraction. In addition, each robot attribute is configured to substantially isolate the robot behaviors from the at least one hardware abstraction.

  3. Generic Kalman Filter Software

    NASA Technical Reports Server (NTRS)

    Lisano, Michael E., II; Crues, Edwin Z.

    2005-01-01

    The Generic Kalman Filter (GKF) software provides a standard basis for the development of application-specific Kalman-filter programs. Historically, Kalman filters have been implemented by customized programs that must be written, coded, and debugged anew for each unique application, then tested and tuned with simulated or actual measurement data. Total development times for typical Kalman-filter application programs have ranged from months to weeks. The GKF software can simplify the development process and reduce the development time by eliminating the need to re-create the fundamental implementation of the Kalman filter for each new application. The GKF software is written in the ANSI C programming language. It contains a generic Kalman-filter-development directory that, in turn, contains a code for a generic Kalman filter function; more specifically, it contains a generically designed and generically coded implementation of linear, linearized, and extended Kalman filtering algorithms, including algorithms for state- and covariance-update and -propagation functions. The mathematical theory that underlies the algorithms is well known and has been reported extensively in the open technical literature. Also contained in the directory are a header file that defines generic Kalman-filter data structures and prototype functions and template versions of application-specific subfunction and calling navigation/estimation routine code and headers. Once the user has provided a calling routine and the required application-specific subfunctions, the application-specific Kalman-filter software can be compiled and executed immediately. During execution, the generic Kalman-filter function is called from a higher-level navigation or estimation routine that preprocesses measurement data and post-processes output data. The generic Kalman-filter function uses the aforementioned data structures and five implementation- specific subfunctions, which have been developed by the user on

  4. Generic Sentences in English and French.

    ERIC Educational Resources Information Center

    Herschensohn, Julia

    Previous accounts of "generic" have been either too broad in including several sentence types as generic, or too narrow in limiting the definition of generic to the noun or verb alone. This research critically examines data and previous treatments of the generic verb, generic noun, and generic sentence. Because every generic sentence may…

  5. Generic Survey Procedures.

    ERIC Educational Resources Information Center

    Matross, Ron; Roesler, Jon

    Hints on conducting surveys appropriate for university use are outlined, and sample checklists and forms are provided. The following research elements concerning generic surveys are covered: sequences of events for surveys conducted by mail (15 weeks) and telephone (11 weeks); algorithms for estimating materials costs and quantities; a catalog of…

  6. Generic phytosanitary irradiation treatments

    NASA Astrophysics Data System (ADS)

    Hallman, Guy J.

    2012-07-01

    The history of the development of generic phytosanitary irradiation (PI) treatments is discussed beginning with its initial proposal in 1986. Generic PI treatments in use today are 150 Gy for all hosts of Tephritidae, 250 Gy for all arthropods on mango and papaya shipped from Australia to New Zealand, 300 Gy for all arthropods on mango shipped from Australia to Malaysia, 350 Gy for all arthropods on lychee shipped from Australia to New Zealand and 400 Gy for all hosts of insects other than pupae and adult Lepidoptera shipped to the United States. Efforts to develop additional generic PI treatments and reduce the dose for the 400 Gy treatment are ongoing with a broad based 5-year, 12-nation cooperative research project coordinated by the joint Food and Agricultural Organization/International Atomic Energy Agency Program on Nuclear Techniques in Food and Agriculture. Key groups identified for further development of generic PI treatments are Lepidoptera (eggs and larvae), mealybugs and scale insects. A dose of 250 Gy may suffice for these three groups plus others, such as thrips, weevils and whiteflies.

  7. A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases.

    PubMed

    Gallop, Katy; Kerr, Cicely; Simmons, Stacey; McIver, Bryan; Cohen, Ezra E W

    2015-02-01

    This study explored the impact of differentiated thyroid cancer (DTC) on health-related quality of life (HRQL) at different treatment phases and evaluated the validity of published DTC utilities and generic health utility measures (EQ-5D and SF-6D) for economic evaluation of treatments for radio-iodine (RAI) refractory DTC. Focus groups and interviews were conducted with DTC patients grouped by treatment phase. Qualitative thematic analysis was conducted on interview/focus group transcripts. A thematic coding framework was developed to compare experiences between treatment phases and inform development of a conceptual model. Model concepts were mapped to EQ-5D and SF-6D domains/items. Eight focus groups and 11 individual interviews were conducted with 52 DTC patients. Fifty symptoms and HRQL concepts were identified. The impact of DTC and DTC treatment on emotional and cognitive functioning was reported across the treatment phases. The impact on daily activities, mobility, and energy levels was greatest for patients with recurring/persistent or RAI-refractory DTC. Of the 50 concepts, 25 and 27 mapped directly onto domains/items in the EQ-5D and SF-6D, respectively. The SF-6D covered a broader range of DTC impact on emotional/physical problems and daily/social activities than did the EQ-5D. The conceptual model summarizes the wide-ranging impact of DTC and its treatment on patients' HRQL, particularly for those with recurring/persistent or RAI-refractory DTC. Findings suggest that published DTC utilities lack validity for RAI-refractory DTC and that the SF-6D may be more sensitive to HRQL impact of DTC than the EQ-5D.

  8. What use is generic prescribing?

    PubMed Central

    Archer, Michael

    1985-01-01

    The dispensing of generic preparations at four dispensing chemist shops was investigated by means of a questionnaire. Certain generic prescriptions result in the dispensing of proprietary products despite the existence of generic preparations, and the pharmacist may be reimbursed for the cost of the proprietary drug which has been dispensed. Not all generic prescriptions result in the dispensing of cheaper drugs because of the methods of payment to chemists. If doctors write more generic prescriptions there will ultimately be more dispensing of generic products. Even in the case of drugs still under patent, prescribing by generic name should be encouraged. The savings achieved by generic prescribing are to some extent at the cost of the dispensing chemists. The method and scale of payments for dispensing requires urgent review. PMID:4032358

  9. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).

    PubMed

    Rahman, Md Motiur; Alatawi, Yasser; Cheng, Ning; Qian, Jingjing; Peissig, Peggy L; Berg, Richard L; Page, David C; Hansen, Richard A

    2017-09-20

    The US Food and Drug Administration Adverse Event Reporting System (FAERS), a post-marketing safety database, can be used to differentiate brand versus generic safety signals. To explore the methods for identifying and analyzing brand versus generic adverse event (AE) reports. Public release FAERS data from January 2004 to March 2015 were analyzed using alendronate and carbamazepine as examples. Reports were classified as brand, generic, and authorized generic (AG). Disproportionality analyses compared reporting odds ratios (RORs) of selected known labeled serious adverse events stratifying by brand, generic, and AG. The homogeneity of these RORs was compared using the Breslow-Day test. The AG versus generic was the primary focus since the AG is identical to brand but marketed as a generic, therefore minimizing generic perception bias. Sensitivity analyses explored how methodological approach influenced results. Based on 17,521 US event reports involving alendronate and 3733 US event reports involving carbamazepine (immediate and extended release), no consistently significant differences were observed across RORs for the AGs versus generics. Similar results were obtained when comparing reporting patterns over all time and just after generic entry. The most restrictive approach for classifying AE reports yielded smaller report counts but similar results. Differentiation of FAERS reports as brand versus generic requires careful attention to risk of product misclassification, but the relative stability of findings across varying assumptions supports the utility of these approaches for potential signal detection.

  10. Generic safety documentation model

    SciTech Connect

    Mahn, J.A.

    1994-04-01

    This document is intended to be a resource for preparers of safety documentation for Sandia National Laboratories, New Mexico facilities. It provides standardized discussions of some topics that are generic to most, if not all, Sandia/NM facilities safety documents. The material provides a ``core`` upon which to develop facility-specific safety documentation. The use of the information in this document will reduce the cost of safety document preparation and improve consistency of information.

  11. Generic Distributed Simulation Architecture

    SciTech Connect

    Booker, C.P.

    1999-05-14

    A Generic Distributed Simulation Architecture is described that allows a simulation to be automatically distributed over a heterogeneous network of computers and executed with very little human direction. A prototype Framework is presented that implements the elements of the Architecture and demonstrates the feasibility of the concepts. It provides a basis for a future, improved Framework that will support legacy models. Because the Framework is implemented in Java, it may be installed on almost any modern computer system.

  12. Generics: keep a balanced view.

    PubMed

    2014-02-01

    Once the different kinds of commercial protection (patents, etc.) granted to the manufacturer of an "originator" drug have expired, the drug in question may be copied by other companies. These copies are known as generics. The characteristics and pharmaceutical quality of generics are governed by international standards. The marketing authorisation procedure for generic drugs dispenses with preclinical and clinical trials, which already exist for the originator drug. In contrast, proof of bioequivalence must be provided. In practice, this means demonstrating that the effects of the generic are similar (but not necessarily identical) to those of the originator drug. Slight differences between a generic and its brand-name counterpart are allowed, provided they do not markedly affect the efficacy or adverse effect profile in comparison to the originator drug. The accepted degree of difference between a generic and the original brand-name drug is the same as the acceptable difference between two batches of the originator drug. The rules governing generic manufacturing conditions are identical to those applying to originator drugs. And issues raised by drug production abroad, particularly to Asian countries, apply to originator just as much as to generic drugs. Generics represent a significant source of financial savings for society. In France, various measures have been introduced to encourage doctors, pharmacists and patients, respectively, to prescribe, dispense and use generics. Criticisms of the efficacy or quality of generics are often unfounded and sometimes deliberately orchestrated. Smear campaigns conducted by drug companies that market originator drugs, and also by some healthcare professionals, sow confusion, to the detriment of generic use. There is no tangible proof that generics are less safe than originator drugs, provided they are chosen wisely, taking into account factors such as their packaging quality. It is up to healthcare professionals to decide

  13. Are biosimilars really generics?

    PubMed

    Misra, Anoop

    2010-04-01

    Ever since the formation of the first biotechnology company almost three decades ago, more than 150 biopharmaceutical products have been marketed across the globe. The oldest of these biotechnology-derived products are now at the end of their patent lives, as a result of which, the development of 'biosimilars' is increasing. The review highlights aspects in which biosimilars differ from generic drugs. The active substance of a biosimilar medicine is similar to the one of the biological reference medicine; however, biosimilars differ from generics of pharmacological drugs in aspects like size and complexity of the active substance, and the nature of the manufacturing process. The manufacture of a biopharmaceutical product is complex and involves several isolation and purification steps. These procedures are proprietary to the manufacturer of the originator product and hence even minor changes in production can have serious implications in terms of safety and efficacy of the product. Biosimilars should not be brought to market using the same procedure applied to generics, and existing and future regulation should prevent inappropriate and automatic substitution of a biosimilar for a reference biopharmaceutical product.

  14. Generic medicines: solutions for a sustainable drug market?

    PubMed

    Dylst, Pieter; Vulto, Arnold; Godman, Brian; Simoens, Steven

    2013-10-01

    Generic medicines offer equally high-quality treatment as originator medicines do at much lower prices. As such, they represent a considerable opportunity for authorities to obtain substantial savings. At the moment, the pharmaceutical landscape is changing and many pharmaceutical companies have altered their development and commercial strategies, combining both originator and generic divisions. In spite of this, the generic medicines industry is currently facing a number of challenges: delayed market access; the limited price differential with originator medicines; the continuous downwards pressure on prices; and the negative perception regarding generic medicines held by some key stakeholder groups. This could jeopardize the long-term sustainability of the generic manufacturing industry. Therefore, governments must focus on demand-side policies, alongside policies to accelerate market access, as the generic medicines industry will only be able to deliver competitive and sustainable prices if they are ensured a high volume. In the future, the generic medicines industry will increasingly look to biosimilars and generic versions of orphan drugs to expand their business.

  15. Physician perceptions about generic drugs.

    PubMed

    Shrank, William H; Liberman, Joshua N; Fischer, Michael A; Girdish, Charmaine; Brennan, Troyen A; Choudhry, Niteesh K

    2011-01-01

    With constrained health-care resources, there is a need to understand barriers to cost-effective medication use. To study physician perceptions about generic medications. Physicians used 5-point Likert scales to report perceptions about cost-related medication nonadherence, the efficacy and quality of generic medications, preferences for generic use, and the implications of dispensing medication samples. Descriptive statistics were used to assess physician perceptions and logistic regression models were used to evaluate predictors of physician perceptions. Among the invited sample, 839 (30.4%) responded and 506 (18.3%) were eligible and included in the final study population. Over 23% of physicians surveyed expressed negative perceptions about efficacy of generic drugs, almost 50% reported negative perceptions about quality of generic medications, and more than one quarter do not prefer to use generics as first-line medications for themselves or for their family. Physicians over the age of 55 years were 3.3 times more likely to report negative perceptions about generic quality, 5.8 times more likely to report that they would not use generics themselves, and 7.5 times more likely to state that they would not recommend generics for family members (p < 0.05 for all). Physicians reported that pharmaceutical company representatives are the most common (75%) source of information about market entry of a generic medication. Almost half of the respondents expressed concern that free samples may adversely affect subsequent affordability, yet two thirds of respondents provide free samples. A meaningful proportion of physicians expressed negative perceptions about generic medications, representing a potential barrier to generic use. Payors and policymakers trying to encourage generic use may consider educational campaigns targeting older physicians.

  16. Generic medications in ophthalmology.

    PubMed

    Zore, Matt; Harris, Alon; Tobe, Leslie Abrams; Siesky, Brent; Januleviciene, Ingrida; Behzadi, Jennifer; Amireskandari, Annahita; Egan, Patrick; Garff, Kevin; Wirostko, Barbara

    2013-03-01

    The purpose of this review is to discuss the process of genericisation of medications in the US and Europe with a focus on ophthalmic drugs. Regulatory guidelines of the US Food and Drug Administration and the European Medicines Agency will be discussed, and the advantages and concerns of genericisation will be explored. We will look at various studies concerning the safety and efficacy of generic drugs compared to their branded counterparts. In particular, the challenges of assuring bioequivalence and therapeutic equivalence in topical ophthalmic drugs will be examined.

  17. Side effects of generic competition?

    PubMed

    Hellström, Jörgen; Rudholm, Niklas

    2004-10-01

    This study examined the relationship between generic drug market shares and the number of reported side effects. Yearly time-series data for the number of reported side effects and information on market shares, prices, and quantities from 1972 to 1996 were used in this study. Poisson and negative binomial regression models were used in the statistical analysis. The results show that increased generic market share increases the number of reported side effects for all estimated models. When studying the relationship at the substance level, increasing generic market shares increases the number of side effects for 7 of the 15 substances. Generic substitution laws and measures to increase generic competition may thus have unintended consequences since these results show a positive relationship between generic market shares and reported side effects.

  18. Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.

    PubMed

    Hansen, Richard A; Qian, Jingjing; Berg, Richard; Linneman, James; Seoane-Vazquez, Enrique; Dutcher, Sarah K; Raofi, Saeid; Page, C David; Peissig, Peggy

    2017-04-01

    Generic drugs contain identical active ingredients as their corresponding brand drugs and are pharmaceutically equivalent and bioequivalent, whereas authorized generic drugs (AGs) contain both identical active and inactive ingredients as their corresponding brand drugs but are marketed as generics. This study compares generic-to-brand switchback rates between generic and AGs. Retrospective cohort study. Claims and electronic health record data from a regional U.S. health care system. The full cohort consisted of 5542 unique patients who received select branded drugs during the 6 months prior to their generic drug market availability (between 1999 and 2014) and then were switched to an AG or generic drug within 30 months of generic drug entry. For these patients, 5929 unique patient-drug combinations (867 with AGs and 5062 with generic drugs) were evaluated. Ten drugs with AGs and generics marketed between 1999 and 2014 were evaluated. The date of the first generic prescription was considered the index date for each drug, and it marked the beginning of follow-up to evaluate the occurrence of generic-to-brand switchback patterns over the subsequent 30 months. Switchback rates were compared between patients receiving AGs versus those receiving generics using multivariable Cox proportional hazards models, controlling for individual drug effects, age, sex, Charlson Comorbidity Score, pre-index drug use characteristics, and pre-index health care utilization. Among the 5542 unique patients who switched from brand to generic or brand to AG, 264 (4.8%) switched back to the brand drug. Overall switchback rates were similar for AGs compared with generics (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.65-1.15). The likelihood of switchback was higher for alendronate (HR 1.64, 95% CI 1.20-2.23) and simvastatin (HR 1.81, 95% CI 1.30-2.54) and lower for amlodipine (HR 0.27, 95% CI 0.17-0.42) compared with the other drugs evaluated. Overall switchback rates were similar

  19. Galois' Remarkable Subgroups

    ERIC Educational Resources Information Center

    Lunsford, Matt D.

    2011-01-01

    Mathematics is a creative process, and unfortunately, that process is often hidden from students of the discipline. This is certainly the case in the area of mathematics commonly referred to as abstract algebra. Current pedagogy conceals from the student many of the great ideas generated by significant problems in the history of the discipline. In…

  20. Galois' Remarkable Subgroups

    ERIC Educational Resources Information Center

    Lunsford, Matt D.

    2011-01-01

    Mathematics is a creative process, and unfortunately, that process is often hidden from students of the discipline. This is certainly the case in the area of mathematics commonly referred to as abstract algebra. Current pedagogy conceals from the student many of the great ideas generated by significant problems in the history of the discipline. In…

  1. A generic multibody simulation

    NASA Technical Reports Server (NTRS)

    Hopping, K. A.; Kohn, W.

    1986-01-01

    Described is a dynamic simulation package which can be configured for orbital test scenarios involving multiple bodies. The rotational and translational state integration methods are selectable for each individual body and may be changed during a run if necessary. Characteristics of the bodies are determined by assigning components consisting of mass properties, forces, and moments, which are the outputs of user-defined environmental models. Generic model implementation is facilitated by a transformation processor which performs coordinate frame inversions. Transformations are defined in the initialization file as part of the simulation configuration. The simulation package includes an initialization processor, which consists of a command line preprocessor, a general purpose grammar, and a syntax scanner. These permit specifications of the bodies, their interrelationships, and their initial states in a format that is not dependent on a particular test scenario.

  2. Generic criticality safety issues

    SciTech Connect

    Hively, L.M.

    1991-01-01

    An independent group has been designated by Martin Marietta Energy Systems, Inc., (MMES) to internally review Safety Analysis Reports for Packaging (SARPs) that describe containers for shipment of radioactive material. This group is called the Energy Systems Independent Review Group (ESIRG), reporting to the MMES Transportation Safety Manager as part of a central staff function. The ESIRG focus is Y-12 Plant packages, with additional review responsibilities for the Paducah Tiger UF{sub 6} overpack and 6M package. Review questions are posed directly to the SARP preparers. This paper addresses three generic issues that arose during the ESIRG criticality reviews: analysis tools, uncertainties in results, and resulting (finite) probability of criticality. 6 refs., 1 tab.

  3. Generic torus canards

    NASA Astrophysics Data System (ADS)

    Vo, Theodore

    2017-10-01

    Torus canards are special solutions of fast/slow systems that alternate between attracting and repelling manifolds of limit cycles of the fast subsystem. A relatively new dynamic phenomenon, torus canards have been found in neural applications to mediate the transition from tonic spiking to bursting via amplitude-modulated spiking. In R3, torus canards are degenerate: they require one-parameter families of 2-fast/1-slow systems in order to be observed and even then, they only occur on exponentially thin parameter intervals. The addition of a second slow variable unfolds the torus canard phenomenon, making it generic and robust. That is, torus canards in fast/slow systems with (at least) two slow variables occur on open parameter sets. So far, generic torus canards have only been studied numerically, and their behaviour has been inferred based on averaging and canard theory. This approach, however, has not been rigorously justified since the averaging method breaks down near a fold of periodics, which is exactly where torus canards originate. In this work, we combine techniques from Floquet theory, averaging theory, and geometric singular perturbation theory to show that the average of a torus canard is a folded singularity canard. In so doing, we devise an analytic scheme for the identification and topological classification of torus canards in fast/slow systems with two fast variables and k slow variables, for any positive integer k. We demonstrate the predictive power of our results in a model for intracellular calcium dynamics, where we explain the mechanisms underlying a novel class of elliptic bursting rhythms, called amplitude-modulated bursting, by constructing the torus canard analogues of mixed-mode oscillations. We also make explicit the connection between our results here with prior studies of torus canards and torus canard explosion in R3, and discuss how our methods can be extended to fast/slow systems of arbitrary (finite) dimension.

  4. Generic concepts in Nectriaceae

    PubMed Central

    Lombard, L.; van der Merwe, N.A.; Groenewald, J.Z.; Crous, P.W.

    2015-01-01

    The ascomycete family Nectriaceae (Hypocreales) includes numerous important plant and human pathogens, as well as several species used extensively in industrial and commercial applications as biodegraders and biocontrol agents. Members of the family are unified by phenotypic characters such as uniloculate ascomata that are yellow, orange-red to purple, and with phialidic asexual morphs. The generic concepts in Nectriaceae are poorly defined, since DNA sequence data have not been available for many of these genera. To address this issue we performed a multi-gene phylogenetic analysis using partial sequences for the 28S large subunit (LSU) nrDNA, the internal transcribed spacer region and intervening 5.8S nrRNA gene (ITS), the large subunit of the ATP citrate lyase (acl1), the RNA polymerase II largest subunit (rpb1), RNA polymerase II second largest subunit (rpb2), α-actin (act), β-tubulin (tub2), calmodulin (cmdA), histone H3 (his3), and translation elongation factor 1-alpha (tef1) gene regions for available type and authentic strains representing known genera in Nectriaceae, including several genera for which no sequence data were previously available. Supported by morphological observations, the data resolved 47 genera in the Nectriaceae. We re-evaluated the status of several genera, which resulted in the introduction of six new genera to accommodate species that were initially classified based solely on morphological characters. Several generic names are proposed for synonymy based on the abolishment of dual nomenclature. Additionally, a new family is introduced for two genera that were previously accommodated in the Nectriaceae. PMID:26955195

  5. A Generic Metadata Query Tool.

    ERIC Educational Resources Information Center

    Verhoeven, B.; Duval, E.; Olivie, H.

    This paper discusses a generic query tool that enables an end user to query a metadata store through filters that impose search criteria on attributes. The Metadata Query Tool (MQT) is generic in the sense that it dynamically creates its user interface, based on configuration files that define the metadata scheme and the query functionalities.…

  6. Encouraging generic use can yield significant savings.

    PubMed

    Zimmerman, Christina

    2012-11-01

    Key findings. (1) Zero copayment for generic drugs is the greatest influencer of generic statin utilization. (2) Both higher copayments for generic drugs and lower copayments for competing brands are associated with a decreased probability of using generic statins. (3) Prior authorization and step therapy requirements for brand-name statins are associated with an increased use of generic drugs. (4) Greater use of generic statins should reduce costs for patients, plans, and Medicare.

  7. Dimensional Regularization is Generic

    NASA Astrophysics Data System (ADS)

    Fujikawa, Kazuo

    The absence of the quadratic divergence in the Higgs sector of the Standard Model in the dimensional regularization is usually regarded to be an exceptional property of a specific regularization. To understand what is going on in the dimensional regularization, we illustrate how to reproduce the results of the dimensional regularization for the λϕ4 theory in the more conventional regularization such as the higher derivative regularization; the basic postulate involved is that the quadratically divergent induced mass, which is independent of the scale change of the physical mass, is kinematical and unphysical. This is consistent with the derivation of the Callan-Symanzik equation, which is a comparison of two theories with slightly different masses, for the λϕ4 theory without encountering the quadratic divergence. In this sense the dimensional regularization may be said to be generic in a bottom-up approach starting with a successful low energy theory. We also define a modified version of the mass independent renormalization for a scalar field which leads to the homogeneous renormalization group equation. Implications of the present analysis on the Standard Model at high energies and the presence or absence of SUSY at LHC energies are briey discussed.

  8. New generic indexing technology

    NASA Technical Reports Server (NTRS)

    Freeston, Michael

    1996-01-01

    There has been no fundamental change in the dynamic indexing methods supporting database systems since the invention of the B-tree twenty-five years ago. And yet the whole classical approach to dynamic database indexing has long since become inappropriate and increasingly inadequate. We are moving rapidly from the conventional one-dimensional world of fixed-structure text and numbers to a multi-dimensional world of variable structures, objects and images, in space and time. But, even before leaving the confines of conventional database indexing, the situation is highly unsatisfactory. In fact, our research has led us to question the basic assumptions of conventional database indexing. We have spent the past ten years studying the properties of multi-dimensional indexing methods, and in this paper we draw the strands of a number of developments together - some quite old, some very new, to show how we now have the basis for a new generic indexing technology for the next generation of database systems.

  9. Generic flux coupling analysis.

    PubMed

    Reimers, Arne C; Goldstein, Yaron; Bockmayr, Alexander

    2015-04-01

    Flux coupling analysis (FCA) has become a useful tool for aiding metabolic reconstructions and guiding genetic manipulations. Originally, it was introduced for constraint-based models of metabolic networks that are based on the steady-state assumption. Recently, we have shown that the steady-state assumption can be replaced by a weaker lattice-theoretic property related to the supports of metabolic fluxes. In this paper, we further extend our approach and develop an efficient algorithm for generic flux coupling analysis that works with any kind of qualitative pathway model. We illustrate our method by thermodynamic flux coupling analysis (tFCA), which allows studying steady-state metabolic models with loop-law thermodynamic constraints. These models do not satisfy the lattice-theoretic properties required in our previous work. For a selection of genome-scale metabolic network reconstructions, we discuss both theoretically and practically, how thermodynamic constraints strengthen the coupling results that can be obtained with classical FCA. A prototype implementation of tFCA is available at http://hoverboard.io/L4FC. Copyright © 2015 Elsevier Inc. All rights reserved.

  10. Generic Substitution Issues: Brand-generic Substitution, Generic-generic Substitution, and Generic Substitution of Narrow Therapeutic Index (NTI)/Critical Dose Drugs

    PubMed Central

    PAVELIU, Marian Sorin; BENGEA, Simona; PAVELIU, Fraga Silvia

    2011-01-01

    ABSTRACT Doctors accuse individual variability or lack of quality of generic drugs for adverse reactions or lack of efficacy. The variability of effect of generic substitution, although accepted by clinicians as possible, is little discussed or even understood by them. The situation is really serious in the case of generic substitution of drugs with narrow therapeutic index (NTI) or critical dose. In this paper we review the basic notions of variability and effectiveness of generic medication and change of attitude that would improve the use of these drugs. PMID:21977191

  11. Generic interpreters and microprocessor verification

    NASA Technical Reports Server (NTRS)

    Windley, Phillip J.

    1990-01-01

    The following topics are covered in viewgraph form: (1) generic interpreters; (2) Viper microprocessors; (3) microprocessor verification; (4) determining correctness; (5) hierarchical decomposition; (6) interpreter theory; (7) AVM-1; (8) phase-level specification; and future work.

  12. The Generic Data Capture Facility

    NASA Astrophysics Data System (ADS)

    Connell, Edward B.; Barnes, William P.; Stallings, William H.

    The Generic Data Capture Facility, which can provide data capture support for a variety of different types of spacecraft while enabling operations costs to be carefully controlled, is discussed. The data capture functions, data protection, isolation of users from data acquisition problems, data reconstruction, and quality and accounting are addressed. The TDM and packet data formats utilized by the system are described, and the development of generic facilities is considered.

  13. The Generic Data Capture Facility

    NASA Technical Reports Server (NTRS)

    Connell, Edward B.; Barnes, William P.; Stallings, William H.

    1987-01-01

    The Generic Data Capture Facility, which can provide data capture support for a variety of different types of spacecraft while enabling operations costs to be carefully controlled, is discussed. The data capture functions, data protection, isolation of users from data acquisition problems, data reconstruction, and quality and accounting are addressed. The TDM and packet data formats utilized by the system are described, and the development of generic facilities is considered.

  14. Hanford Generic Interim Safety Basis

    SciTech Connect

    Lavender, J.C.

    1994-09-09

    The purpose of this document is to identify WHC programs and requirements that are an integral part of the authorization basis for nuclear facilities that are generic to all WHC-managed facilities. The purpose of these programs is to implement the DOE Orders, as WHC becomes contractually obligated to implement them. The Hanford Generic ISB focuses on the institutional controls and safety requirements identified in DOE Order 5480.23, Nuclear Safety Analysis Reports.

  15. Generic Example Proving Criteria for All

    ERIC Educational Resources Information Center

    Yopp, David; Ely, Rob; Johnson­-Leung, Jennifer

    2015-01-01

    We review literature that discusses generic example proving and highlight ambiguities that pervade our research community's discourse about generic example arguments. We distinguish between pedagogical advice for choosing good examples that can serve as generic examples when teaching and advice for developing generic example arguments. We provide…

  16. Generic Example Proving Criteria for All

    ERIC Educational Resources Information Center

    Yopp, David; Ely, Rob; Johnson­-Leung, Jennifer

    2015-01-01

    We review literature that discusses generic example proving and highlight ambiguities that pervade our research community's discourse about generic example arguments. We distinguish between pedagogical advice for choosing good examples that can serve as generic examples when teaching and advice for developing generic example arguments. We provide…

  17. Generic medications for hepatitis C.

    PubMed

    Jensen, Donald M; Sebhatu, Phoebe; Reau, Nancy S

    2016-07-01

    The recent development and approval of expensive but highly effective oral agents against hepatitis C has led to restrictions and access limitations in many countries with limited healthcare budgets. Generic formulations of many of these agents are available at a fraction of the retail price in several countries because of generic licensure agreements. The discounted alternatives are only accessible in developing countries and require manufacturing and distribution regulations to ensure the quality and bioequivalence of the new drug formulations. The continued medication access limitations have driven great interest in the practice of personal drug importation of the generic formulations. This review and debate will address the medical and legal issues involved in the purchase and importation of these medicines. © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

  18. 76 FR 57767 - Proposed Generic Communication; Draft NRC Generic Letter 2011-XX: Seismic Risk Evaluations for...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2011-09-16

    ... From the Federal Register Online via the Government Publishing Office NUCLEAR REGULATORY COMMISSION Proposed Generic Communication; Draft NRC Generic Letter 2011-XX: Seismic Risk Evaluations for... NRC Generic Letter 2011- XX: Seismic Risk Evaluations for Operating Reactors. This action is...

  19. Software synthesis using generic architectures

    NASA Technical Reports Server (NTRS)

    Bhansali, Sanjay

    1993-01-01

    A framework for synthesizing software systems based on abstracting software system designs and the design process is described. The result of such an abstraction process is a generic architecture and the process knowledge for customizing the architecture. The customization process knowledge is used to assist a designer in customizing the architecture as opposed to completely automating the design of systems. Our approach using an implemented example of a generic tracking architecture which was customized in two different domains is illustrated. How the designs produced using KASE compare to the original designs of the two systems, and current work and plans for extending KASE to other application areas are described.

  20. Generic Software Architecture for Launchers

    NASA Astrophysics Data System (ADS)

    Carre, Emilien; Gast, Philippe; Hiron, Emmanuel; Leblanc, Alain; Lesens, David; Mescam, Emmanuelle; Moro, Pierre

    2015-09-01

    The definition and reuse of generic software architecture for launchers is not so usual for several reasons: the number of European launcher families is very small (Ariane 5 and Vega for these last decades); the real time constraints (reactivity and determinism needs) are very hard; low levels of versatility are required (implying often an ad hoc development of the launcher mission). In comparison, satellites are often built on a generic platform made up of reusable hardware building blocks (processors, star-trackers, gyroscopes, etc.) and reusable software building blocks (middleware, TM/TC, On Board Control Procedure, etc.). If some of these reasons are still valid (e.g. the limited number of development), the increase of the available CPU power makes today an approach based on a generic time triggered middleware (ensuring the full determinism of the system) and a centralised mission and vehicle management (offering more flexibility in the design and facilitating the long term maintenance) achievable. This paper presents an example of generic software architecture which could be envisaged for future launchers, based on the previously described principles and supported by model driven engineering and automatic code generation.

  1. Conformal differential invariants

    NASA Astrophysics Data System (ADS)

    Kruglikov, Boris

    2017-03-01

    We compute the Hilbert polynomial and the Poincaré function counting the number of fixed jet-order differential invariants of conformal metric structures modulo local diffeomorphisms, and we describe the field of rational differential invariants separating generic orbits of the diffeomorphism pseudogroup action. This resolves the local recognition problem for conformal structures.

  2. 27 CFR 4.24 - Generic, semi-generic, and non-generic designations of geographic significance.

    Code of Federal Regulations, 2010 CFR

    2010-04-01

    ... 27 Alcohol, Tobacco Products and Firearms 1 2010-04-01 2010-04-01 false Generic, semi-generic, and non-generic designations of geographic significance. 4.24 Section 4.24 Alcohol, Tobacco Products and Firearms ALCOHOL AND TOBACCO TAX AND TRADE BUREAU, DEPARTMENT OF THE TREASURY LIQUORS LABELING...

  3. 27 CFR 4.24 - Generic, semi-generic, and non-generic designations of geographic significance.

    Code of Federal Regulations, 2014 CFR

    2014-04-01

    ... 27 Alcohol, Tobacco Products and Firearms 1 2014-04-01 2014-04-01 false Generic, semi-generic, and non-generic designations of geographic significance. 4.24 Section 4.24 Alcohol, Tobacco Products and Firearms ALCOHOL AND TOBACCO TAX AND TRADE BUREAU, DEPARTMENT OF THE TREASURY ALCOHOL LABELING...

  4. 27 CFR 4.24 - Generic, semi-generic, and non-generic designations of geographic significance.

    Code of Federal Regulations, 2012 CFR

    2012-04-01

    ... 27 Alcohol, Tobacco Products and Firearms 1 2012-04-01 2012-04-01 false Generic, semi-generic, and non-generic designations of geographic significance. 4.24 Section 4.24 Alcohol, Tobacco Products and Firearms ALCOHOL AND TOBACCO TAX AND TRADE BUREAU, DEPARTMENT OF THE TREASURY LIQUORS LABELING...

  5. 27 CFR 4.24 - Generic, semi-generic, and non-generic designations of geographic significance.

    Code of Federal Regulations, 2011 CFR

    2011-04-01

    ... 27 Alcohol, Tobacco Products and Firearms 1 2011-04-01 2011-04-01 false Generic, semi-generic, and non-generic designations of geographic significance. 4.24 Section 4.24 Alcohol, Tobacco Products and Firearms ALCOHOL AND TOBACCO TAX AND TRADE BUREAU, DEPARTMENT OF THE TREASURY LIQUORS LABELING...

  6. 27 CFR 4.24 - Generic, semi-generic, and non-generic designations of geographic significance.

    Code of Federal Regulations, 2013 CFR

    2013-04-01

    ... 27 Alcohol, Tobacco Products and Firearms 1 2013-04-01 2013-04-01 false Generic, semi-generic, and non-generic designations of geographic significance. 4.24 Section 4.24 Alcohol, Tobacco Products and Firearms ALCOHOL AND TOBACCO TAX AND TRADE BUREAU, DEPARTMENT OF THE TREASURY ALCOHOL LABELING...

  7. 40 CFR 721.10198 - Dialkylcornoilamidopropionate (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ...) TOXIC SUBSTANCES CONTROL ACT SIGNIFICANT NEW USES OF CHEMICAL SUBSTANCES Significant New Uses for Specific Chemical Substances § 721.10198 Dialkylcornoilamidopropionate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically...

  8. 40 CFR 721.10198 - Dialkylcornoilamidopropionate (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ...) TOXIC SUBSTANCES CONTROL ACT SIGNIFICANT NEW USES OF CHEMICAL SUBSTANCES Significant New Uses for Specific Chemical Substances § 721.10198 Dialkylcornoilamidopropionate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically...

  9. 40 CFR 721.10198 - Dialkylcornoilamidopropionate (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ...) TOXIC SUBSTANCES CONTROL ACT SIGNIFICANT NEW USES OF CHEMICAL SUBSTANCES Significant New Uses for Specific Chemical Substances § 721.10198 Dialkylcornoilamidopropionate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically...

  10. 40 CFR 721.10198 - Dialkylcornoilamidopropionate (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ...) TOXIC SUBSTANCES CONTROL ACT SIGNIFICANT NEW USES OF CHEMICAL SUBSTANCES Significant New Uses for Specific Chemical Substances § 721.10198 Dialkylcornoilamidopropionate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically...

  11. 40 CFR 721.9929 - Polyurea (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Polyurea (generic). 721.9929 Section... Substances § 721.9929 Polyurea (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a polyurea (PMN P-01-716) is subject...

  12. Pure versus hybrid: performance implications of Porter's generic strategies.

    PubMed

    Kumar, K; Subramanian, R; Yauger, C

    1997-01-01

    This article identifies the strategic types in the hospital industry based on the hospital's use of Porter's generic strategies in their pure and hybrid forms. The article also examines differences in performance of hospitals across strategic types. Results indicate that hospitals that follow a focussed cost leadership strategy, in general, have superior performance on a variety of performance measures, while hospitals that use a combination of cost leadership and differentiation perform the poorest. Implications of findings for hospital administrators are also discussed.

  13. 76 FR 69294 - Proposed Generic Communication Draft Generic Letter on Seismic Risk Evaluations for Operating...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2011-11-08

    ... COMMISSION Proposed Generic Communication Draft Generic Letter on Seismic Risk Evaluations for Operating... public comment Draft Generic Letter 2011-XX: Seismic Risk Evaluations for Operating Reactors. The public... for public comment Draft Generic Letter 2011-XX: Seismic Risk Evaluations for Operating Reactors...

  14. Patients' perceptions of generic drugs in Greece.

    PubMed

    Skaltsas, Leonora N; Vasileiou, Konstantinos Z

    2015-11-01

    The use of generic drugs is growing increasingly around the world and in Greece, in particular, in order to reduce pharmaceutical expenditure. However, patients' perceptions and attitudes about generics have only partially been studied so far in Greece. This study aimed to examine the factors that influence the attitude of patients and consumers regarding generic drugs. A questionnaire survey of 364 patients visiting a pharmacy was conducted. The questionnaire consisted of 29 questions, including questions regarding their knowledge about generics, the reasons for using them, their previous experience, their willingness for generic substitution, and the factors behind these choices. Nearly half of the participants in the survey know the term 'generic' and that it has a lower price compared to the brand name drug. Their views on safety and efficacy vary significantly and the main source of information on generics is the media and the internet. The lack of knowledge is the main barrier for attitudes of doctors. Health professionals play the most influential role for the substitution of a branded drug by a generic, followed by the cost of the generic. Almost half of the patients know about generic drugs, with their lower price being the most popular feature which most patients are familiar with. It seems that primarily the doctor and, subsequently the pharmacist play the most important role in a patient's decision to replace his/her medicine with a generic. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

  15. Generic Language in Parent-Child Conversations

    PubMed Central

    Gelman, Susan A.; Goetz, Peggy J.; Sarnecka, Barbara W.; Flukes, Jonathan

    2011-01-01

    Generic knowledge concerns kinds of things (e.g., birds fly; a chair is for sitting; gold is a metal). Past research demonstrated that children spontaneously develop generic knowledge by preschool age. The present study examines when and how children learn to use the multiple devices provided by their language to express generic knowledge. We hypothesize that children assume, in the absence of specifying information or context, that nouns refer to generic kinds, as a default. Thus, we predict that (a) Children should talk about kinds from an early age. (b) Children should learn generic forms with only minimal parental scaffolding. (c) Children should recognize a variety of different linguistic forms as generic. Results from longitudinal samples of adult-child conversations support all three hypotheses. We also report individual differences in the use of generics, suggesting that children differ in their tendency to form the abstract generalizations so expressed. PMID:21765807

  16. Competition in prescription drug markets: the roles of trademarks, advertising, and generic names.

    PubMed

    Feldman, Roger; Lobo, Félix

    2013-08-01

    We take on two subjects of controversy among economists-advertising and trademarks-in the context of the market for generic drugs. We outline a model in which trademarks for drug names reduce search costs but increase product differentiation. In this particular framework, trademarks may not benefit consumers. In contrast, the generic names of drugs or "International Nonproprietary Names" (INN) have unquestionable benefits in both economic theory and empirical studies. We offer a second model where advertising of a brand-name drug creates recognition for the generic name. The monopoly patent-holder advertises less than in the absence of a competitive spillover.

  17. Generic clozapine: a cost-saving alternative to brand name clozapine?

    PubMed

    Tse, Gordon; Thompson, Deborah; Procyshyn, Ric M

    2003-01-01

    As a consequence of its prevalence, early onset and chronicity, schizophrenia imposes clinical and economic impediments to healthcare practitioners and society alike. Among the many antipsychotics available to treat the symptoms of this devastating illness, clozapine has emerged and differentiated itself from the others as the agent most efficacious for the treatment of refractory patients. Since the patent for Clozaril (Novartis) expired in 1998, three manufacturers of generic clozapine have submitted abbreviated new drug applications to the US FDA for review and approval to market a generic clozapine product. In each case, the US FDA deemed the generic formulations to be bioequivalent to the brand name Clozaril. Apart from case reports, industry-sponsored studies have been conducted comparing Clozaril with two generic formulations. In one case, a generic formulation of clozapine manufactured by Creighton Products Corporation (formerly a subsidiary [generic house] of Sandoz Pharmaceuticals) was found to be bioequivalent to Clozaril. On the other hand, studies (sponsored by Novartis) have challenged the bioequivalence, therapeutic equivalence and interchangeability between Clozaril and a generic formulation manufactured by Zenith Goldline Pharmaceuticals (now IVAX Corporation). The IVAX Corporation-sponsored studies refuted these claims citing data from two patient registry database studies and one small clinical trial. Apart from a single in-house bioequivalence study, no further investigations have been conducted with a third generic formulation manufactured by Mylan Pharmaceutical. Although the clinical significance of the above discrepancy is obvious, what is less than obvious is the pharmacoeconomic implications that arises from this debate. Clearly, if the brand name and generic formulations are 'truly' bioequivalent, then the cost savings realised would be the difference in acquisition cost. On the other hand, if the various formulations are not

  18. The Controversy over Generic Antiepileptic Drugs

    PubMed Central

    Shaw, Susan J.; Hartman, Adam L.

    2010-01-01

    As patent protection ends for the next generation of antiepileptic drugs (AEDs), a complex debate continues over generic substitution of AEDs. On one hand, generic drug formulations provide cost savings for patients and society. On the other hand, patients with epilepsy and physicians are wary about the adequacy and efficacy of the Food and Drug Administration's (FDA) standards for generics. This article reviews current and proposed bioequivalence test procedures, summarizes new generic AED formulations and their costs, and discusses potential pitfalls in the current standards. These shortcomings include certain pharmacokinetic factors and clinical pharmacologic factors that may affect bioequivalence of generic AEDs, and statistical limitations of the standards. While the drug concentration differences between the brand name drug and each generic formulation are unlikely to be substantial, the differences with generic-to-generic switches will be greater and potentially clinically significant. Conversely, owing to their more favorable pharmacokinetic profile, newer AEDs may be less prone to problems with generic substitution than older ones. Unfortunately, very few data are available to guide decisions regarding what is best for an individual patient. Based on new prediction methods, generic substitution should be safe for many patients but identifying them ultimately requires more rigorous study. PMID:22477799

  19. Generic Crystalline Disposal Reference Case

    SciTech Connect

    Painter, Scott Leroy; Chu, Shaoping; Harp, Dylan Robert; Perry, Frank Vinton; Wang, Yifeng

    2015-02-20

    A generic reference case for disposal of spent nuclear fuel and high-level radioactive waste in crystalline rock is outlined. The generic cases are intended to support development of disposal system modeling capability by establishing relevant baseline conditions and parameters. Establishment of a generic reference case requires that the emplacement concept, waste inventory, waste form, waste package, backfill/buffer properties, EBS failure scenarios, host rock properties, and biosphere be specified. The focus in this report is on those elements that are unique to crystalline disposal, especially the geosphere representation. Three emplacement concepts are suggested for further analyses: a waste packages containing 4 PWR assemblies emplaced in boreholes in the floors of tunnels (KBS-3 concept), a 12-assembly waste package emplaced in tunnels, and a 32-assembly dual purpose canister emplaced in tunnels. In addition, three failure scenarios were suggested for future use: a nominal scenario involving corrosion of the waste package in the tunnel emplacement concepts, a manufacturing defect scenario applicable to the KBS-3 concept, and a disruptive glaciation scenario applicable to both emplacement concepts. The computational approaches required to analyze EBS failure and transport processes in a crystalline rock repository are similar to those of argillite/shale, with the most significant difference being that the EBS in a crystalline rock repository will likely experience highly heterogeneous flow rates, which should be represented in the model. The computational approaches required to analyze radionuclide transport in the natural system are very different because of the highly channelized nature of fracture flow. Computational workflows tailored to crystalline rock based on discrete transport pathways extracted from discrete fracture network models are recommended.

  20. Generic trending and analysis system

    NASA Technical Reports Server (NTRS)

    Keehan, Lori; Reese, Jay

    1994-01-01

    The Generic Trending and Analysis System (GTAS) is a generic spacecraft performance monitoring tool developed by NASA Code 511 and Loral Aerosys. It is designed to facilitate quick anomaly resolution and trend analysis. Traditionally, the job of off-line analysis has been performed using hardware and software systems developed for real-time spacecraft contacts; then, the systems were supplemented with a collection of tools developed by Flight Operations Team (FOT) members. Since the number of upcoming missions is increasing, NASA can no longer afford to operate in this manner. GTAS improves control center productivity and effectiveness because it provides a generic solution across multiple missions. Thus, GTAS eliminates the need for each individual mission to develop duplicate capabilities. It also allows for more sophisticated tools to be developed because it draws resources from several projects. In addition, the GTAS software system incorporates commercial off-the-shelf tools software (COTS) packages and reuses components of other NASA-developed systems wherever possible. GTAS has incorporated lessons learned from previous missions by involving the users early in the development process. GTAS users took a proactive role in requirements analysis, design, development, and testing. Because of user involvement, several special tools were designed and are now being developed. GTAS users expressed considerable interest in facilitating data collection for long term trending and analysis. As a result, GTAS provides easy access to large volumes of processed telemetry data directly in the control center. The GTAS archival and retrieval capabilities are supported by the integration of optical disk technology and a COTS relational database management system.

  1. Children’s developing intuitions about the truth conditions and implications of novel generics vs. quantified statements

    PubMed Central

    Brandone, Amanda C.; Gelman, Susan A; Hedglen, Jenna

    2014-01-01

    Generic statements express generalizations about categories and present a unique semantic profile that is distinct from quantified statements. This paper reports two studies examining the development of children’s intuitions about the semantics of generics and how they differ from statements quantified by all, most, and some. Results reveal that, like adults, preschoolers (1) recognize that generics have flexible truth conditions and are capable of representing a wide range of prevalence levels; and (2) interpret novel generics as having near-universal prevalence implications. Results further show that by age 4, children are beginning to differentiate the meaning of generics and quantified statements; however, even 7- to 11-year-olds are not adult-like in their intuitions about the meaning of most-quantified statements. Overall, these studies suggest that by preschool, children interpret generics in much the same way that adults do; however, mastery of the semantics of quantified statements follows a more protracted course. PMID:25297340

  2. Patients’ beliefs about generic medicines in Malaysia

    PubMed Central

    Wong, Zhi Y.; Hassali, Mohamed A.; Alrasheedy, Alian A.; Saleem, Fahad; Yahaya, Abdul H.; Aljadhey, Hisham

    2014-01-01

    Background: Acceptance of generic medicines by patients is an essential factor given that they are the end users of these medicines. In fact, adequate knowledge and positive perceptions are prerequisite to patients’ acceptance and use of generic medicines. Objective: To assess the current belief and views of patients about generic medicines in Malaysia. Method: This was a self-administered questionnaire-based study. The study was conducted with patients visiting outpatient pharmacy department at a tertiary care hospital in Malaysia. The Malaysian version of Generic Medicines Scale (GMS) was used. The GMS consists of two subscales: efficacy and similarity of generic medicines to original brand medicines. The efficacy subscale consists of 10 items while the similarity subscale consists of 6 items. The responses to the items were framed as a five-point Likert scale (1=strongly disagree to 5=strongly agree). Results: A total of 202 out of 300 patients participated in the study, giving a response rate of 67.3%. In this study, only 49% of them (n=99) knew the term ‘generic medicine’. Moreover, only 53.5% of the respondents (n=108) believed that the efficacy of generic medicines was the same as original brand medicines. In terms of quality, only 44% of the respondents (n=89) disagreed that generic medicines were of a lower quality. About one third (n=65, 32.2%) believed that generic medicines were cheaper because they were less efficacious. In terms of side effects, 44.5% of the respondents (n=90) believed that generic medicines had the same side effect profile as original brand medicines. Conclusions: The study finding showed that almost half of the respondents had negative belief in generic medicines. Similarly, many patients were not aware of the similarities and differences between generic and original brand medicines. Therefore, there is a need to provide patients with adequate information about generic medicines. PMID:25580171

  3. Descriptive Model of Generic WAMS

    SciTech Connect

    Hauer, John F.; DeSteese, John G.

    2007-06-01

    The Department of Energy’s (DOE) Transmission Reliability Program is supporting the research, deployment, and demonstration of various wide area measurement system (WAMS) technologies to enhance the reliability of the Nation’s electrical power grid. Pacific Northwest National Laboratory (PNNL) was tasked by the DOE National SCADA Test Bed Program to conduct a study of WAMS security. This report represents achievement of the milestone to develop a generic WAMS model description that will provide a basis for the security analysis planned in the next phase of this study.

  4. GLAD: A Generic LAttice Debugger

    SciTech Connect

    Lee, M.J.

    1991-11-01

    Today, numerous simulation and analysis codes exist for the design, commission, and operation of accelerator beam lines. There is a need to develop a common user interface and database link to run these codes interactively. This paper will describe a proposed system, GLAD (Generic LAttice Debugger), to fulfill this need. Specifically, GLAD can be used to find errors in beam lines during commissioning, control beam parameters during operation, and design beam line optics and error correction systems for the next generation of linear accelerators and storage rings.

  5. Generic thin-shell gravastars

    SciTech Connect

    Martin-Moruno, Prado; Visser, Matt; Garcia, Nadiezhda Montelongo; Lobo, Francisco S.N. E-mail: nmontelongo@fis.cinvestav.mx E-mail: matt.visser@msor.vuw.ac.nz

    2012-03-01

    We construct generic spherically symmetric thin-shell gravastars by using the cut-and-paste procedure. We take considerable effort to make the analysis as general and unified as practicable; investigating both the internal physics of the transition layer and its interaction with 'external forces' arising due to interactions between the transition layer and the bulk spacetime. Furthermore, we discuss both the dynamic and static situations. In particular, we consider 'bounded excursion' dynamical configurations, and probe the stability of static configurations. For gravastars there is always a particularly compelling configuration in which the surface energy density is zero, while surface tension is nonzero.

  6. Generic Airspace Concepts and Research

    NASA Technical Reports Server (NTRS)

    Mogford, Richard H.

    2010-01-01

    The purpose of this study was to evaluate methods for reducing the training and memorization required to manage air traffic in mid-term, Next Generation Air Transportation System (NextGen) airspace. We contrasted the performance of controllers using a sector information display and NextGen automation tools while working with familiar and unfamiliar sectors. The airspace included five sectors from Oakland and Salt Lake City Centers configured as a "generic center" called "West High Center." The Controller Information Tool was used to present essential information for managing these sectors. The Multi Aircraft Control System air traffic control simulator provided data link and conflict detection and resolution. There were five experienced air traffic controller participants. Each was familiar with one or two of the five sectors, but not the others. The participants rotated through all five sectors during the ten data collection runs. The results addressing workload, traffic management, and safety, as well as controller and observer comments, supported the generic sector concept. The unfamiliar sectors were comparable to the familiar sectors on all relevant measures.

  7. Generic Hypersonic Inlet Module Analysis

    NASA Technical Reports Server (NTRS)

    Cockrell, Chares E., Jr.; Huebner, Lawrence D.

    2004-01-01

    A computational study associated with an internal inlet drag analysis was performed for a generic hypersonic inlet module. The purpose of this study was to determine the feasibility of computing the internal drag force for a generic scramjet engine module using computational methods. The computational study consisted of obtaining two-dimensional (2D) and three-dimensional (3D) computational fluid dynamics (CFD) solutions using the Euler and parabolized Navier-Stokes (PNS) equations. The solution accuracy was assessed by comparisons with experimental pitot pressure data. The CFD analysis indicates that the 3D PNS solutions show the best agreement with experimental pitot pressure data. The internal inlet drag analysis consisted of obtaining drag force predictions based on experimental data and 3D CFD solutions. A comparative assessment of each of the drag prediction methods is made and the sensitivity of CFD drag values to computational procedures is documented. The analysis indicates that the CFD drag predictions are highly sensitive to the computational procedure used.

  8. Toward a generic UGV autopilot

    NASA Astrophysics Data System (ADS)

    Moore, Kevin L.; Whitehorn, Mark; Weinstein, Alejandro J.; Xia, Junjun

    2009-05-01

    Much of the success of small unmanned air vehicles (UAVs) has arguably been due to the widespread availability of low-cost, portable autopilots. While the development of unmanned ground vehicles (UGVs) has led to significant achievements, as typified by recent grand challenge events, to date the UGV equivalent of the UAV autopilot is not available. In this paper we describe our recent research aimed at the development of a generic UGV autopilot. Assuming we are given a drive-by-wire vehicle that accepts as inputs steering, brake, and throttle commands, we present a system that adds sonar ranging sensors, GPS/IMU/odometry, stereo camera, and scanning laser sensors, together with a variety of interfacing and communication hardware. The system also includes a finite state machine-based software architecture as well as a graphical user interface for the operator control unit (OCU). Algorithms are presented that enable an end-to-end scenario whereby an operator can view stereo images as seen by the vehicle and can input GPS waypoints either from a map or in the vehicle's scene-view image, at which point the system uses the environmental sensors as inputs to a Kalman filter for pose estimation and then computes control actions to move through the waypoint list, while avoiding obstacles. The long-term goal of the research is a system that is generically applicable to any drive-by-wire unmanned ground vehicle.

  9. A Generic Bioheat Transfer Thermal Model for a Perfused Tissue

    PubMed Central

    Vaughan, J. Thomas

    2009-01-01

    A thermal model was needed to predict temperatures in a perfused tissue, which satisfied the following three criteria. One, the model satisfied conservation of energy. Two, the heat transfer rate from blood vessels to tissue was modeled without following a vessel path. Three, the model applied to any unheated and heated tissue. To meet these criteria, a generic bioheat transfer model (BHTM) was derived here by conserving thermal energy in a heated, vascularized, finite tissue and by making a few simplifying assumptions. Two linear, coupled differential equations were obtained with the following two variables: tissue volume averaged temperature and blood volume averaged temperature. The generic model was compared to the widely employed, empirical Pennes’ BHTM. The comparison showed that the Pennes’ perfusion term wCp(1−ε) should be interpreted as a local vasculature dependent heat transfer coefficient term. Suggestions are presented for further adaptations of the general BHTM for specific tissues using imaging techniques and numerical simulations. PMID:19640142

  10. A generic bioheat transfer thermal model for a perfused tissue.

    PubMed

    Shrivastava, Devashish; Vaughan, J Thomas

    2009-07-01

    A thermal model was needed to predict temperatures in a perfused tissue, which satisfied the following three criteria. One, the model satisfied conservation of energy. Two, the heat transfer rate from blood vessels to tissue was modeled without following a vessel path. Three, the model applied to any unheated and heated tissue. To meet these criteria, a generic bioheat transfer model (BHTM) was derived here by conserving thermal energy in a heated vascularized finite tissue and by making a few simplifying assumptions. Two linear coupled differential equations were obtained with the following two variables: tissue volume averaged temperature and blood volume averaged temperature. The generic model was compared with the widely employed empirical Pennes' BHTM. The comparison showed that the Pennes' perfusion term wC(p)(1-epsilon) should be interpreted as a local vasculature dependent heat transfer coefficient term. Suggestions are presented for further adaptations of the general BHTM for specific tissues using imaging techniques and numerical simulations.

  11. [Generic drugs in morocco: survey of physicians].

    PubMed

    Zaoui, Sanaa; Hakkou, Farid; Filali, Houda

    2011-01-01

    To assess the knowledge of physicians about generic drugs and their prescribing habits, with a view to making proposals for developing the use of generic drug in Morocco. Prospective study conducted among 100 physicians working in different sectors, using a questionnaire comprising 14 questions. The points raised in this questionnaire focused on assessing the knowledge of physicians about generic drugs, their prescribing habits, and their point of view towards the rights of substitution. The prescription of generic medicines is more than 20% of drug prescriptions in less than half of doctors. For 68% of physicians, a generic is not always effective. When the definition of generic drug only 66% of physicians mentioned bioequivalence with the brand-name drug, and when the definition of bioequivalence, for almost half (51%) of physicians, a generic drug bioequivalent to the brand-name drug is a drug with the same half-life. Eighty-eight percent (88%) of the doctors prescribe generic drugs when lower cost is met. Seventy percent of physicians (70%) prescribe generics when bioequivalence is demonstrated with the brand-name drug. Sixty-eight percent (68%) of doctors are against the substitution because it presents an obstacle to their freedom of prescription. In order to increase the use of generic drugs, better information for physicians is necessary. Other ways can be implemented, first establish the quality of Moroccan generic by bioequivalence studies and think about steps to put in place to encourage doctors and pharmacists to prescribe and dispense generic drugs, particularly the rights of substitution. © 2011 Société Française de Pharmacologie et de Thérapeutique.

  12. Generic domain models in software engineering

    NASA Technical Reports Server (NTRS)

    Maiden, Neil

    1992-01-01

    This paper outlines three research directions related to domain-specific software development: (1) reuse of generic models for domain-specific software development; (2) empirical evidence to determine these generic models, namely elicitation of mental knowledge schema possessed by expert software developers; and (3) exploitation of generic domain models to assist modelling of specific applications. It focuses on knowledge acquisition for domain-specific software development, with emphasis on tool support for the most important phases of software development.

  13. Determinants of generic drug substitution in Switzerland

    PubMed Central

    2011-01-01

    Background Since generic drugs have the same therapeutic effect as the original formulation but at generally lower costs, their use should be more heavily promoted. However, a considerable number of barriers to their wider use have been observed in many countries. The present study examines the influence of patients, physicians and certain characteristics of the generics' market on generic substitution in Switzerland. Methods We used reimbursement claims' data submitted to a large health insurer by insured individuals living in one of Switzerland's three linguistic regions during 2003. All dispensed drugs studied here were substitutable. The outcome (use of a generic or not) was modelled by logistic regression, adjusted for patients' characteristics (gender, age, treatment complexity, substitution groups) and with several variables describing reimbursement incentives (deductible, co-payments) and the generics' market (prices, packaging, co-branded original, number of available generics, etc.). Results The overall generics' substitution rate for 173,212 dispensed prescriptions was 31%, though this varied considerably across cantons. Poor health status (older patients, complex treatments) was associated with lower generic use. Higher rates were associated with higher out-of-pocket costs, greater price differences between the original and the generic, and with the number of generics on the market, while reformulation and repackaging were associated with lower rates. The substitution rate was 13% lower among hospital physicians. The adoption of the prescribing practices of the canton with the highest substitution rate would increase substitution in other cantons to as much as 26%. Conclusions Patient health status explained a part of the reluctance to substitute an original formulation by a generic. Economic incentives were efficient, but with a moderate global effect. The huge interregional differences indicated that prescribing behaviours and beliefs are probably the

  14. Rational use of generic psychotropic drugs.

    PubMed

    Carbon, Maren; Correll, Christoph U

    2013-05-01

    For economic reasons, the generic substitution of branded medications is common and welcome. These replacements are based on the concept of bioequivalence, which is considered equal to therapeutic equivalence. Regulatory standards for bioequivalence require the 90 % confidence intervals of group averages of pharmacokinetic measures of a generic and the original drug to overlap within ±20 %. However, therapeutic equivalence has been challenged for several psychotropic agents by retrospective studies and case reports. To evaluate the degree of bioequivalence and therapeutic equivalence of branded and generic psychotropic drugs, we performed an electronic search (from database inception until 24 May 2012 and without language restrictions) in PubMed/MEDLINE, Cochrane Library, and Web of Science. Search terms were "(generic) AND (psychotropic OR psychoactive OR antipsychotic OR antiepileptic OR antidepressant OR stimulant OR benzodiazepine)" or the respective individual substances. We included clinical studies, regardless of design, comparing branded with generic psychotropic drug formulations, identifying 35 such studies. We also included case reports/series reporting on outcomes after a switch between brand and generic psychotropics, identifying 145 clinical cases. Bioequivalence studies in healthy controls or animals, in-vitro studies, and health economics studies without medical information were excluded. An overview of the few randomized controlled studies supports that US FDA regulations assure clinically adequate drug delivery in the majority of patients switched from brand to generic. However, with a growing number of competing generic products for one substance, and growing economic pressure to substitute with the currently cheapest generic, frequent generic-generic switches, often unbeknownst to prescribing clinicians, raise concerns, particularly for antiepileptics/mood stabilizers. Generic-generic switches may vary by more than ±20 % from each other in

  15. Analysis of French generic medicines retail market: why the use of generic medicines is limited.

    PubMed

    Dylst, Pieter; Vulto, Arnold; Simoens, Steven

    2014-12-01

    The market share of generic medicines in France is low compared to other European countries. This perspective paper provides an overview of the generic medicines retail market in France and how the current policy environment may affect the long-term sustainability. Looking at the French generic medicines retail market and the surrounding regulatory framework, all conditions seem to be in place to create a healthy generic medicines market: the country has well-respected regulatory authorities, generic medicines enter the market in a timely manner and prices of generic medicines are competitive compared with other European countries. Despite the success of the demand-side policies targeted at pharmacists and patients, those targeted at physicians were less successful due to a lack of enforcement and a lack of trust in generic medicines by French physicians. Recommendations to increase the use of generic medicines in France round off this perspective paper.

  16. Comparing the biological impact of glatiramer acetate with the biological impact of a generic.

    PubMed

    Towfic, Fadi; Funt, Jason M; Fowler, Kevin D; Bakshi, Shlomo; Blaugrund, Eran; Artyomov, Maxim N; Hayden, Michael R; Ladkani, David; Schwartz, Rivka; Zeskind, Benjamin

    2014-01-01

    For decades, policies regarding generic medicines have sought to provide patients with economical access to safe and effective drugs, while encouraging the development of new therapies. This balance is becoming more challenging for physicians and regulators as biologics and non-biological complex drugs (NBCDs) such as glatiramer acetate demonstrate remarkable efficacy, because generics for these medicines are more difficult to assess. We sought to develop computational methods that use transcriptional profiles to compare branded medicines to generics, robustly characterizing differences in biological impact. We combined multiple computational methods to determine whether differentially expressed genes result from random variation, or point to consistent differences in biological impact of the generic compared to the branded medicine. We applied these methods to analyze gene expression data from mouse splenocytes exposed to either branded glatiramer acetate or a generic. The computational methods identified extensive evidence that branded glatiramer acetate has a more consistent biological impact across batches than the generic, and has a distinct impact on regulatory T cells and myeloid lineage cells. In summary, we developed a computational pipeline that integrates multiple methods to compare two medicines in an innovative way. This pipeline, and the specific findings distinguishing branded glatiramer acetate from a generic, can help physicians and regulators take appropriate steps to ensure safety and efficacy.

  17. Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic

    PubMed Central

    Bakshi, Shlomo; Blaugrund, Eran; Artyomov, Maxim N.; Hayden, Michael R.; Ladkani, David; Schwartz, Rivka; Zeskind, Benjamin

    2014-01-01

    For decades, policies regarding generic medicines have sought to provide patients with economical access to safe and effective drugs, while encouraging the development of new therapies. This balance is becoming more challenging for physicians and regulators as biologics and non-biological complex drugs (NBCDs) such as glatiramer acetate demonstrate remarkable efficacy, because generics for these medicines are more difficult to assess. We sought to develop computational methods that use transcriptional profiles to compare branded medicines to generics, robustly characterizing differences in biological impact. We combined multiple computational methods to determine whether differentially expressed genes result from random variation, or point to consistent differences in biological impact of the generic compared to the branded medicine. We applied these methods to analyze gene expression data from mouse splenocytes exposed to either branded glatiramer acetate or a generic. The computational methods identified extensive evidence that branded glatiramer acetate has a more consistent biological impact across batches than the generic, and has a distinct impact on regulatory T cells and myeloid lineage cells. In summary, we developed a computational pipeline that integrates multiple methods to compare two medicines in an innovative way. This pipeline, and the specific findings distinguishing branded glatiramer acetate from a generic, can help physicians and regulators take appropriate steps to ensure safety and efficacy. PMID:24421904

  18. Generic Language and Judgements about Category Membership: Can Generics Highlight Properties as Central?

    ERIC Educational Resources Information Center

    Hollander, Michelle A.; Gelman, Susan A.; Raman, Lakshmi

    2009-01-01

    Many languages distinguish generic utterances (e.g., "Tigers are ferocious") from non-generic utterances (e.g., "Those tigers are ferocious"). Two studies examined how generic language specially links properties and categories. We used a novel-word extension task to ask if 4- to 5-year-old children and adults distinguish…

  19. Generic Language and Judgements about Category Membership: Can Generics Highlight Properties as Central?

    ERIC Educational Resources Information Center

    Hollander, Michelle A.; Gelman, Susan A.; Raman, Lakshmi

    2009-01-01

    Many languages distinguish generic utterances (e.g., "Tigers are ferocious") from non-generic utterances (e.g., "Those tigers are ferocious"). Two studies examined how generic language specially links properties and categories. We used a novel-word extension task to ask if 4- to 5-year-old children and adults distinguish…

  20. Generic linear microcircuit test requirements

    NASA Astrophysics Data System (ADS)

    Tanemura, Steve K.; Mitchell, Ronald R.

    1991-04-01

    The Generic Linear Microcircuit Test Requirements Program is outlined. The objective was to develop new series-4000 test specifications to standardize testing of linear devices. The drafts developed will replace the existing series-4000 methods in MIL-STD-883C. New series-4000 drafts for 11 device families were developed, which will cover the majority of the linear microcircuits used in military systems. The test methods specified in each draft referenced a variety of sources including M38510 slash sheets, industry standard procedures, literature, existing test methods in MIL-STD-883C, and newly developed methods. Completion of these drafts will provide more consistent testing of linear devices. All aspects of the program are reviewed.

  1. [Original brands and generic preparations].

    PubMed

    Petersen, K U

    2000-01-15

    Modern guidelines of drug approval aim at interchangeability of drugs containing the same active ingredients. Therapeutic equivalence of original and generic drugs is assumed as soon as bioequivalence is documented. For this to be accepted, first, pharmaceutical equivalence must prevail (the same amount of active substances in the same dosage forms) and, second, differences in bioavailabilities must not exceed certain limits. Drastic deviations from the original--not infrequent in the past--have become rare under the new sets of rules. However, there is still room for sometimes stunning discrepancies between approved drugs, since the current procedures--mainly for economic reasons--do not cover some potentially relevant aspects: Usually, studies are performed on young, healthy, mostly male volunteers; possible effects of meals on bioavailability are not investigated and, after approval of a drug, maintenance of attested quality--as with all manufacturers--is not monitored. Moreover, the tolerated deviations from the bioavailability of the original drug are quite large; with certain substances, a change from the generic drug with the lowest bioavailability to that with the highest could mean transition from low efficacy to a toxic dose level. Documented examples include carbamazepine, phenytoin, levothyroxin, verapamil, and aspirin. In conclusion, even today's sophisticated rules do not suffice to cover all eventualities. In particular, drugs with a narrow therapeutic range require close scrutiny in product selection. Pertinent are drug documentation as well as the distinguishing features of the respective manufacturers, mainly scientific support and record of product reliability. Besides the sometimes insufficient official documentation, the internet has been gaining importance as a source of information.

  2. Authorized generic drugs, price competition, and consumers' welfare.

    PubMed

    Berndt, Ernst R; Mortimer, Richard; Bhattacharjya, Ashoke; Parece, Andrew; Tuttle, Edward

    2007-01-01

    The growing frequency of authorized generics has important implications for the welfare of prescription drug consumers. Authorized generic entry could affect the timing of generic entry, brand-name and generic prices, and generic penetration. We reviewed 1999-2003 data and found that generic entry in the absence of short-run exclusivity restrictions benefits consumers through lower short-run prices. We suggest that these benefits likely also result from authorized generics. We posit that long-run prices and shares are likely essentially unaffected by authorized generics and that potential costs to consumers from any delayed generic entry are likely small.

  3. Children's Interpretation of Generic Noun Phrases.

    ERIC Educational Resources Information Center

    Hollander, Michelle A.; Gelman, Susan A.; Star, Jon

    2002-01-01

    Two studies used a comprehension task and an elicited production task to examine whether preschool children and adults appreciated the semantic properties of generic utterances. Findings indicated that in both tasks, 4-year-olds and adults treated generics ("bears live in caves") as distinct from both indefinites ("some") and universal quantifiers…

  4. Generic Language Facilitates Children's Cross-Classification

    ERIC Educational Resources Information Center

    Nguyen, Simone P.; Gelman, A.

    2012-01-01

    Four studies examined the role of generic language in facilitating 4- and 5-year-old children's ability to cross-classify. Participants were asked to classify an item into a familiar (taxonomic or script) category, then cross-classify it into a novel (script or taxonomic) category with the help of a clue expressed in either generic or specific…

  5. Developmental Changes in the Understanding of Generics

    ERIC Educational Resources Information Center

    Gelman, Susan A.; Bloom, Paul

    2007-01-01

    Generic sentences (such as "Birds lay eggs") are important in that they refer to kinds (e.g., birds as a group) rather than individuals (e.g., the birds in the henhouse). The present set of studies examined aspects of how generic nouns are understood by English speakers. Adults and children (4- and 5-year-olds) were presented with scenarios about…

  6. Generic drugs in dermatology: part I.

    PubMed

    Payette, Michael; Grant-Kels, Jane M

    2012-03-01

    The cost of health care in the United States is increasing. In order to help control these rising costs, all parties involved in the delivery of health care, including dermatologists, need to be part of the solution of ethically reducing the cost of delivery of care. One potential means of meeting this goal is to increase the use of generic medications in daily practice. Generic medications can offer equally efficacious therapy at significantly lower prices, which can translate into large scale savings for the individual patient, the payer, and the overall health care system. Herein we provide an overview of new drug development, review the history of the generic drug industry, describe how generic drugs are approved by the US Food and Drug Administration, and define the concepts of bioequivalence and therapeutic equivalence. In part II, we explore various factors impacting generic drug use, provide cost analyses of dermatologic brand name and generic drugs, and review data addressing potential differences in the effectiveness of brand name versus generic drugs in dermatology. The cost of brand name and generic medications is highly variable by pharmacy, state, and payer. We used one source (www.drugstore.com) as an example and for consistency across all medications discussed herein. Prices included here may not reflect actual retail prices across the United States. Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

  7. HTGR generic technology program plan (FY 80)

    SciTech Connect

    Not Available

    1980-01-01

    Purpose of the program is to develop base technology and to perform design and development common to the HTGR Steam Cycle, Gas Turbine, and Process Heat Plants. The generic technology program breaks into the base technology, generic component, pebble-bed study, technology transfer, and fresh fuel programs. (DLC)

  8. Generic Language Facilitates Children's Cross-Classification

    ERIC Educational Resources Information Center

    Nguyen, Simone P.; Gelman, A.

    2012-01-01

    Four studies examined the role of generic language in facilitating 4- and 5-year-old children's ability to cross-classify. Participants were asked to classify an item into a familiar (taxonomic or script) category, then cross-classify it into a novel (script or taxonomic) category with the help of a clue expressed in either generic or specific…

  9. Defining Generic Skills. At a Glance.

    ERIC Educational Resources Information Center

    National Centre for Vocational Education Research, Leabrook (Australia).

    Generic skills--skills that apply across a variety of jobs and life contexts--are taking on increased importance in Australia and internationally. There is a high demand for generic skills in the workplace because employers seek to ensure business success by recruiting and retaining employees who have a variety of skills and personal attributes as…

  10. Children's Interpretation of Generic Noun Phrases.

    ERIC Educational Resources Information Center

    Hollander, Michelle A.; Gelman, Susan A.; Star, Jon

    2002-01-01

    Two studies used a comprehension task and an elicited production task to examine whether preschool children and adults appreciated the semantic properties of generic utterances. Findings indicated that in both tasks, 4-year-olds and adults treated generics ("bears live in caves") as distinct from both indefinites ("some") and universal quantifiers…

  11. Generic Proving: Reflections on Scope and Method

    ERIC Educational Resources Information Center

    Leron, Uri; Zaslavsky, Orit

    2013-01-01

    We analyze the role of generic proofs in helping students access difficult proofs more easily and naturally. We present three examples of generic proving--an elementary one on numbers, a more advanced one on permutations, and yet more advanced one on groups--and consider the affordances and pitfalls of the method by reflecting on these examples. A…

  12. Generic drug approval: a US perspective.

    PubMed

    Nagori, B P; Mathur, V; Garg, S

    2011-03-01

    Generic drugs are identical or bioequivalent versions of the brand name drugs. They are the economic alternative of the costlier brand name drugs. This article presents a general overview of the procedure and regulatory aspects relating to generic drug approval in the US. A computerized search was conducted to find literature on generic drug approval in the US. The literature was searched using the following key words: generic drug, brand name drug, Hatch-Waxman Act, Medicare Act, NDA, ANDA, CTD and exclusivity. The search results were filtered for the literature describing and analyzing the procedure and regulatory provisions for generic drug approval in the US. After the screening total 19 applicable literature remained. In the US standardized procedures for the recognition of generic drugs have been laid down under the Drug Price Competition and Patent Term Restoration Act, 1984 (the Hatch-Waxman Act). Provisions of this Act such as patent challenge, patent term extension and data exclusivity have created profound effects on the approval, sale and distribution of the pharmaceuticals in the US. The Hatch-Waxman Act is an excellent piece of legislation that takes care of the rights of both the brand name and generic drug companies. This article presents only an overview of generic drug approvals and for all practical purposes official resources should be referred.

  13. Generic Skills. Keys to Job Performance.

    ERIC Educational Resources Information Center

    Smith, Arthur De W.

    The generic skills studies in Canada have as their objectives the formulation of generic skills, the identification of their uses for certain occupational groups, and the preparation of specifications for instructional modules in an attempt to provide greater flexibility to workers, employers, and vocational training programs. Another objective of…

  14. Mapping Generic Skills Curricula: A Recommended Methodology

    ERIC Educational Resources Information Center

    Robley, Will; Whittle, Sue; Murdoch-Eaton, Deborah

    2005-01-01

    Since the 1997 Dearing Report, generic skills development has become an essential part of higher education in the UK. Generic skills programmes are, in the main, either run in parallel with existing curricula or "embedded" within them. In 1993 the General Medical Council introduced student selected components (SSCs) into the UK medical…

  15. [Generic drugs: good or bad? Physician's knowledge of generic drugs and prescribing habits].

    PubMed

    García, A J; Martos, F; Leiva, F; Sánchez de la Cuesta, F

    2003-01-01

    In this article we analyze the responses of 1220 Spanish physicians who participated in a survery about generic drugs. A previously validated questionnaire was sent to physicians through the Spanish Medical Councils of the different provinces. Four items were analyzed: what doctors know about generic drugs (knowledge); physicians' prescribing habits concerning these drugs (attitude and professional competence); how prescription of generic drugs effects pharmaceutical costs amd, finally, what doctors believe a generic drug should be. The influence of physician-related variables (age, type of contract, specialty, workload, etc.) on prescribing of generic drugs was also analyzed. In view of the results, we believe that to rationalize expenditure through and appropriate policy on generic drugs Spanish health authorities should offer more and better training and information (clear and independent) about what generic drugs are.

  16. 78 FR 59911 - Generic Information Collection for Land Management Planning

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-09-30

    ... Forest Service Generic Information Collection for Land Management Planning AGENCY: Forest Service, USDA... information collection, Generic Information Collection for Land Management Planning. DATES: Comments must be... Friday. SUPPLEMENTARY INFORMATION: Title: Generic Information Collection for Land Management...

  17. Administration diluents differentiate Neoral from a generic cyclosporine oral solution.

    PubMed

    Kovarik, John M; Barilla, Denise; McMahon, Louis; Wang, Yibin; Kisicki, James; Schmouder, Robert

    2002-08-01

    A non-microemulsion cyclosporine oral solution was recently recalled from the market because of the lack of bioequivalence when administered with apple juice compared with water as the diluent. This open-label, randomized, two-period, crossover study assessed the effect of apple juice on Neoral, a microemulsion cyclosporine oral solution. The study enrolled 34 subjects who received 180 mg Neoral oral solution diluted in 200 mL tap water or apple juice. Cyclosporine was measured in whole blood by a liquid chromatography method. Pharmacokinetic parameters were compared by standard bioequivalence tests. With water vs. apple juice, cyclosporine Cmax was 1263 +/- 203 vs. 1191 +/- 225 ng/mL and AUC was 4714 +/- 1117 vs. 4788 +/- 1320 ng h/mL, respectively. Bioequivalence was demonstrated for both parameters. These data were comparable with those from a previous study in which subjects received 180 mg Neoral oral solution with orange juice. Cyclosporine bioavailability is unaltered when Neoral is administered diluted in apple juice or orange juice compared with tap water which conforms to the cyclosporine product label.

  18. Generic drugs in dermatology: part II.

    PubMed

    Payette, Michael; Grant-Kels, Jane M

    2012-03-01

    In part I, we discussed new drug development, reviewed the history of the generic drug industry, described how generic drugs are approved by the US Food and Drug Administration, and defined the concepts of bioequivalence and therapeutic equivalence. Herein, we explore various factors impacting generic drug use across the different parties involved: the prescriber, the pharmacist, the patient, and the payer. We also include original cost analysis of dermatologic brand name and generic drugs and show the potential cost savings that can be achieved through generic substitution. We conclude with a review of the data addressing potential differences in the effectiveness of brand name versus generic drugs in dermatology. The cost of brand name and generic medications is highly variable by pharmacy, state, and payer. We used one source (www.drugstore.com) as an example and for consistency across all medications discussed herein. Prices included here may not reflect actual retail prices across the United States. Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

  19. Risks and benefits of generic antiepileptic drugs.

    PubMed

    Gómez-Alonso, Juan; Kanner, Andrés M; Herranz, José Luis; Molins, Albert; Gil-Nagel, Antonio

    2008-11-01

    In most therapeutic areas, prescribing generic drugs seems to lower costs without sacrificing efficacy. The use of generic drugs for treating epilepsy may, however, be more controversial. A systematic review of the literature on generic antiepileptic drugs has been carried out based primarily on a bibliographical search in the Medline database. Published studies are usually of a descriptive nature and are sometimes based on generic drugs that were approved in times when regulatory agency requirements were not as strict as they are now. Experts claim that a change in pharmaceutical formulations could cause seizure recurrence in cases that had been successfully controlled in the past, with severe effects on patients. Meanwhile, several health organizations have provided inconsistent recommendations on the use of generic antiepileptic drugs. In order to obtain scientific evidence on the potential risks and benefits of interchanging branded and generic antiepileptic drugs, high methodological comparative studies are necessary. These studies could bring consensus about the role of generic drugs for treating epilepsy.

  20. Generic antibiotic drugs: is effectiveness guaranteed?

    PubMed

    Gauzit, R; Lakdhari, M

    2012-04-01

    There are recently published arguments suggesting all generic antibiotic drugs do not present the full reliability needed to claim therapeutic equivalence with branded drugs. The problem is especially crucial for generic intravenous drugs, which do not need any bioequivalence study before they can be marketed. The evaluation of generic antibiotic drug effectiveness yields an important dispersion of results according to antibiotic agents and for the same antibiotic agent all generic drugs are not equivalent. There are differences at all levels: drug components, levels of impurity, pharmacokinetics, pharmacokinetic/pharmacodynamic relationship, in vitro effectiveness, therapeutic effectiveness in experimental models, etc. So that finally, the specifications approved in the initial submission file of a brand name drugs are not always respected by a generic drug. There is also a specific problem of taste and treatment acceptability for pediatric oral antibiotic drugs. Available data on clinical effectiveness is excessively rare. The marketing of a great number of generic drugs of the same specialty is followed by a sometimes very important increase of their use, even in countries where consumption is low. The corollary of this increase in consumption is an increase of resistance, and this is especially true for oral fluoroquinolones. Even if most of this information needs to be verified, it seems necessary to review regulations for marketing authorization of generic antibiotic drugs.

  1. A reappraisal of generic bisphosphonates in osteoporosis.

    PubMed

    Kanis, J A; Reginster, J-Y; Kaufman, J-M; Ringe, J-D; Adachi, J D; Hiligsmann, M; Rizzoli, R; Cooper, C

    2012-01-01

    The competitive price of generic bisphosphonates has had a marked effect on practice guidelines, but an increasing body of evidence suggests that they have more limited effectiveness than generally assumed. The purpose of this study is to review the impact of generic bisphosphonates on effectiveness in the treatment of osteoporosis. This study is a literature review. A substantial body of evidence indicates that many generic formulations of alendronate are more poorly tolerated than the proprietary preparations which results in significantly poorer adherence and thus effectiveness. Poorer effectiveness may result from faster disintegration times of many generics that increase the likelihood of adherence of particulate matter to the oesophageal mucosa. Unfortunately, market authorisation, based on the bioequivalence of generics with a proprietary formulation, does not take into account the potential concerns about safety. The poor adherence of many generic products has implications for guideline development, cost-effectiveness and impact of treatment on the burden of disease. The impact of generic bisphosphonates requires formal testing to re-evaluate their role in the management of osteoporosis.

  2. Generic oncology drugs: are they all safe?

    PubMed

    Yang, Y Tony; Nagai, Sumimasa; Chen, Brian K; Qureshi, Zaina P; Lebby, Akida A; Kessler, Samuel; Georgantopoulos, Peter; Raisch, Dennis W; Sartor, Oliver; Hermanson, Terhi; Kane, Robert C; Hrushesky, William J; Riente, Joshua J; Norris, LeAnn B; Bobolts, Laura R; Armitage, James O; Bennett, Charles L

    2016-11-01

    Although the availability of generic oncology drugs allows access to contemporary care and reduces costs, there is international variability in the safety of this class of drugs. In this Series paper, we review clinical, policy, safety, and regulatory considerations for generic oncology drugs focusing on the USA, Canada, the European Union (EU), Japan, China, and India. Safety information about generic formulations is reviewed from one agent in each class, for heavy metal drugs (cisplatin), targeted agents (imatinib), and cytotoxic agents (docetaxel). We also review regulatory reports from Japan and the USA, countries with the largest pharmaceutical expenditures. Empirical studies did not identify safety concerns in the USA, Canada, the EU, and Japan, where regulations and enforcement are strong. Although manufacturing problems for generic pharmaceuticals exist in India, where 40% of all generic pharmaceuticals used in the USA are manufactured, increased inspections and communication by the US Food and Drug Administration are occurring, facilitating oversight and enforcement. No safety outbreaks among generic oncology drugs were reported in developed countries. For developing countries, oversight is less intensive, and concerns around drug safety still exist. Regulatory agencies should collaboratively develop procedures to monitor the production, shipment, storage, and post-marketing safety of generic oncology drugs. Regulatory agencies for each country should also aim towards identical definitions of bioequivalence, the cornerstone of regulatory approval. Copyright © 2016 Elsevier Ltd. All rights reserved.

  3. Generic Magnetic Fusion Reactor Revisited

    NASA Astrophysics Data System (ADS)

    Sheffield, John; Milora, Stanley

    2015-11-01

    The original Generic Magnetic Fusion Reactor paper was published in 1986. This update describes what has changed in 30 years. Notably, the construction of ITER is providing important benchmark numbers for technologies and costs. In addition, we use a more conservative neutron wall flux and fluence. But these cost-increasing factors are offset by greater optimism on the thermal-electric conversion efficiency and potential availability. The main examples show the cost of electricity (COE) as a function of aspect ratio and neutron flux to the first wall. The dependence of the COE on availability, thermo-electric efficiency, electrical power output, and the present day's low interest rates is also discussed. Interestingly, at fixed aspect ratio there is a shallow minimum in the COE at neutron flux around 2.5 MW/m2. The possibility of operating with only a small COE penalty at even lower wall loadings (to 1.0 MW/m2 at larger plant size) and the use of niobium-titanium coils are also investigated. J. Sheffield was supported by ORNL subcontract 4000088999 with the University of Tennessee.

  4. Generic theory for channel sinuosity.

    PubMed

    Lazarus, Eli D; Constantine, José Antonio

    2013-05-21

    Sinuous patterns traced by fluid flows are a ubiquitous feature of physical landscapes on Earth, Mars, the volcanic floodplains of the Moon and Venus, and other planetary bodies. Typically discussed as a consequence of migration processes in meandering rivers, sinuosity is also expressed in channel types that show little or no indication of meandering. Sinuosity is sometimes described as "inherited" from a preexisting morphology, which still does not explain where the inherited sinuosity came from. For a phenomenon so universal as sinuosity, existing models of channelized flows do not explain the occurrence of sinuosity in the full variety of settings in which it manifests, or how sinuosity may originate. Here we present a generic theory for sinuous flow patterns in landscapes. Using observations from nature and a numerical model of flow routing, we propose that flow resistance (representing landscape roughness attributable to topography or vegetation density) relative to surface slope exerts a fundamental control on channel sinuosity that is effectively independent of internal flow dynamics. Resistance-dominated surfaces produce channels with higher sinuosity than those of slope-dominated surfaces because increased resistance impedes downslope flow. Not limited to rivers, the hypothesis we explore pertains to sinuosity as a geomorphic pattern. The explanation we propose is inclusive enough to account for a wide variety of sinuous channel types in nature, and can serve as an analytical tool for determining the sinuosity a landscape might support.

  5. Fast generic polar harmonic transforms.

    PubMed

    Hoang, Thai V; Tabbone, Salvatore

    2014-07-01

    Generic polar harmonic transforms have recently been proposed to extract rotation-invariant features from images and their usefulness has been demonstrated in a number of pattern recognition problems. However, direct computation of these transforms from their definition is inefficient and is usually slower than some efficient computation strategies that have been proposed for other methods. This paper presents a number of novel computation strategies to compute these transforms rapidly. The proposed methods are based on the inherent recurrence relations among complex exponential and trigonometric functions used in the definition of the radial and angular kernels of these transforms. The employment of these relations leads to recursive and addition chain-based strategies for fast computation of harmonic function-based kernels. Experimental results show that the proposed method is about 10× faster than direct computation and 5× faster than fast computation of Zernike moments using the q-recursive strategy. Thus, among all existing rotation-invariant feature extraction methods, polar harmonic transforms are the fastest.

  6. Distinguishability of generic quantum states

    NASA Astrophysics Data System (ADS)

    Puchała, Zbigniew; Pawela, Łukasz; Życzkowski, Karol

    2016-06-01

    Properties of random mixed states of dimension N distributed uniformly with respect to the Hilbert-Schmidt measure are investigated. We show that for large N , due to the concentration of measure, the trace distance between two random states tends to a fixed number D ˜=1 /4 +1 /π , which yields the Helstrom bound on their distinguishability. To arrive at this result, we apply free random calculus and derive the symmetrized Marchenko-Pastur distribution, which is shown to describe numerical data for the model of coupled quantum kicked tops. Asymptotic value for the root fidelity between two random states, √{F }=3/4 , can serve as a universal reference value for further theoretical and experimental studies. Analogous results for quantum relative entropy and Chernoff quantity provide other bounds on the distinguishablity of both states in a multiple measurement setup due to the quantum Sanov theorem. We study also mean entropy of coherence of random pure and mixed states and entanglement of a generic mixed state of a bipartite system.

  7. Generic OPC UA Server Framework

    NASA Astrophysics Data System (ADS)

    Nikiel, Piotr P.; Farnham, Benjamin; Filimonov, Viatcheslav; Schlenker, Stefan

    2015-12-01

    This paper describes a new approach for generic design and efficient development of OPC UA servers. Development starts with creation of a design file, in XML format, describing an object-oriented information model of the target system or device. Using this model, the framework generates an executable OPC UA server application, which exposes the per-design OPC UA address space, without the developer writing a single line of code. Furthermore, the framework generates skeleton code into which the developer adds the necessary logic for integration to the target system or device. This approach allows both developers unfamiliar with the OPC UA standard, and advanced OPC UA developers, to create servers for the systems they are experts in while greatly reducing design and development effort as compared to developments based purely on COTS OPC UA toolkits. Higher level software may further benefit from the explicit OPC UA server model by using the XML design description as the basis for generating client connectivity configuration and server data representation. Moreover, having the XML design description at hand facilitates automatic generation of validation tools. In this contribution, the concept and implementation of this framework is detailed along with examples of actual production-level usage in the detector control system of the ATLAS experiment at CERN and beyond.

  8. Generic theory for channel sinuosity

    PubMed Central

    Lazarus, Eli D.; Constantine, José Antonio

    2013-01-01

    Sinuous patterns traced by fluid flows are a ubiquitous feature of physical landscapes on Earth, Mars, the volcanic floodplains of the Moon and Venus, and other planetary bodies. Typically discussed as a consequence of migration processes in meandering rivers, sinuosity is also expressed in channel types that show little or no indication of meandering. Sinuosity is sometimes described as “inherited” from a preexisting morphology, which still does not explain where the inherited sinuosity came from. For a phenomenon so universal as sinuosity, existing models of channelized flows do not explain the occurrence of sinuosity in the full variety of settings in which it manifests, or how sinuosity may originate. Here we present a generic theory for sinuous flow patterns in landscapes. Using observations from nature and a numerical model of flow routing, we propose that flow resistance (representing landscape roughness attributable to topography or vegetation density) relative to surface slope exerts a fundamental control on channel sinuosity that is effectively independent of internal flow dynamics. Resistance-dominated surfaces produce channels with higher sinuosity than those of slope-dominated surfaces because increased resistance impedes downslope flow. Not limited to rivers, the hypothesis we explore pertains to sinuosity as a geomorphic pattern. The explanation we propose is inclusive enough to account for a wide variety of sinuous channel types in nature, and can serve as an analytical tool for determining the sinuosity a landscape might support. PMID:23610390

  9. Generic physical protection logic trees

    SciTech Connect

    Paulus, W.K.

    1981-10-01

    Generic physical protection logic trees, designed for application to nuclear facilities and materials, are presented together with a method of qualitative evaluation of the trees for design and analysis of physical protection systems. One or more defense zones are defined where adversaries interact with the physical protection system. Logic trees that are needed to describe the possible scenarios within a defense zone are selected. Elements of a postulated or existing physical protection system are tagged to the primary events of the logic tree. The likelihood of adversary success in overcoming these elements is evaluated on a binary, yes/no basis. The effect of these evaluations is propagated through the logic of each tree to determine whether the adversary is likely to accomplish the end event of the tree. The physical protection system must be highly likely to overcome the adversary before he accomplishes his objective. The evaluation must be conducted for all significant states of the site. Deficiencies uncovered become inputs to redesign and further analysis, closing the loop on the design/analysis cycle.

  10. Perception of Generic Prescription Drugs and Utilization of Generic Drug Discount Programs

    PubMed Central

    Omojasola, Anthony; Hernandez, Mike; Sansgiry, Sujit; Jones, Lovell

    2012-01-01

    Objective Our study aimed to assess patient’s perceptions of generic drugs and utilization of generic drug discount programs. Design, Setting and Participants A survey was administered to adult participants at community health centers and community-based organizations in Houston, Texas, USA (n=525). Main Outcome Measures Multivariate logistic regression was used to quantify the strength of association between generic drug perception and utilization of generic drug discount programs. Results Respondents who agreed that “Generic prescription drugs are as effective as brand name prescription drugs,” were 3 times as likely to utilize generic drug discount programs (AOR: 3.0, 95% CI: 1.8–4.8, P<.001). Compared to non-Hispanic Whites, African Americans (OR: 10.2; 95% CI: 1.4–76.4) and Hispanics (OR: 10.3; 95% CI: 1.3–79.4) were 10 times as likely to agree that generic drugs have more side effects than brand name drugs. Conclusion Race/ethnicity had no impact in utilization of generic drug discount programs, despite racial disparities in perception toward generic drugs’ side effects and generic drugs being inferior to brand name drugs. PMID:23140080

  11. Generic substitution, financial interests, and imperfect agency.

    PubMed

    Rischatsch, Maurus; Trottmann, Maria; Zweifel, Peter

    2013-06-01

    Policy makers around the world seek to encourage generic substitution. In this paper, the importance of prescribing physicians' imperfect agency is tested using the fact that some Swiss jurisdictions allow physicians to dispense drugs on their own account (physician dispensing, PD) while others disallow it. We estimate a model of physician drug choice with the help of drug claim data, finding a significant positive association between PD and the use of generics. While this points to imperfect agency, generics are prescribed more often to patients with high copayments or low incomes.

  12. Generic tacrolimus in solid organ transplantation.

    PubMed

    Taube, D; Jones, G; O'Beirne, J; Wennberg, L; Connor, A; Rasmussen, A; Backman, L

    2014-05-01

    The availability of a wide range of immunosuppressive therapies has revolutionized the management of patients who have undergone solid organ transplantation (SOT). However, the cost of immunosuppressive drugs remains high. This situation has led to the development of generic equivalents, which are similar in quality, safety, and efficacy to their approved innovator drugs. There are data available for three generic brands, tacrolimus (Intas), tacrolimus (PharOS), and tacrolimus (Sandoz). Bioequivalence has been demonstrated for generic tacrolimus (Sandoz) within a narrow therapeutic range to its innovator tacrolimus drug (Prograf) in both healthy volunteers and kidney transplant patients. Clinical experience with this generic tacrolimus formulation has also been established in both de novo and conversion patients who have undergone kidney and liver transplantation, as well as in conversion of other SOT patients, including lung and heart recipients.

  13. [Generic competences in medical undergraduate education].

    PubMed

    Kääpä, Pekka; Hoffren, Johanna

    2010-01-01

    In medical practice physicians need both vocational and generic competences. The importance of generic competences In medical undergraduate curriculum is often poorly appreciated. We assessed by questionnaires the opinions of medical students of the importance of generic competences in medical practice and of their anticipated development during undergraduate medical education in the University of Turku. Students thought that application of medical knowledge in practice, information acquisition, independent working and problem solving skills are important in medical practice and are also well-handled in undergraduate education. On the other hand, students felt that competences, like coping at work, tolerance of uncertainty and organizing skills are often needed in medical profession, but are insufficiently considered in basic education. The balance between importance in medical practice and educational development of generic competences should be more explicitly considered in undergraduate medical teaching.

  14. Are generic drugs really inferior medicines?

    PubMed

    Moore, N; Berdaï, D; Bégaud, B

    2010-09-01

    In this issue Gagne et al. report an elegant case-crossover study of seizures in patients on antiepileptic drugs. They found that a dispensation episode approximately triples the risk of having a seizure within 21 days, but the risk is not statistically different whether the dispensation was of the same brand-name or generic drug as previously used or a switch from brand-name to a generic or from a generic to a brand name. The cause of the seizure might be a delay in taking medication or late redispensation, among others, but apparently the nature of the product dispensed is not relevant in this study; this may alleviate some of the concerns about generic drugs and epilepsy.

  15. [Economy of generic drugs in Latin America].

    PubMed

    Tobar, Federico

    2008-01-01

    In terms of economics, implementing generic drug policy is nothing other than consolidating (or even, creating) drug markets that set competitive prices, the result of which favors public access to essential drugs. This article approaches the topic of generic drugs from the economic perspective by examining various regulatory models in order to evaluate and leverage generic drug policy implementation options as a mechanism for battling some of the markets' specific weaknesses. The conclusion is that there is no single unequivocal method for promoting the use of generic drugs, and that the most favorable way to integrate markets may be through a broad combination of alternatives. These alternatives are grouped and analyzed according to the market issues or challenges that must be overcome. Several options are then identified based on the degree of market consolidation to be obtained.

  16. Hydrodynamic design of generic pump components

    NASA Technical Reports Server (NTRS)

    Eastland, A. H. J.; Dodson, H. C.

    1991-01-01

    Inducer and impellar base geometries were defined for a fuel pump for a generic generator cycle. Blade surface data and inlet flowfield definition are available in sufficient detail to allow computational fluid dynamic analysis of the two components.

  17. [Medical mistakes due to generic substitution].

    PubMed

    Rölfing, Jan Hendrik Duedal

    2012-08-27

    Generic substitution is a major cause of medical mistakes in the general population. Danish legislation obligates pharmacies to substitute prescribed medicine with the cheapest equivalent formulation, despite variations in product name, packaging, shape and colour. Consequently, medical mistakes occur. Scientific evidence on the consequences of generic substitution is sparse. Call upon fellow health workers to report medical mistakes to the national entities and scientific peers, in order to increase awareness and scientific evidence about the problem.

  18. [Generic drugs in the treatment of epilepsy].

    PubMed

    González de Dios, J; Ochoa-Sangrador, C; Sempere, A P

    We discuss some controversial aspects with prescription of generic drugs (GD) and the problems concerning bioequivalence, mainly in the case of drugs with non-linear pharmacokinetics and/or narrow therapeutic rank, like the antiepileptic drugs (AED). There is considerable debate about GD in the treatment of epilepsy, with clearly advantages (cost saving) and disadvantages (loss of seizure control or drug toxicity) in prescribing generics anticonvulsants. We make a systematic review of the literature in primary (PubMed) and secondary (Tripdatabase and Cochrane Library) bibliographic databases in relation to GD and AED. The main information is about classical AED (phenytoin, carbamazepine, valproic acid and primidone) and we don't found studies in this area about the new AED. The level of evidence is, generally, weak, based on case-series and expert opinion without explicit critical appraisal (except in phenytoin with level of evidence moderate, based on some analytical studies). In Spain, at this moment, there are only two generic AED, one-classical (carbamazepine) and one-new (gabapentin). The American Academy of Neurology and Epilepsy Foundation maintains that the individual and physician should be notified and give their consent before a switch in antiepileptic medications is made, whether it involves generic substitution for brand name products, or generic to generic substitutions.

  19. The diffusion of generics after patent expiry in Germany.

    PubMed

    Fischer, Katharina Elisabeth; Stargardt, Tom

    2016-11-01

    To identify the influences on the diffusion of generics after patent expiry, we analyzed 65 generic entries using prescription data of a large German sickness fund between 2007 and 2012 in a sales model. According to theory, several elements are responsible for technology diffusion: (1) time reflecting the rate of adaption within the social system, (2) communication channels, and (3) the degree of incremental innovation, e.g., the modifications of existing active ingredient's strength. We investigated diffusion in two ways: (1) generic market share (percentage of generic prescriptions of all prescriptions of a substance) and, (2) generic sales quantity (number of units sold) over time. We specified mixed regression models. Generic diffusion takes considerable time. An average generic market share of about 75 % was achieved not until 48 months. There was a positive effect of time since generic entry on generic market share (p < 0.001) and sales (p < 0.001). Variables describing the communication channels and the degree of innovation influenced generic market share (mostly p < 0.001), but not generic sales quantity. Market structure, e.g., the number of generic manufacturers (p < 0.001) and prices influenced both generic market share and sales. Imperfections in generic uptake through informational cascades seem to be largely present. Third-party payers could enhance means to promote generic diffusion to amplify savings through generic entry.

  20. 42 CFR 447.506 - Authorized generic drugs.

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... 42 Public Health 4 2014-10-01 2014-10-01 false Authorized generic drugs. 447.506 Section 447.506... (CONTINUED) MEDICAL ASSISTANCE PROGRAMS PAYMENTS FOR SERVICES Payment for Drugs § 447.506 Authorized generic drugs. (a) Authorized generic drug defined. For the purposes of this subpart, an authorized generic...

  1. 42 CFR 447.506 - Authorized generic drugs.

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... 42 Public Health 4 2013-10-01 2013-10-01 false Authorized generic drugs. 447.506 Section 447.506... (CONTINUED) MEDICAL ASSISTANCE PROGRAMS PAYMENTS FOR SERVICES Payment for Drugs § 447.506 Authorized generic drugs. (a) Authorized generic drug defined. For the purposes of this subpart, an authorized generic...

  2. 42 CFR 447.506 - Authorized generic drugs.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 42 Public Health 4 2010-10-01 2010-10-01 false Authorized generic drugs. 447.506 Section 447.506... (CONTINUED) MEDICAL ASSISTANCE PROGRAMS PAYMENTS FOR SERVICES Payment for Drugs § 447.506 Authorized generic drugs. (a) Authorized generic drug defined. For the purposes of this subpart, an authorized generic...

  3. 42 CFR 447.506 - Authorized generic drugs.

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... 42 Public Health 4 2012-10-01 2012-10-01 false Authorized generic drugs. 447.506 Section 447.506... (CONTINUED) MEDICAL ASSISTANCE PROGRAMS PAYMENTS FOR SERVICES Payment for Drugs § 447.506 Authorized generic drugs. (a) Authorized generic drug defined. For the purposes of this subpart, an authorized generic...

  4. 42 CFR 447.506 - Authorized generic drugs.

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... 42 Public Health 4 2011-10-01 2011-10-01 false Authorized generic drugs. 447.506 Section 447.506... (CONTINUED) MEDICAL ASSISTANCE PROGRAMS PAYMENTS FOR SERVICES Payment for Drugs § 447.506 Authorized generic drugs. (a) Authorized generic drug defined. For the purposes of this subpart, an authorized generic...

  5. A Generic Expert Scheduling System Architecture and Toolkit: GUESS (Generically Used Expert Scheduling System)

    NASA Technical Reports Server (NTRS)

    Liebowitz, Jay; Krishnamurthy, Vijaya; Rodens, Ira; Houston, Chapman; Liebowitz, Alisa; Baek, Seung; Radko, Joe; Zeide, Janet

    1996-01-01

    Scheduling has become an increasingly important element in today's society and workplace. Within the NASA environment, scheduling is one of the most frequently performed and challenging functions. Towards meeting NASA's scheduling needs, a research version of a generic expert scheduling system architecture and toolkit has been developed. This final report describes the development and testing of GUESS (Generically Used Expert Scheduling System).

  6. Effects of generic versus non-generic feedback on motor learning in children.

    PubMed

    Chiviacowsky, Suzete; Drews, Ricardo

    2014-01-01

    Non-generic feedback refers to a specific event and implies that performance is malleable, while generic feedback implies that task performance reflects an inherent ability. The present study examined the influences of generic versus non-generic feedback on motor performance and learning in 10-year-old children. In the first experiment, using soccer ball kicking at a target as a task, providing participants with generic feedback resulted in worse performance than providing non-generic feedback, after both groups received negative feedback. The second experiment measured more permanent effects. Results of a retention test, performed one day after practicing a throwing task, showed that participants who received non-generic feedback during practice outperformed the generic feedback group, after receiving a negative feedback statement. The findings demonstrate the importance of the wording of feedback. Even though different positive feedback statements may not have an immediate influence on performance, they can affect performance, and presumably individuals' motivation, when performance is (purportedly) poor. Feedback implying that performance is malleable, rather than due to an inherent ability, seems to have the potential to inoculate learners against setbacks--a situation frequently encountered in the context of motor performance and learning.

  7. Using Masculine Generics: Does Generic He' Increase Male Bias in the User's Imagery?

    ERIC Educational Resources Information Center

    Hamilton, Mykol C.

    1988-01-01

    Studies the effect of the use of the male generic on imagery. Finds that male bias is higher in the masculine generic condition than in the unbiased condition, and that male subjects are more male-biased than female subjects. Discusses findings in terms of linguistic relativity, prototypicality, and activation of multiple meanings. (FMW)

  8. Generic perturbations of linear integrable Hamiltonian systems

    NASA Astrophysics Data System (ADS)

    Bounemoura, Abed

    2016-11-01

    In this paper, we investigate perturbations of linear integrable Hamiltonian systems, with the aim of establishing results in the spirit of the KAM theorem (preservation of invariant tori), the Nekhoroshev theorem (stability of the action variables for a finite but long interval of time) and Arnold diffusion (instability of the action variables). Whether the frequency of the integrable system is resonant or not, it is known that the KAM theorem does not hold true for all perturbations; when the frequency is resonant, it is the Nekhoroshev theorem that does not hold true for all perturbations. Our first result deals with the resonant case: we prove a result of instability for a generic perturbation, which implies that the KAM and the Nekhoroshev theorem do not hold true even for a generic perturbation. The case where the frequency is nonresonant is more subtle. Our second result shows that for a generic perturbation the KAM theorem holds true. Concerning the Nekhrosohev theorem, it is known that one has stability over an exponentially long (with respect to some function of ɛ -1) interval of time and that this cannot be improved for all perturbations. Our third result shows that for a generic perturbation one has stability for a doubly exponentially long interval of time. The only question left unanswered is whether one has instability for a generic perturbation (necessarily after this very long interval of time).

  9. [Analysis of generic drug supply in France].

    PubMed

    Taboulet, F; Haramburu, F; Latry, Ph

    2003-09-01

    The list of generic medicines (LGM), published since 1997 by the Agence Française de Sécurité Sanitaire des Produits de Santé (AFFSSaPS), the French Medicine Agency, concerns a special part of the medicines reimbursed by the National Health Insurance (Social Security). The objectives of the present study were: i) to describe the components of this list, based on pharmaceutical, economical and therapeutic characteristics, ii) to study differences between generic and reference products (formulations, excipients, prices, etc.), iii) to analyze information on excipients provided to health care professionals. The 21st version of the LGM (April 2001) was used. Therapeutic value was retrieved from the 2001 AFSSaPS report on the therapeutic value of 4490 reimbursed medicines. Information on excipients in the LGM and the Vidal dictionary (reference prescription book in France) was compared. The products included in the LGM represent 20% of all reimbursed medicines. The mean price differences between generics and their reference products vary between 30 and 50% for more than two thirds of the generic groups. The therapeutic value of the products of the LGM was judged important in 71% of cases (vs 63% for the 4409 assessed medicines) and insufficient in 13% of cases (vs 19%). Information on excipients is often missing and sometimes erroneous. Although the LGM is regularly revised and thus the generic market in perpetual change, the 2001 cross description of this pharmaceutical market provides much informations and raises some concern.

  10. Some drugs more equal than others: pseudo-generics and commercial practice.

    PubMed

    Probyn, Andrew J

    2004-11-08

    This article analyses the impact of the Department of Health and Ageing's brand price premium policy for some products listed on the Pharmaceutical Benefits Scheme. The policy, introduced in 1990, allows pharmaceutical companies to charge patients an out-of-pocket expense for post-patent brands of pharmaceuticals. One of the policy's intended goals was to increase consumer awareness of price differentials between competing brands, with a view to encouraging greater use of cheaper generic products. More than fourteen years since its introduction, it is debatable whether the policy has achieved this aim. This article looks at how the brand price premium policy can be exploited by global pharmaceutical giants to entrench big-name brands in the Australian pharmaceutical market and, in some cases, prevent 'true' competition from generic pharmaceuticals. This is being done through the establishment of 'pseudo-generics' that are sourced from the same factory floor as the original product.

  11. Generic Rigidity for Circle Diffeomorphisms with Breaks

    NASA Astrophysics Data System (ADS)

    Kocić, Saša

    2016-06-01

    We prove that {C^r}-smooth ({r > 2}) circle diffeomorphisms with a break, i.e., circle diffeomorphisms with a single singular point where the derivative has a jump discontinuity, are generically, i.e., for almost all irrational rotation numbers, not {C^{1+\\varepsilon}}-rigid, for any {\\varepsilon > 0}. This result complements our recent proof, joint with Khanin (Geom Funct Anal 24:2002-2028, 2014), that such maps are generically {C^1}-rigid. It stands in remarkable contrast to the result of Yoccoz (Ann Sci Ec Norm Sup 17:333-361, 1984) that {C^r}-smooth circle diffeomorphisms are generically {C^{r-1-κ}}-rigid, for any {κ > 0}.

  12. The formal verification of generic interpreters

    NASA Technical Reports Server (NTRS)

    Windley, P.; Levitt, K.; Cohen, G. C.

    1991-01-01

    The task assignment 3 of the design and validation of digital flight control systems suitable for fly-by-wire applications is studied. Task 3 is associated with formal verification of embedded systems. In particular, results are presented that provide a methodological approach to microprocessor verification. A hierarchical decomposition strategy for specifying microprocessors is also presented. A theory of generic interpreters is presented that can be used to model microprocessor behavior. The generic interpreter theory abstracts away the details of instruction functionality, leaving a general model of what an interpreter does.

  13. Generic dynamic scaling in kinetic roughening

    PubMed

    Ramasco; Lopez; Rodriguez

    2000-03-06

    We study the dynamic scaling hypothesis in invariant surface growth. We show that the existence of power-law scaling of the correlation functions (scale invariance) does not determine a unique dynamic scaling form of the correlation functions, which leads to the different anomalous forms of scaling recently observed in growth models. We derive all the existing forms of anomalous dynamic scaling from a new generic scaling ansatz. The different scaling forms are subclasses of this generic scaling ansatz associated with bounds on the roughness exponent values. The existence of a new class of anomalous dynamic scaling is predicted and compared with simulations.

  14. Generic programming in POOMA and PETE

    SciTech Connect

    Crotinger, J.A.; Cummings, J.C.; Haney, S.W.; Humphrey, W.F.; Karmesin, S.R.; Reynders, J.V.; Smith, S.A.; Williams, T.J.

    1998-12-31

    POOMA is a C++ framework for developing portable scientific applications for serial and parallel computers using high-level physical abstractions. PETE is the expression template library used by POOMA. This paper discusses generic programming techniques that are used to achieve flexibility and high performance in POOMA and PETE. POOMA uses an engine class that factors the data representation out of its array classes. PETE`s expression templates are used to build up and operate efficiently on expressions. PETE itself uses generic techniques to adapt to a variety of client-class interfaces, and to provide a powerful and flexible compile-time expression-tree traversal mechanism.

  15. Space Generic Open Avionics Architecture (SGOAA): Overview

    NASA Technical Reports Server (NTRS)

    Wray, Richard B.; Stovall, John R.

    1992-01-01

    A space generic open avionics architecture created for NASA is described. It will serve as the basis for entities in spacecraft core avionics, capable of being tailored by NASA for future space program avionics ranging from small vehicles such as Moon ascent/descent vehicles to large ones such as Mars transfer vehicles or orbiting stations. The standard consists of: (1) a system architecture; (2) a generic processing hardware architecture; (3) a six class architecture interface model; (4) a system services functional subsystem architectural model; and (5) an operations control functional subsystem architectural model.

  16. Generic Entry, Reformulations, and Promotion of SSRIs

    PubMed Central

    Donohue, Julie M.; Koss, Catherine; Berndt, Ernst R.; Frank, Richard G.

    2009-01-01

    Background Previous research has shown that a manufacturer’s promotional strategy for a brand-name drug is typically affected by generic entry. However, little is known about how newer strategies to extend patent life, including product reformulation introduction or obtaining approval to market for additional clinical indications, influence promotion. Objective To examine the relationship between promotional expenditures, generic entry, reformulation entry, and new indication approval. Study Design/Setting We used quarterly data on national product-level promotional spending (including expenditures for physician detailing and direct-to-consumer advertising (DTCA), and the retail value of free samples distributed in physician offices) for selective serotonin reuptake inhibitors (SSRIs) over the period 1997 through 2004. We estimated econometric models of detailing, DTCA, and total quarterly promotional expenditures as a function of the timing of generic entry, entry of new product formulations, and Food and Drug Administration (FDA) approval for new clinical indications for existing medications in the SSRI class. Main Outcome Measure Expenditures by pharmaceutical manufacturers for promotion of antidepressant medications. Results Over the period 1997–2004, there was considerable variation in the composition of promotional expenditures across the SSRIs. Promotional expenditures for the original brand molecule decreased dramatically when a reformulation of the molecule was introduced. Promotional spending (both total and detailing alone) for a specific molecule was generally lower after generic entry than before, although the effect of generic entry on promotional spending appears to be closely linked with the choice of product reformulation strategy pursued by the manufacturer. Detailing expenditures for Paxil were increased after the manufacturer received FDA approval to market the drug for generalized anxiety disorder (GAD), while the likelihood of DTCA outlays

  17. External validity of a generic safety climate scale for lone workers across different industries and companies.

    PubMed

    Lee, Jin; Huang, Yueng-hsiang; Robertson, Michelle M; Murphy, Lauren A; Garabet, Angela; Chang, Wen-Ruey

    2014-02-01

    The goal of this study was to examine the external validity of a 12-item generic safety climate scale for lone workers in order to evaluate the appropriateness of generalized use of the scale in the measurement of safety climate across various lone work settings. External validity evidence was established by investigating the measurement equivalence (ME) across different industries and companies. Confirmatory factor analysis (CFA)-based and item response theory (IRT)-based perspectives were adopted to examine the ME of the generic safety climate scale for lone workers across 11 companies from the trucking, electrical utility, and cable television industries. Fairly strong evidence of ME was observed for both organization- and group-level generic safety climate sub-scales. Although significant invariance was observed in the item intercepts across the different lone work settings, absolute model fit indices remained satisfactory in the most robust step of CFA-based ME testing. IRT-based ME testing identified only one differentially functioning item from the organization-level generic safety climate sub-scale, but its impact was minimal and strong ME was supported. The generic safety climate scale for lone workers reported good external validity and supported the presence of a common feature of safety climate among lone workers. The scale can be used as an effective safety evaluation tool in various lone work situations. Copyright © 2013 Elsevier Ltd. All rights reserved.

  18. Performance implications of Porter's generic strategies in Slovak hospitals.

    PubMed

    Hlavacka, S; Bacharova, L; Rusnakova, V; Wagner, R

    2001-01-01

    The aim of the study was to examine the use of Porter's generic strategies and their effect on performance in the context of the Slovak hospital industry. Using mail survey the study first identified the natural taxonomy of four strategic types of Slovak hospitals, based on their use of Porter's generic strategies in pure form and in combination. Next the study examined whether different strategic types were associated with different levels of organisational performance, while controlling for such variables as size and location, which have been argued to influence the hospital performance. The findings indicate that hospitals which follow a "stuck-in-the-middle" strategy, in general, have superior performance on all used performance measures, while hospitals that place only low emphasis on cost leadership, differentiation and focus, labelled "wait and see" in this study, perform the poorest. The study concludes that the research provided body of knowledge relevant for the Slovak hospital industry, that may be used by hospital managers in the strategy formulation process as well as by the researches in exploring the influence of different contingencies on hospitals' strategic orientation.

  19. Differential geometry techniques for sets of nonlinear partial differential equations

    NASA Technical Reports Server (NTRS)

    Estabrook, Frank B.

    1990-01-01

    An attempt is made to show that the Cartan theory of partial differential equations can be a useful technique for applied mathematics. Techniques for finding consistent subfamilies of solutions that are generically rich and well-posed and for introducing potentials or other usefully consistent auxiliary fields are introduced. An extended sample calculation involving the Korteweg-de Vries equation is given.

  20. Differential geometry techniques for sets of nonlinear partial differential equations

    NASA Technical Reports Server (NTRS)

    Estabrook, Frank B.

    1990-01-01

    An attempt is made to show that the Cartan theory of partial differential equations can be a useful technique for applied mathematics. Techniques for finding consistent subfamilies of solutions that are generically rich and well-posed and for introducing potentials or other usefully consistent auxiliary fields are introduced. An extended sample calculation involving the Korteweg-de Vries equation is given.

  1. Should Physicians be Encouraged to use Generic Names and to Prescribe Generic Drugs?

    PubMed

    Riaz, Haris; Krasuski, Richard A

    2016-06-01

    While using the brand names seems like a trivial issue at the outset, using these names is inherently problematic. Cardiovascular drugs remain the most commonly prescribed drugs by the physicians. The junior doctors are likely to introject practices of their seniors and consequently to reciprocate from the experiences learnt from their preceptors. Using the generic names may be one way to facilitate prescription of the generic drugs who have a better cost profile and similar efficacy than the more expensive branded drugs. In this editorial, we have outlined several arguments to suggest the importance of using the generic names in academic discussions and clinical documentation. Copyright © 2016 Elsevier Inc. All rights reserved.

  2. The importance of being first: evidence from Canadian generic pharmaceuticals.

    PubMed

    Hollis, Aidan

    2002-12-01

    This paper uses pooled cross-section data on Canadian ethical drug sales to examine the effect of entry timing on sales of generic drugs. The data is for all drugs for which the first generic competitor entered during the years 1994-1997. It is found that the first generic entrant has a lasting competitive advantage: being first into the market appears to lead to an increase of around 30% in market share (among generics) over a period of at least 4 years. This finding has considerable implications for the current policy of allowing brandname drug companies to issue pseudo-generic equivalents as a preemptive strike against true generic competitors.

  3. European Generic Medicines Association (EGA)--16th Annual Conference.

    PubMed

    Kennedy, Bob

    2010-08-01

    The 16th Annual Conference of the European Generic Medicines Association (EGA), held in Rome, included topics covering new developments and challenges in the generic medicines industry in Europe. This conference report highlights selected presentations on developments for generics in the Italian healthcare system, a summary of the EGA pharmaceutical sector inquiry on the delayed market entry of generics, developments and trends in the European generics market, the evolution and growth of the global generics industry, and a CEO perspective on the challenges facing the industry.

  4. Comparison of Generic Accelerated Nursing Students

    ERIC Educational Resources Information Center

    Kaddorura, Mahmood; Williams, Collette

    2012-01-01

    Case study pedagogy is a teaching strategy in which teachers hope to help students develop and use critical thinking (CT) abilities. This study compared CT skills of 75 second year generic accelerated baccalaureate nursing students during their Fundamentals of Nursing course before and after being educated using case study pedagogical method.…

  5. Focussing on Generic Skills in Training Packages.

    ERIC Educational Resources Information Center

    Dawe, Susan

    A study assessed whether training packages gave sufficient focus to attainment of generic skills and examined approaches that can be used to enhance the delivery of these skills so students are better prepared for the new demands of the workplace. A literature review and consultations with stakeholders provided information on development of the…

  6. Baldrige Theory into Practice: A Generic Model

    ERIC Educational Resources Information Center

    Arif, Mohammed

    2007-01-01

    Purpose: The education system globally has moved from a push-based or producer-centric system to a pull-based or customer centric system. Malcolm Baldrige Quality Award (MBQA) model happens to be one of the latest additions to the pull based models. The purpose of this paper is to develop a generic framework for MBQA that can be used by…

  7. Using a Generic Invasion Game for Assessment

    ERIC Educational Resources Information Center

    Harvey, Stephen

    2007-01-01

    Tactical approaches to teaching are, arguably, still under-utilized in physical education settings, and this may be due to the lack of pertinent assessment materials. The purpose of this article is to present a generic invasion-game unit and to link it to a variety of assessment materials using three tactical components from the Game Performance…

  8. Generic Certificates. Agricultural Economic Report Number 594.

    ERIC Educational Resources Information Center

    Glauber, Joseph W.

    The Food Security Act of 1985 authorizes the U.S. Department of Agriculture to issue generic certificates in lieu of cash payments due to program participants and merchants of agricultural products under provisions of several programs. The certificates may be used to acquire stocks held as collateral on government loans or owned by the Commodity…

  9. A Generic Biokinetic Model for C-14

    SciTech Connect

    Manger, Ryan P

    2011-01-01

    The generic biokinetic model currently recommended by the International Commission on Radiological Protection (ICRP) for the treatment of systemic radiocarbon assumes uniform distribution of activity in tissues and a biological half-time of 40 d. This model is intended to generate cautiously high estimates of dose per unit intake of C-14 and, in fact, generally predicts a much higher effective dose than systemic models that have been developed on the basis of biokinetic studies of specific carbon compounds. The simplistic model formulation precludes its application as a bioassay model or adjustment to fit case-specific bioassay data. This paper proposes a new generic biokinetic model for systemic radiocarbon that is less conservative than the current ICRP model but maintains sufficient conservatism to overestimate the effective dose coefficients generated by most radiocarbon-compound-specific models. The proposed model includes two systemic pools with different biological half-times representing an initial systemic form of absorbed radiocarbon, a submodel describing the behaviour of labelled carbon dioxide produced in vivo, and three excretion pathways: breath, urine and faeces. Generic excretion rates along each path are based on multi-phase excretion curves observed in experimental studies of radiocarbons. The generic model structure is designed so that the user may adjust the level of dosimetric conservatism to fit the information at hand and may adjust parameter values for consistency with subject-specific or site-specific bioassay data.

  10. Genericity and Aspect in L2 Acquisition

    ERIC Educational Resources Information Center

    Slabakova, Roumyana; Montrul, Silvina

    2003-01-01

    In this experimental study, we focus on the following semantic universal: if a habitual clause reading, then generic pronominal subject; if an episodic clause reading, then specific pronominal subject. We argue that although this set of two conditionals is a universal property of all natural languages, English-speaking second-language (L2)…

  11. Comparison of Generic Accelerated Nursing Students

    ERIC Educational Resources Information Center

    Kaddorura, Mahmood; Williams, Collette

    2012-01-01

    Case study pedagogy is a teaching strategy in which teachers hope to help students develop and use critical thinking (CT) abilities. This study compared CT skills of 75 second year generic accelerated baccalaureate nursing students during their Fundamentals of Nursing course before and after being educated using case study pedagogical method.…

  12. A Critique of Generic Learning Outcomes

    ERIC Educational Resources Information Center

    Brown, Stephen

    2007-01-01

    Generic Learning Outcomes (GLOs) are intended to enable cultural heritage organisations to be aware of the effectiveness of the environment for learning that they provide and to provide quantitative evidence of the impact of museums libraries and archives on learning, nationally. This paper presents a logical critique of their strengths and…

  13. 40 CFR 721.3062 - Haloarylalkylketoester (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... SUBSTANCES CONTROL ACT SIGNIFICANT NEW USES OF CHEMICAL SUBSTANCES Significant New Uses for Specific Chemical Substances § 721.3062 Haloarylalkylketoester (generic). Link to an amendment published at 79 FR 34637, June 18, 2014. (a) Chemical substance and significant new uses subject to reporting. (1) The...

  14. Baldrige Theory into Practice: A Generic Model

    ERIC Educational Resources Information Center

    Arif, Mohammed

    2007-01-01

    Purpose: The education system globally has moved from a push-based or producer-centric system to a pull-based or customer centric system. Malcolm Baldrige Quality Award (MBQA) model happens to be one of the latest additions to the pull based models. The purpose of this paper is to develop a generic framework for MBQA that can be used by…

  15. Focussing on Generic Skills in Training Packages.

    ERIC Educational Resources Information Center

    Dawe, Susan

    A study assessed whether training packages gave sufficient focus to attainment of generic skills and examined approaches that can be used to enhance the delivery of these skills so students are better prepared for the new demands of the workplace. A literature review and consultations with stakeholders provided information on development of the…

  16. The Portuguese generic medicines market: a policy analysis.

    PubMed

    Simoens, Steven

    2009-04-01

    This study aims to conduct a descriptive analysis of the policy environment surrounding the generic medicines retail market in Portugal. The policy analysis focuses on supply-side measures (i.e. market access, pricing, reference-pricing and reimbursement of generic medicines) and demand-side measures (i.e. incentives for physicians to prescribe, for pharmacists to dispense and for patients to use generic medicines). The policy analysis was based on an international literature review. Also, a simulation exercise was carried out to compute potential savings from substituting generic for originator medicines in Portugal using IMS Health data. Portugal has developed a successful generic medicines market by increasing reimbursement of generic medicines (until October 2005), by introducing a reference-pricing system, by encouraging physicians to prescribe by international non-proprietary name (INN), and by allowing generic substitution by pharmacists. However, the development of the generic medicines market has been hindered by the existence of copies, pricing regulation, certain features of the reference-pricing system, weak incentives for physicians to prescribe generic medicines and a financial disincentive for pharmacists to dispense generic medicines. Increased generic substitution would be expected to reduce public expenditure on originator medicines by 45%. The development of the Portuguese generic medicines market has mainly been fuelled by supply-side measures. To support the further expansion of the market, policy makers need to strengthen demand-side measures inciting physicians to prescribe, pharmacists to dispense and patients to use generic medicines.

  17. Pharmacists' experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin.

    PubMed

    Olsson, Erika; Kälvemark Sporrong, Sofia

    2012-12-01

    Generic drug substitution reduces costs for medicines, but the downsides include unintentional double medication, confusion and anxiety among patients. Information from pharmacists affects patients' experiences of substitution with generic drugs. The aim of this study was to explore experiences and attitudes to generic substitution among Swedish community pharmacists. An interview guide was developed. Semi-structured interviews with community pharmacists were conducted and transcribed verbatim. Analysis was inductive; extracts from the transcripts were compared and combined to form themes and subcategories. Pharmacists from a heterogeneous convenience sample of pharmacies were interviewed until data saturation had been achieved. Sixteen pharmacists were interviewed. Three main themes and twelve subcategories were identified, with the main themes being the role of the pharmacist, pharmacists' concerns regarding patients, and the generic drug. Pharmacists found it positive that generic substitution decreases the costs for pharmaceuticals but also emphasized that the switch can confuse and worry patients, which could result in less benefit from treatment. Respondents claimed that generic substitution has changed the focus in the pharmacist-patient meeting towards economics and regulations. According to the interviewed pharmacists generic substitution is not primarily an issue of generic versus brand-name products, but concerns above all the challenges that the switch implies for patients and pharmacists. To prevent known confusion and concerns among patients it is important that community pharmacists acquire the necessary tools and knowledge to manage this situation; pharmacists themselves as well as pharmacy owners and authorities share responsibility for this. © 2012 The Authors. IJPP © 2012 Royal Pharmaceutical Society.

  18. Prescribing generic drugs using a generic name: Are we teaching it right?

    PubMed

    Kamath, Ashwin

    2016-01-01

    The Indian Medical Council (Professional conduct, Etiquette and Ethics) Regulations, 2002, state that "Every physician should, as far as possible, prescribe drugs with generic names and he/she shall ensure that there is a rational prescription and use of drugs.". Undergraduate medical students are introduced to drug nomenclature early on during their pharmacology course. They are told that generic name or, more appropriately, non-proprietary name (usually international non-proprietary name INN), is to be used while writing prescriptions.

  19. Psychiatrists' decision making between branded and generic drugs.

    PubMed

    Hamann, Johannes; Mendel, Rosmarie; Kissling, Werner; Leucht, Stefan

    2013-07-01

    To study psychiatrists' decision making between generic and branded antipsychotics or antidepressants a hypothetical decision scenario involving decisions between branded and generic drugs was presented to a sample of German psychiatrists. Factors influencing this decision were identified using a regression analysis. n=410 Psychiatrists participated in the survey. Psychiatrists were more likely to choose branded drugs when imagining choosing the drug for themselves (vs. recommending a drug to a patient). In addition, psychiatrists were more likely to choose generic antidepressants than generic antipsychotics. Additional predictors for choosing a generic drug were a higher share of outpatients, less negative attitudes toward generics and higher uncertainty tolerance. In conclusion, psychiatrists' decision making in choosing between branded or generic antidepressants or antipsychotics is to a large extent influenced by vague attitudes towards properties of generics and branded drugs as well as by "non-evidence based" factors such as uncertainty tolerance. Copyright © 2013. Published by Elsevier B.V.

  20. Requirements for generic antiepileptic medicines: a clinical perspective.

    PubMed

    Trinka, Eugen; Krämer, Günter; Graf, Martin

    2011-12-01

    Many antiepileptic drugs (AEDs) are now available as a generic product. This can potentially save the healthcare providers massive costs. Hence, governmental authorities have introduced rules and incentives for clinicians to switch from the original branded AED to a generic product. Clinicians and patients with epilepsy are reluctant to switch. The licensing of generic AEDs is based on the equation that bioavailability means therapeutic equivalence. However, from a clinical standpoint one has to consider several other relevant issues: (1) Do generic AEDs have the same efficacy, safety and quality? (2) Can generic AEDs be used as substitutions for brand AEDs? (3) Can generic products of AEDs be used interchangeably? (4) Does the generic AED manufacturer guarantee the long-term consistency of availability on the market? (4) Do generic AEDs reduce the costs, and--if so--are these costs worth any additional risk to patient's safety? This article reviews the clinical issues related to current bioequivalence, prescribability, and switchability of AEDs.

  1. Generic omeprazole delayed-release capsules: in vitro performance evaluations.

    PubMed

    Moore, Terry; Smith, Anjanette; Ye, Wei; Toler, Duckhee Y; Westenberger, Benjamin J; Lionberger, Robert; Raw, Andre; Yu, Lawrence; Buhse, Lucinda F

    2009-08-01

    After the patent on omeprazole delayed-release capsules expired, Food and Drug Administration (FDA) approved several generic omeprazole delayed-release capsule applications. FDA has received some complaints concerning a lack of therapeutic effect of the generic omeprazole delayed-release capsules. To investigate the quality of five different marketed generic omeprazole delayed-release capsules. The dissolution characteristics of these generic omeprazole delayed-release capsules were determined according to the United States Pharmacopeia (USP). Additional dissolution studies under simulated in vivo physiological conditions were also conducted to determine whether generic omeprazole capsules would perform similarly under these conditions. The experimental data show that all the generic omeprazole delayed-release capsules met the USP standards. The in vitro dissolution of generic drugs is similar to that of the brand omeprazole product. There is no scientific evidence to support the claims that the generic omeprazole delayed-release capsules perform differently from the brand omeprazole product in vitro.

  2. Generic penetration in the retail atypical antipsychotic market.

    PubMed

    Lenderts, Susan; Kalali, Amir H; Buckley, Peter

    2010-03-01

    In this article, we explore the penetration of generic atypical antipsychotics in the United States market before and after the availability of generic risperidone in July 2008. Analysis suggests that, overall, generic penetration into the atypical antipsychotic market has grown from approximately three percent in January 2008 to more than 25 percent in December 2009. Similar trends are uncovered when branded and generic prescriptions are analyzed by specialty.

  3. The Development of a Generic Pharmaceutical Training Institute.

    ERIC Educational Resources Information Center

    Lindeman, Lynn William; Boerner, Hank

    The manufacture of generic drugs is a growing industry, generally composed of small companies that are more dependent than brand-name companies on hiring entry-level workers. To provide standardized training for employees in the generic drug manufacturing field, the Generic Pharmaceutical Training Institute (GPTI) was established by a partnership…

  4. 40 CFR 721.10689 - Organo zinc salts (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Organo zinc salts (generic). 721.10689... Substances § 721.10689 Organo zinc salts (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as organo zinc salts (PMN P-13-225...

  5. 40 CFR 721.638 - Silyl amine, potassium salt (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Silyl amine, potassium salt (generic... Substances § 721.638 Silyl amine, potassium salt (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as silyl amine, potassium salt...

  6. 40 CFR 721.638 - Silyl amine, potassium salt (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Silyl amine, potassium salt (generic... Substances § 721.638 Silyl amine, potassium salt (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as silyl amine, potassium salt...

  7. 40 CFR 721.638 - Silyl amine, potassium salt (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Silyl amine, potassium salt (generic... Substances § 721.638 Silyl amine, potassium salt (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as silyl amine, potassium salt...

  8. 40 CFR 721.638 - Silyl amine, potassium salt (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Silyl amine, potassium salt (generic... Substances § 721.638 Silyl amine, potassium salt (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as silyl amine, potassium salt...

  9. 40 CFR 721.638 - Silyl amine, potassium salt (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Silyl amine, potassium salt (generic... Substances § 721.638 Silyl amine, potassium salt (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as silyl amine, potassium salt...

  10. Generic Skills in Vocational Education and Training: Research Readings

    ERIC Educational Resources Information Center

    Gibb, Jennifer, Ed.

    2004-01-01

    Possessing generic or employability skills is vital in the current labour market. The vocational education and training (VET) sector, like other education sectors, must ensure its clients gain and develop generic skills. This volume of readings summarises NCVER managed research into generic skills undertaken in 2001 and 2002. The work covers four…

  11. 40 CFR 721.8660 - Propionic acid methyl ester (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Propionic acid methyl ester (generic... Substances § 721.8660 Propionic acid methyl ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a propionic acid methyl ester...

  12. A developmental analysis of generic nouns in Southern Peruvian Quechua.

    PubMed

    Mannheim, Bruce; Gelman, Susan A; Escalante, Carmen; Huayhua, Margarita; Puma, Rosalía

    2010-01-01

    Generic noun phrases (e.g., "Cats like to drink milk") are a primary means by which adults express generalizations to children, yet they pose a challenging induction puzzle for learners. Although prior research has established that English speakers understand and produce generic noun phrases by preschool age, little is known regarding the cross-cultural generality of generic acquisition. Southern Peruvian Quechua provides a valuable comparison because, unlike English, it is a highly inflected language in which generics are marked by the absence rather than the presence of any linguistic markers. Moreover, Quechua is spoken in a cultural context that differs markedly from the highly educated, middle-class contexts within which earlier research on generics was conducted. We presented participants from 5 age groups (3-6, 7-9, 10-12, 14-35, and 36-90 years of age) with two tasks that examined the ability to distinguish generic from non-generic utterances. In Study 1, even the youngest children understood generics as applying broadly to a category (like "all") and distinct from indefinite reference ("some"). However, there was a developmental lag before children understood that generics, unlike "all", can include exceptions. Study 2 revealed that generic interpretations are more frequent for utterances that (a) lack specifying markers and (b) are animate. Altogether, generic interpretations are found among the youngest participants, and may be a default mode of quantification. These data demonstrate the cross-cultural importance of generic information in linguistic expression.

  13. 40 CFR 721.3110 - Polycarboxylic acid ester (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Polycarboxylic acid ester (generic... Substances § 721.3110 Polycarboxylic acid ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a polycarboxylic acid ester...

  14. 40 CFR 721.3110 - Polycarboxylic acid ester (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Polycarboxylic acid ester (generic... Substances § 721.3110 Polycarboxylic acid ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a polycarboxylic acid ester...

  15. 40 CFR 721.9973 - Zirconium dichlorides (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Zirconium dichlorides (generic). 721... Substances § 721.9973 Zirconium dichlorides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as zirconium dichlorides (PMNs...

  16. Genericization: A Theory of Semantic Broadening in the Marketplace.

    ERIC Educational Resources Information Center

    Clankie, Shawn M.

    2000-01-01

    Genericization theory developed as a response to claims from outside of linguistics that generic use in brand names (for example, using Kleenex as a generic noun for all facial tissues, or Xerox for all photocopiers) is the result of marketing factors or misuse by consumers. This paper examines the linguistic factors that create an environment…

  17. Drug patent expirations and the speed of generic entry.

    PubMed Central

    Bae, J P

    1997-01-01

    OBJECTIVE: Using recent data, to analyze the generic drug entry phenomenon to determine the factors that influence the speed and likelihood of generic drug entries. DATA SOURCES: Data for 81 drugs that have lost patent between 1987 and 1994. Patent and exclusive marketing rights expiration dates: Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalent Evaluations (1986-1989). Generic entry dates: FDA Drug and Device Product Approvals (Jan. 1987-Dec. 1994). Numbers of pending generic applications: FDA Office of Generic Drugs Quantitative Report-ANDAs and AADAs (Nov. 1990-Jan. 1993). Sales revenue: Pharmaceutical Data Services, Walsh-America. STUDY DESIGN: This study appropriately recognizes generic entry as a survival problem, and uses a proportional hazard method for analysis. PRINCIPAL FINDINGS: (1) There is a negative relationship between an innovative drug's sales revenue and the time to generic entry. (2) Entries of generics tend to be slower for drugs that have either very few or a very large number of competing brands in the marketplace. (3) The time to generic entry increased overall between 1987 and 1994. (4) Drugs that primarily treat chronic symptoms tend to enter faster than the types of drugs that primarily treat acute illnesses. CONCLUSIONS: The analysis shows that the generic industry is targeting large-revenue products and chronic drug markets. Entry of a generic drug is influenced by the existing branded substitutes in the marketplace. Surprisingly, the generic drug entry process has slowed despite many changes that would facilitate entry. PMID:9108806

  18. 40 CFR 721.1655 - Alkylbenzenesulfonic acid (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Alkylbenzenesulfonic acid (generic... Substances § 721.1655 Alkylbenzenesulfonic acid (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkylbenzenesulfonic acid (PMN...

  19. 40 CFR 721.1680 - Substituted benzoic acid (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Substituted benzoic acid (generic... Substances § 721.1680 Substituted benzoic acid (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as substituted benzoic acid (PMN P...

  20. 40 CFR 721.3110 - Polycarboxylic acid ester (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Polycarboxylic acid ester (generic... Substances § 721.3110 Polycarboxylic acid ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a polycarboxylic acid ester...

  1. 40 CFR 721.10320 - Fatty acid amide (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Fatty acid amide (generic). 721.10320... Substances § 721.10320 Fatty acid amide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as fatty acid amide (PMN P-03-186) is subject...

  2. 40 CFR 721.3110 - Polycarboxylic acid ester (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Polycarboxylic acid ester (generic... Substances § 721.3110 Polycarboxylic acid ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a polycarboxylic acid ester...

  3. 40 CFR 721.1655 - Alkylbenzenesulfonic acid (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Alkylbenzenesulfonic acid (generic... Substances § 721.1655 Alkylbenzenesulfonic acid (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkylbenzenesulfonic acid (PMN...

  4. 40 CFR 721.1680 - Substituted benzoic acid (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Substituted benzoic acid (generic... Substances § 721.1680 Substituted benzoic acid (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as substituted benzoic acid (PMN P...

  5. 40 CFR 721.10431 - Phosphoric acid esters (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Phosphoric acid esters (generic). 721... Substances § 721.10431 Phosphoric acid esters (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as phosphoric acid esters (PMNs P...

  6. 40 CFR 721.1680 - Substituted benzoic acid (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Substituted benzoic acid (generic... Substances § 721.1680 Substituted benzoic acid (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as substituted benzoic acid (PMN P...

  7. 40 CFR 721.1655 - Alkylbenzenesulfonic acid (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Alkylbenzenesulfonic acid (generic... Substances § 721.1655 Alkylbenzenesulfonic acid (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkylbenzenesulfonic acid (PMN...

  8. 40 CFR 721.1680 - Substituted benzoic acid (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Substituted benzoic acid (generic... Substances § 721.1680 Substituted benzoic acid (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as substituted benzoic acid (PMN P...

  9. 40 CFR 721.10463 - Fatty acid amides (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Fatty acid amides (generic). 721.10463... Substances § 721.10463 Fatty acid amides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as fatty acid amides (PMN P-03-388...

  10. 40 CFR 721.1655 - Alkylbenzenesulfonic acid (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Alkylbenzenesulfonic acid (generic... Substances § 721.1655 Alkylbenzenesulfonic acid (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkylbenzenesulfonic acid (PMN...

  11. 40 CFR 721.5546 - Halogen substituted oxetanes (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Halogen substituted oxetanes (generic... Substances § 721.5546 Halogen substituted oxetanes (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as halogen substituted...

  12. 40 CFR 721.5546 - Halogen substituted oxetanes (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Halogen substituted oxetanes (generic... Substances § 721.5546 Halogen substituted oxetanes (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as halogen substituted...

  13. 40 CFR 721.5546 - Halogen substituted oxetanes (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Halogen substituted oxetanes (generic... Substances § 721.5546 Halogen substituted oxetanes (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as halogen substituted...

  14. 40 CFR 721.5546 - Halogen substituted oxetanes (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Halogen substituted oxetanes (generic... Substances § 721.5546 Halogen substituted oxetanes (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as halogen substituted...

  15. 40 CFR 721.5546 - Halogen substituted oxetanes (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Halogen substituted oxetanes (generic... Substances § 721.5546 Halogen substituted oxetanes (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as halogen substituted...

  16. 40 CFR 721.3110 - Polycarboxylic acid ester (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Polycarboxylic acid ester (generic... Substances § 721.3110 Polycarboxylic acid ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a polycarboxylic acid ester...

  17. 40 CFR 721.8660 - Propionic acid methyl ester (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Propionic acid methyl ester (generic... Substances § 721.8660 Propionic acid methyl ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a propionic acid methyl ester...

  18. 40 CFR 721.2585 - Sodium salts of dodecylphenol (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Sodium salts of dodecylphenol (generic... Substances § 721.2585 Sodium salts of dodecylphenol (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as sodium salts...

  19. 40 CFR 721.2585 - Sodium salts of dodecylphenol (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Sodium salts of dodecylphenol (generic... Substances § 721.2585 Sodium salts of dodecylphenol (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as sodium salts...

  20. 40 CFR 721.333 - Dimethyl alkylamine salt (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Dimethyl alkylamine salt (generic... Substances § 721.333 Dimethyl alkylamine salt (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as a Dimethyl alkylamine...

  1. 40 CFR 721.10567 - Amidoamine salt (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Amidoamine salt (generic). 721.10567... Substances § 721.10567 Amidoamine salt (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as amidoamine salt (PMN P-08-300) is subject...

  2. 40 CFR 721.2585 - Sodium salts of dodecylphenol (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Sodium salts of dodecylphenol (generic... Substances § 721.2585 Sodium salts of dodecylphenol (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as sodium salts...

  3. 40 CFR 721.333 - Dimethyl alkylamine salt (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Dimethyl alkylamine salt (generic... Substances § 721.333 Dimethyl alkylamine salt (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as a Dimethyl alkylamine...

  4. 40 CFR 721.333 - Dimethyl alkylamine salt (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Dimethyl alkylamine salt (generic... Substances § 721.333 Dimethyl alkylamine salt (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as a Dimethyl alkylamine...

  5. 40 CFR 721.2585 - Sodium salts of dodecylphenol (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Sodium salts of dodecylphenol (generic... Substances § 721.2585 Sodium salts of dodecylphenol (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as sodium salts...

  6. 40 CFR 721.333 - Dimethyl alkylamine salt (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Dimethyl alkylamine salt (generic... Substances § 721.333 Dimethyl alkylamine salt (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as a Dimethyl alkylamine...

  7. 40 CFR 721.10567 - Amidoamine salt (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Amidoamine salt (generic). 721.10567... Substances § 721.10567 Amidoamine salt (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as amidoamine salt (PMN P-08-300) is subject...

  8. 40 CFR 721.2585 - Sodium salts of dodecylphenol (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Sodium salts of dodecylphenol (generic... Substances § 721.2585 Sodium salts of dodecylphenol (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as sodium salts...

  9. 40 CFR 721.333 - Dimethyl alkylamine salt (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Dimethyl alkylamine salt (generic... Substances § 721.333 Dimethyl alkylamine salt (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as a Dimethyl alkylamine...

  10. 40 CFR 721.10233 - Linear alkyl epoxide (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Linear alkyl epoxide (generic). 721... Substances § 721.10233 Linear alkyl epoxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as linear alkyl epoxide (PMN...

  11. 40 CFR 721.10233 - Linear alkyl epoxide (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Linear alkyl epoxide (generic). 721... Substances § 721.10233 Linear alkyl epoxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as linear alkyl epoxide (PMN...

  12. 40 CFR 721.10233 - Linear alkyl epoxide (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Linear alkyl epoxide (generic). 721... Substances § 721.10233 Linear alkyl epoxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as linear alkyl epoxide (PMN...

  13. 40 CFR 721.10035 - Alkylbenzene sulfonate (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Alkylbenzene sulfonate (generic). 721... Substances § 721.10035 Alkylbenzene sulfonate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkylbenzene sulfonate...

  14. 40 CFR 721.10035 - Alkylbenzene sulfonate (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Alkylbenzene sulfonate (generic). 721... Substances § 721.10035 Alkylbenzene sulfonate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkylbenzene sulfonate...

  15. 40 CFR 721.2155 - Alkoxyamino-alkyl-coumarin (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Alkoxyamino-alkyl-coumarin (generic... Substances § 721.2155 Alkoxyamino-alkyl-coumarin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as...

  16. 40 CFR 721.2155 - Alkoxyamino-alkyl-coumarin (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Alkoxyamino-alkyl-coumarin (generic... Substances § 721.2155 Alkoxyamino-alkyl-coumarin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as...

  17. 40 CFR 721.2155 - Alkoxyamino-alkyl-coumarin (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Alkoxyamino-alkyl-coumarin (generic... Substances § 721.2155 Alkoxyamino-alkyl-coumarin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as...

  18. 40 CFR 721.2155 - Alkoxyamino-alkyl-coumarin (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Alkoxyamino-alkyl-coumarin (generic... Substances § 721.2155 Alkoxyamino-alkyl-coumarin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as...

  19. 40 CFR 721.2155 - Alkoxyamino-alkyl-coumarin (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Alkoxyamino-alkyl-coumarin (generic... Substances § 721.2155 Alkoxyamino-alkyl-coumarin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as...

  20. 40 CFR 721.10163 - Chloro fluoro alkane (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Chloro fluoro alkane (generic). 721... Substances § 721.10163 Chloro fluoro alkane (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as chloro fluoro alkane (PMN...

  1. 40 CFR 721.535 - Halogenated alkane (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Halogenated alkane (generic). 721.535... Substances § 721.535 Halogenated alkane (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as halogenated alkane (PMN P-01-433) is...

  2. 40 CFR 721.1680 - Substituted benzoic acid (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Substituted benzoic acid (generic... Substances § 721.1680 Substituted benzoic acid (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as substituted benzoic acid (PMN P...

  3. 40 CFR 721.2675 - Perfluoroalkyl epoxide (generic name).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Perfluoroalkyl epoxide (generic name... Substances § 721.2675 Perfluoroalkyl epoxide (generic name). (a) Chemical substances and significant new uses subject to reporting. (1) The chemical substance identified generically as perfluoroalkyl epoxide (PMN P...

  4. 40 CFR 721.2675 - Perfluoroalkyl epoxide (generic name).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Perfluoroalkyl epoxide (generic name... Substances § 721.2675 Perfluoroalkyl epoxide (generic name). (a) Chemical substances and significant new uses subject to reporting. (1) The chemical substance identified generically as perfluoroalkyl epoxide (PMN P...

  5. 40 CFR 721.2675 - Perfluoroalkyl epoxide (generic name).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Perfluoroalkyl epoxide (generic name... Substances § 721.2675 Perfluoroalkyl epoxide (generic name). (a) Chemical substances and significant new uses subject to reporting. (1) The chemical substance identified generically as perfluoroalkyl epoxide (PMN P...

  6. 40 CFR 721.2675 - Perfluoroalkyl epoxide (generic name).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Perfluoroalkyl epoxide (generic name... Substances § 721.2675 Perfluoroalkyl epoxide (generic name). (a) Chemical substances and significant new uses subject to reporting. (1) The chemical substance identified generically as perfluoroalkyl epoxide (PMN P...

  7. 40 CFR 721.2675 - Perfluoroalkyl epoxide (generic name).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Perfluoroalkyl epoxide (generic name... Substances § 721.2675 Perfluoroalkyl epoxide (generic name). (a) Chemical substances and significant new uses subject to reporting. (1) The chemical substance identified generically as perfluoroalkyl epoxide (PMN P...

  8. 40 CFR 721.5965 - Substituted S-phenylthiazole (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Substituted S-phenylthiazole (generic... Substances § 721.5965 Substituted S-phenylthiazole (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as substituted s-phenylthiazole...

  9. 40 CFR 721.10431 - Phosphoric acid esters (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Phosphoric acid esters (generic). 721... Substances § 721.10431 Phosphoric acid esters (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as phosphoric acid esters (PMNs P...

  10. 40 CFR 721.10258 - Aromatic hydrocarbon (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Aromatic hydrocarbon (generic). 721... Substances § 721.10258 Aromatic hydrocarbon (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as aromatic hydrocarbon (PMN P-09...

  11. 40 CFR 721.10258 - Aromatic hydrocarbon (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Aromatic hydrocarbon (generic). 721... Substances § 721.10258 Aromatic hydrocarbon (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as aromatic hydrocarbon (PMN P-09...

  12. 40 CFR 721.10258 - Aromatic hydrocarbon (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Aromatic hydrocarbon (generic). 721... Substances § 721.10258 Aromatic hydrocarbon (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as aromatic hydrocarbon (PMN P-09...

  13. 40 CFR 721.5917 - Phenyl azo dye (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Phenyl azo dye (generic). 721.5917... Substances § 721.5917 Phenyl azo dye (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a phenyl azo dye (PMN P-02-17) is subject...

  14. 40 CFR 721.5917 - Phenyl azo dye (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Phenyl azo dye (generic). 721.5917... Substances § 721.5917 Phenyl azo dye (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a phenyl azo dye (PMN P-02-17) is subject...

  15. 40 CFR 721.988 - Pyrazolone azomethine dye (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Pyrazolone azomethine dye (generic... Substances § 721.988 Pyrazolone azomethine dye (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a pyrazolone azomethine...

  16. 40 CFR 721.988 - Pyrazolone azomethine dye (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Pyrazolone azomethine dye (generic... Substances § 721.988 Pyrazolone azomethine dye (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a pyrazolone azomethine...

  17. 40 CFR 721.5917 - Phenyl azo dye (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Phenyl azo dye (generic). 721.5917... Substances § 721.5917 Phenyl azo dye (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a phenyl azo dye (PMN P-02-17) is subject...

  18. 40 CFR 721.5917 - Phenyl azo dye (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Phenyl azo dye (generic). 721.5917... Substances § 721.5917 Phenyl azo dye (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a phenyl azo dye (PMN P-02-17) is subject...

  19. 40 CFR 721.5917 - Phenyl azo dye (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Phenyl azo dye (generic). 721.5917... Substances § 721.5917 Phenyl azo dye (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a phenyl azo dye (PMN P-02-17) is subject...

  20. 40 CFR 721.988 - Pyrazolone azomethine dye (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Pyrazolone azomethine dye (generic... Substances § 721.988 Pyrazolone azomethine dye (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a pyrazolone azomethine...

  1. 40 CFR 721.988 - Pyrazolone azomethine dye (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Pyrazolone azomethine dye (generic... Substances § 721.988 Pyrazolone azomethine dye (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a pyrazolone azomethine...

  2. 40 CFR 721.988 - Pyrazolone azomethine dye (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Pyrazolone azomethine dye (generic... Substances § 721.988 Pyrazolone azomethine dye (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a pyrazolone azomethine...

  3. 40 CFR 721.9959 - Polyurethane polymer (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Polyurethane polymer (generic). 721... Substances § 721.9959 Polyurethane polymer (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a polyurethane polymer (PMN...

  4. 40 CFR 721.9959 - Polyurethane polymer (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Polyurethane polymer (generic). 721... Substances § 721.9959 Polyurethane polymer (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a polyurethane polymer (PMN...

  5. 40 CFR 721.324 - Alkoxylated acrylate polymer (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Alkoxylated acrylate polymer (generic... Substances § 721.324 Alkoxylated acrylate polymer (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkoxylated acrylate...

  6. 40 CFR 721.324 - Alkoxylated acrylate polymer (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Alkoxylated acrylate polymer (generic... Substances § 721.324 Alkoxylated acrylate polymer (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkoxylated acrylate...

  7. 40 CFR 721.555 - Alkyl amino nitriles (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Alkyl amino nitriles (generic). 721... Substances § 721.555 Alkyl amino nitriles (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as alkyl amino nitriles (PMNs P-96...

  8. 40 CFR 721.5350 - Substituted nitrile (generic name).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Substituted nitrile (generic name... Substances § 721.5350 Substituted nitrile (generic name). (a) Chemical substances and significant new uses subject to reporting. (1) The chemical substance identified generically as a substituted nitrile (PMN P-83...

  9. 40 CFR 721.10250 - Zirconium lysine complex (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Zirconium lysine complex (generic... Specific Chemical Substances § 721.10250 Zirconium lysine complex (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as zirconium...

  10. 40 CFR 721.9973 - Zirconium dichlorides (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Zirconium dichlorides (generic). 721... Substances § 721.9973 Zirconium dichlorides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as zirconium dichlorides (PMNs P...

  11. 40 CFR 721.9973 - Zirconium dichlorides (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Zirconium dichlorides (generic). 721... Substances § 721.9973 Zirconium dichlorides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as zirconium dichlorides (PMNs P...

  12. 40 CFR 721.9973 - Zirconium dichlorides (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Zirconium dichlorides (generic). 721... Substances § 721.9973 Zirconium dichlorides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as zirconium dichlorides (PMNs P...

  13. 40 CFR 721.9973 - Zirconium dichlorides (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Zirconium dichlorides (generic). 721... Substances § 721.9973 Zirconium dichlorides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as zirconium dichlorides (PMNs P...

  14. 40 CFR 721.10250 - Zirconium lysine complex (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Zirconium lysine complex (generic... Specific Chemical Substances § 721.10250 Zirconium lysine complex (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as zirconium...

  15. 40 CFR 721.10250 - Zirconium lysine complex (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Zirconium lysine complex (generic... Specific Chemical Substances § 721.10250 Zirconium lysine complex (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as zirconium...

  16. Defining and Comparing Generic Competences in Higher Education

    ERIC Educational Resources Information Center

    Kallioinen, Outi

    2010-01-01

    In this article the author discusses the importance of defining generic competences in alignment with the European definitions. As a case study the generic competences defined by Laurea University of Applied Sciences are compared with European definitions of generic competences. The purpose is to open up the various perspectives within this…

  17. Defining and Comparing Generic Competences in Higher Education

    ERIC Educational Resources Information Center

    Kallioinen, Outi

    2010-01-01

    In this article the author discusses the importance of defining generic competences in alignment with the European definitions. As a case study the generic competences defined by Laurea University of Applied Sciences are compared with European definitions of generic competences. The purpose is to open up the various perspectives within this…

  18. 40 CFR 721.10254 - Substituted acrylamide (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Substituted acrylamide (generic). 721... Substances § 721.10254 Substituted acrylamide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as substituted acrylamide (PMN...

  19. 40 CFR 721.10254 - Substituted acrylamide (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Substituted acrylamide (generic). 721... Substances § 721.10254 Substituted acrylamide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as substituted acrylamide (PMN...

  20. 40 CFR 721.10254 - Substituted acrylamide (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Substituted acrylamide (generic). 721... Substances § 721.10254 Substituted acrylamide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as substituted acrylamide (PMN...

  1. 40 CFR 721.10554 - Iso-tridecanol (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Iso-tridecanol (generic). 721.10554... Substances § 721.10554 Iso-tridecanol (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as iso-tridecanol (PMN P-06-153) is subject...

  2. 40 CFR 721.10554 - Iso-tridecanol (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Iso-tridecanol (generic). 721.10554... Substances § 721.10554 Iso-tridecanol (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as iso-tridecanol (PMN P-06-153) is subject...

  3. 40 CFR 721.646 - Aminofluoran derivative (generic name).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Aminofluoran derivative (generic name... Substances § 721.646 Aminofluoran derivative (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as aminofluoran derivative (PMN...

  4. 40 CFR 721.646 - Aminofluoran derivative (generic name).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Aminofluoran derivative (generic name... Substances § 721.646 Aminofluoran derivative (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as aminofluoran derivative (PMN...

  5. 40 CFR 721.10330 - Pyrazolone derivative (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Pyrazolone derivative (generic). 721... Substances § 721.10330 Pyrazolone derivative (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as pyrazolone derivative (PMN...

  6. 40 CFR 721.646 - Aminofluoran derivative (generic name).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Aminofluoran derivative (generic name... Substances § 721.646 Aminofluoran derivative (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as aminofluoran derivative (PMN...

  7. 40 CFR 721.10172 - Alkylamide derivative (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Alkylamide derivative (generic). 721... Substances § 721.10172 Alkylamide derivative (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkylamide derivative (PMN...

  8. 40 CFR 721.10172 - Alkylamide derivative (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Alkylamide derivative (generic). 721... Substances § 721.10172 Alkylamide derivative (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkylamide derivative (PMN...

  9. 40 CFR 721.646 - Aminofluoran derivative (generic name).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Aminofluoran derivative (generic name... Substances § 721.646 Aminofluoran derivative (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as aminofluoran derivative (PMN...

  10. 40 CFR 721.10330 - Pyrazolone derivative (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Pyrazolone derivative (generic). 721... Substances § 721.10330 Pyrazolone derivative (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as pyrazolone derivative (PMN...

  11. 40 CFR 721.10172 - Alkylamide derivative (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Alkylamide derivative (generic). 721... Substances § 721.10172 Alkylamide derivative (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkylamide derivative (PMN...

  12. 40 CFR 721.10330 - Pyrazolone derivative (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Pyrazolone derivative (generic). 721... Substances § 721.10330 Pyrazolone derivative (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as pyrazolone derivative (PMN...

  13. 40 CFR 721.10172 - Alkylamide derivative (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Alkylamide derivative (generic). 721... Substances § 721.10172 Alkylamide derivative (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkylamide derivative (PMN...

  14. 40 CFR 721.10172 - Alkylamide derivative (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Alkylamide derivative (generic). 721... Substances § 721.10172 Alkylamide derivative (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkylamide derivative (PMN...

  15. 40 CFR 721.646 - Aminofluoran derivative (generic name).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Aminofluoran derivative (generic name... Substances § 721.646 Aminofluoran derivative (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as aminofluoran derivative (PMN...

  16. 40 CFR 721.2083 - Polysubstituted carbomonocyclic hydroxylamine (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... hydroxylamine (generic). 721.2083 Section 721.2083 Protection of Environment ENVIRONMENTAL PROTECTION AGENCY... Specific Chemical Substances § 721.2083 Polysubstituted carbomonocyclic hydroxylamine (generic). (a... generically as a polysubstituted carbomonocyclic hydroxylamine (PMN P-97-878) is subject to reporting under...

  17. 40 CFR 721.2083 - Polysubstituted carbomonocyclic hydroxylamine (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... hydroxylamine (generic). 721.2083 Section 721.2083 Protection of Environment ENVIRONMENTAL PROTECTION AGENCY... Specific Chemical Substances § 721.2083 Polysubstituted carbomonocyclic hydroxylamine (generic). (a... generically as a polysubstituted carbomonocyclic hydroxylamine (PMN P-97-878) is subject to reporting under...

  18. 40 CFR 721.2083 - Polysubstituted carbomonocyclic hydroxylamine (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... hydroxylamine (generic). 721.2083 Section 721.2083 Protection of Environment ENVIRONMENTAL PROTECTION AGENCY... Specific Chemical Substances § 721.2083 Polysubstituted carbomonocyclic hydroxylamine (generic). (a... generically as a polysubstituted carbomonocyclic hydroxylamine (PMN P-97-878) is subject to reporting under...

  19. 40 CFR 721.2083 - Polysubstituted carbomonocyclic hydroxylamine (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... hydroxylamine (generic). 721.2083 Section 721.2083 Protection of Environment ENVIRONMENTAL PROTECTION AGENCY... Specific Chemical Substances § 721.2083 Polysubstituted carbomonocyclic hydroxylamine (generic). (a... generically as a polysubstituted carbomonocyclic hydroxylamine (PMN P-97-878) is subject to reporting under...

  20. 40 CFR 721.2083 - Polysubstituted carbomonocyclic hydroxylamine (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... hydroxylamine (generic). 721.2083 Section 721.2083 Protection of Environment ENVIRONMENTAL PROTECTION AGENCY... Specific Chemical Substances § 721.2083 Polysubstituted carbomonocyclic hydroxylamine (generic). (a... generically as a polysubstituted carbomonocyclic hydroxylamine (PMN P-97-878) is subject to reporting under...

  1. 40 CFR 721.8660 - Propionic acid methyl ester (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Propionic acid methyl ester (generic... Substances § 721.8660 Propionic acid methyl ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a propionic acid methyl...

  2. 40 CFR 721.8660 - Propionic acid methyl ester (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Propionic acid methyl ester (generic... Substances § 721.8660 Propionic acid methyl ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a propionic acid methyl...

  3. 40 CFR 721.8660 - Propionic acid methyl ester (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Propionic acid methyl ester (generic... Substances § 721.8660 Propionic acid methyl ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a propionic acid methyl...

  4. 40 CFR 721.10477 - Acrylate ester (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Acrylate ester (generic). 721.10477... Substances § 721.10477 Acrylate ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as acrylate ester (PMN P-04-290) is subject...

  5. 40 CFR 721.10477 - Acrylate ester (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Acrylate ester (generic). 721.10477... Substances § 721.10477 Acrylate ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as acrylate ester (PMN P-04-290) is subject...

  6. 40 CFR 721.10537 - Acrylate ester (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Acrylate ester (generic). 721.10537... Substances § 721.10537 Acrylate ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as acrylate ester (PMN P-01-579) is subject...

  7. 40 CFR 721.10537 - Acrylate ester (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Acrylate ester (generic). 721.10537... Substances § 721.10537 Acrylate ester (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as acrylate ester (PMN P-01-579) is subject...

  8. 40 CFR 721.2673 - Aromatic epoxide resin (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Aromatic epoxide resin (generic). 721... Substances § 721.2673 Aromatic epoxide resin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as aromatic epoxide resin (PMN P...

  9. 40 CFR 721.5908 - Modified phenolic resin (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Modified phenolic resin (generic). 721... Substances § 721.5908 Modified phenolic resin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as modified phenolic resin (PMN P...

  10. 40 CFR 721.5905 - Modified phenolic resin (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Modified phenolic resin (generic). 721... Substances § 721.5905 Modified phenolic resin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a modified phenolic resin (PMN...

  11. 40 CFR 721.2673 - Aromatic epoxide resin (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Aromatic epoxide resin (generic). 721... Substances § 721.2673 Aromatic epoxide resin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as aromatic epoxide resin (PMN P...

  12. 40 CFR 721.5905 - Modified phenolic resin (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Modified phenolic resin (generic). 721... Substances § 721.5905 Modified phenolic resin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a modified phenolic resin (PMN...

  13. 40 CFR 721.5908 - Modified phenolic resin (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Modified phenolic resin (generic). 721... Substances § 721.5908 Modified phenolic resin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as modified phenolic resin (PMN P...

  14. 40 CFR 721.10460 - Azo nickel complex (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Azo nickel complex (generic). 721... Substances § 721.10460 Azo nickel complex (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as azo nickel complex (PMN...

  15. 40 CFR 721.10460 - Azo nickel complex (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Azo nickel complex (generic). 721... Substances § 721.10460 Azo nickel complex (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as azo nickel complex (PMN...

  16. 40 CFR 721.10113 - Thioether epoxy (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Thioether epoxy (generic). 721.10113... Substances § 721.10113 Thioether epoxy (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as thioether epoxy (PMN P-04-547) is subject...

  17. 40 CFR 721.2755 - Cycloaliphatic epoxy resin (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Cycloaliphatic epoxy resin (generic... Substances § 721.2755 Cycloaliphatic epoxy resin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as cycloaliphatic epoxy resin...

  18. 40 CFR 721.10113 - Thioether epoxy (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Thioether epoxy (generic). 721.10113... Substances § 721.10113 Thioether epoxy (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as thioether epoxy (PMN P-04-547) is subject...

  19. 40 CFR 721.2755 - Cycloaliphatic epoxy resin (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Cycloaliphatic epoxy resin (generic... Substances § 721.2755 Cycloaliphatic epoxy resin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as cycloaliphatic epoxy resin...

  20. 40 CFR 721.2755 - Cycloaliphatic epoxy resin (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Cycloaliphatic epoxy resin (generic... Substances § 721.2755 Cycloaliphatic epoxy resin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as cycloaliphatic epoxy resin...

  1. 40 CFR 721.10113 - Thioether epoxy (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Thioether epoxy (generic). 721.10113... Substances § 721.10113 Thioether epoxy (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as thioether epoxy (PMN P-04-547) is subject...

  2. 40 CFR 721.10113 - Thioether epoxy (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Thioether epoxy (generic). 721.10113... Substances § 721.10113 Thioether epoxy (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as thioether epoxy (PMN P-04-547) is subject...

  3. 40 CFR 721.10113 - Thioether epoxy (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Thioether epoxy (generic). 721.10113... Substances § 721.10113 Thioether epoxy (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as thioether epoxy (PMN P-04-547) is subject...

  4. 40 CFR 721.2755 - Cycloaliphatic epoxy resin (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Cycloaliphatic epoxy resin (generic... Substances § 721.2755 Cycloaliphatic epoxy resin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as cycloaliphatic epoxy resin...

  5. 40 CFR 721.2755 - Cycloaliphatic epoxy resin (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Cycloaliphatic epoxy resin (generic... Substances § 721.2755 Cycloaliphatic epoxy resin (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as cycloaliphatic epoxy resin...

  6. 40 CFR 721.303 - Substituted acetate (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Substituted acetate (generic). 721.303... Substances § 721.303 Substituted acetate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a substituted acetate (PMN P-99...

  7. 40 CFR 721.303 - Substituted acetate (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Substituted acetate (generic). 721.303... Substances § 721.303 Substituted acetate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a substituted acetate (PMN P-99...

  8. 40 CFR 721.10318 - Mannich bases (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Mannich bases (generic). 721.10318... Substances § 721.10318 Mannich bases (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as mannich bases (PMNs P-02-1078 and...

  9. 40 CFR 721.10318 - Mannich bases (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Mannich bases (generic). 721.10318... Substances § 721.10318 Mannich bases (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as mannich bases (PMNs P-02-1078 and...

  10. 40 CFR 721.10318 - Mannich bases (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Mannich bases (generic). 721.10318... Substances § 721.10318 Mannich bases (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as mannich bases (PMNs P-02-1078 and...

  11. 40 CFR 721.10691 - Fatty acid amide (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Fatty acid amide (generic). 721.10691... Substances § 721.10691 Fatty acid amide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as fatty acid amide (PMN P-13-267) is...

  12. 40 CFR 721.10320 - Fatty acid amide (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Fatty acid amide (generic). 721.10320... Substances § 721.10320 Fatty acid amide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as fatty acid amide (PMN P-03-186) is...

  13. 40 CFR 721.10463 - Fatty acid amides (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Fatty acid amides (generic). 721.10463... Substances § 721.10463 Fatty acid amides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as fatty acid amides (PMN...

  14. 40 CFR 721.10680 - Fatty acid amides (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Fatty acid amides (generic). 721.10680... Substances § 721.10680 Fatty acid amides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substances identified generically as fatty acid amides (PMNs...

  15. 40 CFR 721.10320 - Fatty acid amide (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Fatty acid amide (generic). 721.10320... Substances § 721.10320 Fatty acid amide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as fatty acid amide (PMN P-03-186) is...

  16. 40 CFR 721.4610 - Mixed metal oxides (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Mixed metal oxides (generic). 721.4610... Substances § 721.4610 Mixed metal oxides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal oxides (PMN...

  17. 40 CFR 721.10628 - Mixed metal oxalate (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Mixed metal oxalate (generic). 721... Substances § 721.10628 Mixed metal oxalate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal oxalate (PMN...

  18. 40 CFR 721.10006 - Mixed metal oxide (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Mixed metal oxide (generic). 721.10006... Substances § 721.10006 Mixed metal oxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal oxide (PMN...

  19. 40 CFR 721.10628 - Mixed metal oxalate (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Mixed metal oxalate (generic). 721... Substances § 721.10628 Mixed metal oxalate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal oxalate (PMN...

  20. 40 CFR 721.10332 - Lithium metal phosphate (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Lithium metal phosphate (generic). 721... Substances § 721.10332 Lithium metal phosphate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as lithium metal phosphate (PMN...

  1. 40 CFR 721.10006 - Mixed metal oxide (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Mixed metal oxide (generic). 721.10006... Substances § 721.10006 Mixed metal oxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal oxide (PMN...

  2. 40 CFR 721.10495 - Metal silicate (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Metal silicate (generic). 721.10495... Substances § 721.10495 Metal silicate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as metal silicate (PMN P-05-634) is subject...

  3. 40 CFR 721.10332 - Lithium metal phosphate (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Lithium metal phosphate (generic). 721... Substances § 721.10332 Lithium metal phosphate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as lithium metal phosphate (PMN...

  4. 40 CFR 721.5548 - Mixed metal oxide (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Mixed metal oxide (generic). 721.5548... Substances § 721.5548 Mixed metal oxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a mixed metal oxide (PMN P-97-956)...

  5. 40 CFR 721.4610 - Mixed metal oxides (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Mixed metal oxides (generic). 721.4610... Substances § 721.4610 Mixed metal oxides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal oxides (PMN...

  6. 40 CFR 721.5548 - Mixed metal oxide (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Mixed metal oxide (generic). 721.5548... Substances § 721.5548 Mixed metal oxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a mixed metal oxide (PMN P-97-956)...

  7. 40 CFR 721.5548 - Mixed metal oxide (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Mixed metal oxide (generic). 721.5548... Substances § 721.5548 Mixed metal oxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a mixed metal oxide (PMN P-97-956)...

  8. 40 CFR 721.10631 - Mixed metal borate (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Mixed metal borate (generic). 721... Substances § 721.10631 Mixed metal borate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal borate (PMN...

  9. 40 CFR 721.5548 - Mixed metal oxide (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Mixed metal oxide (generic). 721.5548... Substances § 721.5548 Mixed metal oxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a mixed metal oxide (PMN P-97-956)...

  10. 40 CFR 721.4610 - Mixed metal oxides (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Mixed metal oxides (generic). 721.4610... Substances § 721.4610 Mixed metal oxides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal oxides (PMN...

  11. 40 CFR 721.10006 - Mixed metal oxide (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Mixed metal oxide (generic). 721.10006... Substances § 721.10006 Mixed metal oxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal oxide (PMN...

  12. 40 CFR 721.10631 - Mixed metal borate (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Mixed metal borate (generic). 721... Substances § 721.10631 Mixed metal borate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal borate (PMN...

  13. 40 CFR 721.10006 - Mixed metal oxide (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Mixed metal oxide (generic). 721.10006... Substances § 721.10006 Mixed metal oxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal oxide (PMN...

  14. 40 CFR 721.10332 - Lithium metal phosphate (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Lithium metal phosphate (generic). 721... Substances § 721.10332 Lithium metal phosphate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as lithium metal phosphate (PMN...

  15. 40 CFR 721.5548 - Mixed metal oxide (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Mixed metal oxide (generic). 721.5548... Substances § 721.5548 Mixed metal oxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a mixed metal oxide (PMN P-97-956)...

  16. 40 CFR 721.4610 - Mixed metal oxides (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Mixed metal oxides (generic). 721.4610... Substances § 721.4610 Mixed metal oxides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal oxides (PMN...

  17. 40 CFR 721.4610 - Mixed metal oxides (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Mixed metal oxides (generic). 721.4610... Substances § 721.4610 Mixed metal oxides (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal oxides (PMN...

  18. 40 CFR 721.10495 - Metal silicate (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Metal silicate (generic). 721.10495... Substances § 721.10495 Metal silicate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as metal silicate (PMN P-05-634) is subject...

  19. 40 CFR 721.10006 - Mixed metal oxide (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Mixed metal oxide (generic). 721.10006... Substances § 721.10006 Mixed metal oxide (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as mixed metal oxide (PMN...

  20. 40 CFR 721.3080 - Substituted phosphate ester (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Substituted phosphate ester (generic... Substances § 721.3080 Substituted phosphate ester (generic). (a) Chemical substances and significant new uses subject to reporting. (1) The chemical substance identified generically as a substituted phosphate ester...

  1. 40 CFR 721.10302 - Zinc ammonium phosphate (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Zinc ammonium phosphate (generic). 721... Substances § 721.10302 Zinc ammonium phosphate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as zinc ammonium phosphate (PMN P...

  2. 40 CFR 721.10302 - Zinc ammonium phosphate (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Zinc ammonium phosphate (generic). 721... Substances § 721.10302 Zinc ammonium phosphate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as zinc ammonium phosphate (PMN P...

  3. 40 CFR 721.3080 - Substituted phosphate ester (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Substituted phosphate ester (generic... Substances § 721.3080 Substituted phosphate ester (generic). (a) Chemical substances and significant new uses subject to reporting. (1) The chemical substance identified generically as a substituted phosphate ester...

  4. 40 CFR 721.10302 - Zinc ammonium phosphate (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Zinc ammonium phosphate (generic). 721... Substances § 721.10302 Zinc ammonium phosphate (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as zinc ammonium phosphate (PMN P...

  5. 40 CFR 721.3080 - Substituted phosphate ester (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Substituted phosphate ester (generic... Substances § 721.3080 Substituted phosphate ester (generic). (a) Chemical substances and significant new uses subject to reporting. (1) The chemical substance identified generically as a substituted phosphate ester...

  6. 40 CFR 721.3080 - Substituted phosphate ester (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Substituted phosphate ester (generic... Substances § 721.3080 Substituted phosphate ester (generic). (a) Chemical substances and significant new uses subject to reporting. (1) The chemical substance identified generically as a substituted phosphate ester...

  7. 40 CFR 721.3080 - Substituted phosphate ester (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Substituted phosphate ester (generic... Substances § 721.3080 Substituted phosphate ester (generic). (a) Chemical substances and significant new uses subject to reporting. (1) The chemical substance identified generically as a substituted phosphate ester...

  8. 40 CFR 721.10393 - Sodium bromide MDA complex (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Sodium bromide MDA complex (generic... Specific Chemical Substances § 721.10393 Sodium bromide MDA complex (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as sodium...

  9. 40 CFR 721.9959 - Polyurethane polymer (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Polyurethane polymer (generic). 721... Substances § 721.9959 Polyurethane polymer (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a polyurethane polymer (PMN P-01...

  10. 40 CFR 721.9959 - Polyurethane polymer (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Polyurethane polymer (generic). 721... Substances § 721.9959 Polyurethane polymer (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a polyurethane polymer (PMN P-01...

  11. 40 CFR 721.324 - Alkoxylated acrylate polymer (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Alkoxylated acrylate polymer (generic... Substances § 721.324 Alkoxylated acrylate polymer (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkoxylated acrylate polymer...

  12. 40 CFR 721.324 - Alkoxylated acrylate polymer (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Alkoxylated acrylate polymer (generic... Substances § 721.324 Alkoxylated acrylate polymer (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkoxylated acrylate polymer...

  13. 40 CFR 721.9959 - Polyurethane polymer (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Polyurethane polymer (generic). 721... Substances § 721.9959 Polyurethane polymer (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as a polyurethane polymer (PMN P-01...

  14. 40 CFR 721.10524 - Fluorinated alkylsulfonamidol urethane polymer (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... polymer (generic). 721.10524 Section 721.10524 Protection of Environment ENVIRONMENTAL PROTECTION AGENCY... Specific Chemical Substances § 721.10524 Fluorinated alkylsulfonamidol urethane polymer (generic). (a... generically as fluorinated alkylsulfonamidol urethane polymer (PMN P-11-384) is subject to reporting under...

  15. 40 CFR 721.324 - Alkoxylated acrylate polymer (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Alkoxylated acrylate polymer (generic... Substances § 721.324 Alkoxylated acrylate polymer (generic). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance identified generically as alkoxylated acrylate polymer...

  16. 40 CFR 721.10524 - Fluorinated alkylsulfonamidol urethane polymer (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... polymer (generic). 721.10524 Section 721.10524 Protection of Environment ENVIRONMENTAL PROTECTION AGENCY... Specific Chemical Substances § 721.10524 Fluorinated alkylsulfonamidol urethane polymer (generic). (a... generically as fluorinated alkylsulfonamidol urethane polymer (PMN P-11-384) is subject to reporting under...

  17. [The patents game. Generic and biosimilar drugs].

    PubMed

    Villamañán, E; González, D; Armada, E; Ruano, M; Álvarez-Sala, R; Herrero, A

    2016-01-01

    The protection provided by patents on medicines has a limited duration. The expiry of patents expiration allows copies of the drugs to be released, competing with original. At first, they were identical to the original, known as generic drugs, but in recent years, due to the marketing of biological therapies and the expiry of many of their patents, biosimilar drugs have also emerged. These are not exact copies of the original, but, like generic drugs, biosimilar drugs have to demonstrate equivalence to the reference drugs in quality, safety and efficacy. Nevertheless, despite their importance and contribution to sustainability of health system, doctors are sometimes unaware of differences between them, and their impact in terms of clinical and economic effects. An attempt is made to review and clarify certain aspects often unknown by physicians, despite their involvement in their use. Copyright © 2015 SECA. Published by Elsevier Espana. All rights reserved.

  18. Mission specification for three generic mission classes

    NASA Technical Reports Server (NTRS)

    1979-01-01

    Mission specifications for three generic mission classes are generated to provide a baseline for definition and analysis of data acquisition platform system concepts. The mission specifications define compatible groupings of sensors that satisfy specific earth resources and environmental mission objectives. The driving force behind the definition of sensor groupings is mission need; platform and space transportation system constraints are of secondary importance. The three generic mission classes are: (1) low earth orbit sun-synchronous; (2) geosynchronous; and (3) non-sun-synchronous, nongeosynchronous. These missions are chosen to provide a variety of sensor complements and implementation concepts. Each mission specification relates mission categories, mission objectives, measured parameters, and candidate sensors to orbits and coverage, operations compatibility, and platform fleet size.

  19. Generic Stellarator-like Magnetic Fusion Reactor

    NASA Astrophysics Data System (ADS)

    Sheffield, John; Spong, Donald

    2015-11-01

    The Generic Magnetic Fusion Reactor paper, published in 1985, has been updated, reflecting the improved science and technology base in the magnetic fusion program. Key changes beyond inflation are driven by important benchmark numbers for technologies and costs from ITER construction, and the use of a more conservative neutron wall flux and fluence in modern fusion reactor designs. In this paper the generic approach is applied to a catalyzed D-D stellarator-like reactor. It is shown that an interesting power plant might be possible if the following parameters could be achieved for a reference reactor: R/ < a > ~ 4 , confinement factor, fren = 0.9-1.15, < β > ~ 8 . 0 -11.5 %, Zeff ~ 1.45 plus a relativistic temperature correction, fraction of fast ions lost ~ 0.07, Bm ~ 14-16 T, and R ~ 18-24 m. J. Sheffield was supported under ORNL subcontract 4000088999 with the University of Tennessee.

  20. Unsteady Pressures on a Generic Capsule Shape

    NASA Technical Reports Server (NTRS)

    Burnside, Nathan; Ross, James C.

    2015-01-01

    While developing the aerodynamic database for the Orion spacecraft, the low-speed flight regime (transonic and below) proved to be the most difficult to predict and measure accurately. The flow over the capsule heat shield in descent flight was particularly troublesome for both computational and experimental efforts due to its unsteady nature and uncertainty about the boundary layer state. The data described here were acquired as part of a study to improve the understanding of the overall flow around a generic capsule. The unsteady pressure measurements acquired on a generic capsule shape are presented along with a discussion about the effects of various flight conditions and heat-shield surface roughness on the resulting pressure fluctuations.

  1. Savannah River Site generic data base development

    SciTech Connect

    Blanton, C.H.; Eide, S.A.

    1993-06-30

    This report describes the results of a project to improve the generic component failure data base for the Savannah River Site (SRS). A representative list of components and failure modes for SRS risk models was generated by reviewing existing safety analyses and component failure data bases and from suggestions from SRS safety analysts. Then sources of data or failure rate estimates were identified and reviewed for applicability. A major source of information was the Nuclear Computerized Library for Assessing Reactor Reliability, or NUCLARR. This source includes an extensive collection of failure data and failure rate estimates for commercial nuclear power plants. A recent Idaho National Engineering Laboratory report on failure data from the Idaho Chemical Processing Plant was also reviewed. From these and other recent sources, failure data and failure rate estimates were collected for the components and failure modes of interest. This information was aggregated to obtain a recommended generic failure rate distribution (mean and error factor) for each component failure mode.

  2. Savannah River Site generic data base development

    SciTech Connect

    Blanchard , A.

    2000-01-04

    This report describes the results of a project to improve the generic component failure database for the Savannah River Site (SRS). Additionally, guidelines were developed further for more advanced applications of database values. A representative list of components and failure modes for SRS risk models was generated by reviewing existing safety analyses and component failure data bases and from suggestions from SRS safety analysts. Then sources of data or failure rate estimates were identified and reviewed for applicability. A major source of information was the Nuclear Computerized Library for Assessing Reactor Reliability, or NUCLARR. This source includes an extensive collection of failure data and failure rate estimates for commercial nuclear power plants. A recent Idaho National Engineering Laboratory report on failure data from the Idaho Chemical Processing Plant was also reviewed. From these and other recent sources, failure data and failure rate estimates were collected for the components and failure modes of interest. For each component failure mode, this information was aggregated to obtain a recommended generic failure rate distribution (mean and error factor based on a lognormal distribution). Results are presented in a table in this report. A major difference between generic database and previous efforts is that this effort estimates failure rates based on actual data (failure events) rather than on existing failure rate estimates. This effort was successful in that over 75% of the results are now based on actual data. Also included is a section on guidelines for more advanced applications of failure rate data. This report describes the results of a project to improve the generic component failure database for the Savannah River site (SRS). Additionally, guidelines were developed further for more advanced applications of database values.

  3. Generic superweak chaos induced by Hall effect.

    PubMed

    Ben-Harush, Moti; Dana, Itzhack

    2016-05-01

    We introduce and study the "kicked Hall system" (KHS), i.e., charged particles periodically kicked in the presence of uniform magnetic (B) and electric (E) fields that are perpendicular to each other and to the kicking direction. We show that for resonant values of B and E and in the weak-chaos regime of sufficiently small nonintegrability parameter κ (the kicking strength), there exists a generic family of periodic kicking potentials for which the Hall effect from B and E significantly suppresses the weak chaos, replacing it by "superweak" chaos (SWC). This means that the system behaves as if the kicking strength were κ^{2} rather than κ. For E=0, SWC is known to be a classical fingerprint of quantum antiresonance, but it occurs under much less generic conditions, in particular only for very special kicking potentials. Manifestations of SWC are a decrease in the instability of periodic orbits and a narrowing of the chaotic layers, relative to the ordinary weak-chaos case. Also, for global SWC, taking place on an infinite "stochastic web" in phase space, the chaotic diffusion on the web is much slower than the weak-chaos one. Thus, the Hall effect can be relatively stabilizing for small κ. In some special cases, the effect is shown to cause ballistic motion for almost all parameter values. The generic global SWC on stochastic webs in the KHS appears to be the two-dimensional closest analog to the Arnol'd web in higher dimensional systems.

  4. Developing Generic Software for Spacecraft Avionics

    NASA Technical Reports Server (NTRS)

    Smith, Joseph

    2003-01-01

    A proposed approach to the development of software for spacecraft avionics is based partly on a concept of generic software that could be tailored to satisfy requirements for specific missions. The proposed approach would stand in contrast to the conventional approach of first defining avionics requirements for a specific mission, then developing software specific to those requirements. The proposed approach might also be adaptable to programming computers that control and monitor other complex equipment systems that range in scale from automobiles to factories. The concept of a spacecraft avionics functional model (SAFM) is a major element of the proposed approach. An SAFM would be, essentially, a systematic and hierarchical description of the functionality required of the avionics software (and hardware) for a given mission. Although the initial input information used to start the construction of an SAFM would typically amount to a high-level description, the SAFM would thereafter be decomposed to a low level. The resulting low-level version of the model would be used to develop a set of generic requirements that could be expected to include a large fraction of all requirements for a large fraction of all missions. The generic requirements would be used to develop software modules that could be included in, or excluded from, the final flight software to satisfy the requirements of a specific mission.

  5. Generic drug names and social welfare.

    PubMed

    Lobo, Félix; Feldman, Roger

    2013-06-01

    This article studies how well International Nonproprietary Names (INNs), the "generic" names for pharmaceuticals, address the problems of imperfect information. Left in private hands, the identification of medicines leads to confusion and errors. Developed in the 1950s by the World Health Organization, INNs are a common, global, scientific nomenclature designed to overcome this failure. Taking stock after sixty years, we argue that the contribution of INNs to social welfare is paramount. They enhance public health by reducing errors and improving patient safety. They also contribute to economic efficiency by creating transparency as the foundation of competitive generic drug markets, reducing transaction costs, and favoring trade. The law in most countries requires manufacturers to designate pharmaceuticals with INNs in labeling and advertising. Generic substitution is also permitted or mandatory in many countries. But not all the benefits of INNs are fully realized because prescribers may not use them. We advocate strong incentives or even legally binding provisions to extend the use of INNs by prescribing physicians and dispensing pharmacists, but we do not recommend replacing brand names entirely with INNs. Instead, we propose dual use of brand names and INNs in prescribing, as in drug labeling.

  6. Generic Environment for Simulating Launch Operations

    NASA Technical Reports Server (NTRS)

    Steele, Martin; Mollaghasemi, Mansooreh; Rabadi, Ghaith

    2006-01-01

    GEM-FLO (A Generic Simulation Environment for Modeling Future Launch Operations) is a computer program that facilitates creation of discrete-event simulation models of ground processes in which reusable or expendable launch vehicles (RLVs) are prepared for flight. GEM-FLO includes a component, developed in Visual Basic, that generates a graphical user interface (GUI) and a component, developed in the Arena simulation language, that creates a generic discrete-event simulation model. Through the GUI, GEM-FLO elicits RLV design information from the user. The design information can include information on flight hardware elements, resources, and ground processes. GEM-FLO translates the user s responses into mathematical variables and expressions that populate the generic simulation model. The variables and expressions can represent processing times, resource capacities, status variables, and other process parameters needed to configure a simulation model that reflects the ground processing flow and requirements of a specific RLV. Upon execution of the model, GEMFLO puts out data on many measures of performance, including the flight rate, turnaround time, and utilization of resources. This information can serve as the basis for determining whether design goals can be met, and for comparing characteristics of competing RLV designs

  7. Generic documentation tree for science ground segments

    NASA Astrophysics Data System (ADS)

    Pérez-López, F.; Lock, T.; Texier, D.

    2014-08-01

    The competences of the Science Ground Segment, for an ESA science mission, include: science operations planning, science instrument handling, data reception and processing, and archiving as well as providing science support. This paper presents a generic documentation structure applicable during the analysis, definition, implementation and operational phases of an ESA Science Ground Segment. This is the conclusion of the analysis performed in the scope of the current ESAC Science Ground Segment developments and is derived from the experience of previous ESA science missions and the ESA standardization efforts (ECSS Standards). It provides a guideline to support the Science Ground Segment documentation processes during all mission phases; representing a new approach for the development of future ESA science missions, and providing an initial documentation structure that might be tailored depending on the specific scientific, engineering and managerial characteristics of each mission. This paper also describes the process followed to produce the generic documentation tree and how the development and operations experience feedback in the updated versions of this generic documentation tree.

  8. Psychological Versus Generic Critical Thinking as Predictors and Outcome Measures in a Large Undergraduate Human Development Course

    ERIC Educational Resources Information Center

    Williams, Robert L.; Oliver, Renee; Stockdale, Susan

    2004-01-01

    This study examines the differential status of psychological critical thinking and generic critical thinking as predictors of test performance and as outcome measures in a large human development course. Psychological critical thinking proved to be the better predictor of test performance and more responsive to instructional procedures in the…

  9. 76 FR 40981 - Agency Information Collection Activities: Proposed Collection; Comment Request; Generic Clearance...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2011-07-12

    ... Request; Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery AGENCY... service delivery, the Maritime Administration is submitting a Generic Information Collection Request (Generic ICR): ``Generic Clearance for the Collection of Qualitative Feedback on Agency Service...

  10. A trade agreement's impact on access to generic drugs.

    PubMed

    Shaffer, Ellen R; Brenner, Joseph E

    2009-01-01

    Millions of people lack access to affordable medicines. The intellectual property rules in the Central America Free Trade Agreement (CAFTA) provide pharmaceutical companies with monopoly protections that allow them to market some drugs without competition by less costly generics. We examined availability of certain drugs in Guatemala and found that CAFTA intellectual property rules reduced access to some generic drugs already on the market and delayed new entry of other generics. Some drugs protected from competition in Guatemala will become open for generic competition in the United States before generic versions will be legally available in Guatemala.

  11. Two-year-olds use the generic/non-generic distinction to guide their inferences about novel kinds

    PubMed Central

    Graham, Susan A.; Nayer, Samantha L.; Gelman, Susan A.

    2011-01-01

    These studies investigated 24- and 30-month-olds’ sensitivity to generic versus nongeneric language when acquiring knowledge about novel kinds. Toddlers were administered an inductive inference task, during which they heard a generic noun-phrase (e.g., “Blicks drink milk”) or a non-generic noun-phrase (e.g., “This blick drinks milk”) paired with an action (e.g., drinking) modeled on an object. They were then provided with the model and a non-model exemplar and asked to imitate the action. After hearing non-generic phrases, 30-month-olds, but not 24-month-olds, imitated more often with the model than with the non-model exemplar. In contrast, after hearing generic phrases, 30-month-olds imitated equally often with both exemplars. These results suggest that 30-month-olds use the generic/non-generic distinction to guide their inferences about novel kinds. PMID:21410928

  12. Consumer choice between common generic and brand medicines in a country with a small generic market.

    PubMed

    Fraeyman, Jessica; Peeters, Lies; Van Hal, Guido; Beutels, Philippe; De Meyer, Guido R Y; De Loof, Hans

    2015-04-01

    Generic medicines offer an opportunity for governments to contain pharmaceutical expenditures, since generics are generally 10%-80% lower in price than brand medicines. Belgium has a small generic market that takes up 15% of the total pharmaceutical market in packages sold. To determine the knowledge of consumers about the different available packages of a common over-the-counter medicine (acetaminophen) with regard to price advantage, quality, and effectiveness in a country with a small generic market. We conducted an online survey in the general Flemish population using a questionnaire with 25 statements. The questionnaire also contained 2 informative interventions. First, we showed the price per package and per tablet that the patient would pay in the pharmacy. Second, we provided the respondent with general information about generic medication (equivalence, effectiveness, price, and recognition). Before and after the interventions, we probed for preferences and knowledge about the different packages. Multivariate logistic models were used to examine the independent effects of consumer characteristics on responses to the survey statements. We obtained a sample of 1,636 respondents. The general attitude towards generic medication was positive-only 5% would rather not use a generic. Nevertheless, only 17% of the respondents were able to recognize a generic medicine. Older consumers (aged 60 years and above) were more often confused about the different packages (OR = 2.59, 95% CI = 1.76-3.80, P ≤ 0.001). Consumers without a higher education degree tended to be more doubtful about the difference in effectiveness and quality between the different brands (OR = 0.59, 95% CI = 0.44-0.79, P ≤ 0.001). Consumer recognition of the name of the active substance of acetaminophen was poor. When different brands were displayed, possible price advantage seemed to be an important motive to switch to a cheaper brand. Consumers generally found medicines

  13. Money Left on the Table: Generic Drug Prices in Canada

    PubMed Central

    Law, Michael R.

    2013-01-01

    Background: Generic drugs are a major cost-saving opportunity for patients and drug plans. While almost every province has reduced generic drug prices, we have no information on whether these new prices are internationally competitive. Therefore, I compared Canadian prices to those in two other countries. Methods: I used 2009 data from the IMS Brogan Canadian CompuScript and PharmaStat databases and studied the 100 most frequently dispensed generic products in Ontario, which has Canada's lowest generic prices. I compared these prices to those in public drug programs in the United States and New Zealand that use tendering. Using these alternative prices, I calculated the potential savings in Ontario. Results: Of the top 100 generic products, 82 were listed on an international formulary. In 90% of cases, generic products were less expensive in other countries. If Ontario had obtained the lowest comparator price for these products, the annual public sector and overall drug expenditure savings would have been $129 million and $245 million, respectively. Further, the province could have publicly paid for all these generic drugs – both public and private – and saved $87 million compared to current public sector expenditures. Discussion: Even after recent reforms, generic drug prices in Canada remain high by international standards. I found that if Ontario had obtained commonly used generic drugs at international best prices, the province could have publicly paid for all generic drugs and lowered annual expenditures by nearly a quarter-billion dollars. PMID:23968624

  14. Simulation of the AUC Changes after Generic Substitution in Patients

    PubMed Central

    2009-01-01

    To address the debate on the safety of generic substitution quantitatively, the author compared the change in AUC in virtual patients who were simulated for several different scenarios of generic substitution. In four scenarios of original (branded) to generic and generic to generic substitution, 5,000 virtual patients were simulated per scenario using the programming software R. The mean population AUC of generics ranged from 90-110% (scenarios A and B) and 80-123.5% (scenarios C and D) of the AUC of the original. Those patients who had an AUC change (ratio) as a result of drug substitution of less than 0.67 or greater than 1.5 were considered to be in potential danger due to the substitution. We found that less than 6% of patients fell outside of the cutoff range of 0.67-1.5 as a result of original to generic substitution. However, in the case of generic to generic substitution, the proportion was as high as 9-12%. This alerts us to the potential danger of generic substitution, especially for drugs with narrow therapeutic indices. PMID:19270806

  15. Generic medicines: issues and relevance for global health.

    PubMed

    Rana, Proteesh; Roy, Vandana

    2015-12-01

    Generic medicine is a pharmaceutical product which is bioequivalent to the innovator product in terms of dosage form, strength, route of administration, quality, safety, performance characteristics, and intended use. Generic medicines are a cornerstone for providing affordable medicines to patients. The major generic markets in the world include United States of America followed by European Union, Canada, Japan, and Australia. The major suppliers of generic medicines China and India are showing tremendous growth in the generic medicine sector. There are many legal and regulatory issues along with quality concerns associated with the use of the generic products. Lately, bilateral international agreements called free trade agreements, delaying tactics by originator companies like strategic patenting and litigations on generic manufacturers, have been a major setback for the generic medicine industry. These issues need to be addressed to optimize the use of generic medicines. The sustainability of generic medicine sector is crucial for improving access to essential medicines for the worldwide. © 2015 Société Française de Pharmacologie et de Thérapeutique.

  16. Generic seismic ruggedness of power plant equipment

    SciTech Connect

    Merz, K.L. )

    1991-08-01

    This report updates the results of a program with the overall objective of demonstrating the generic seismic adequacy of as much nuclear power plant equipment as possible by means of collecting and evaluating existing seismic qualification test data. These data are then used to construct ruggedness'' spectra below which equipment in operating plants designed to earlier earthquake criteria would be generically adequate. This document is an EPRI Tier 1 Report. The report gives the methodology for the collection and evaluation of data which are used to construct a Generic Equipment Ruggedness Spectrum (GERs) for each equipment class considered. The GERS for each equipment class are included in an EPRI Tier 2 Report with the same title. Associated with each GERS are inclusion rules, cautions, and checklists for field screening of in-place equipment for GERS applicability. A GERS provides a measure of equipment seismic resistance based on available test data. As such, a GERS may also be used to judge the seismic adequacy of similar new or replacement equipment or to estimate the seismic margin of equipment re-evaluated with respect to earthquake levels greater than considered to date, resulting in fifteen finalized GERS. GERS for relays (included in the original version of this report) are now covered in a separate report (NP-7147). In addition to the presentation of GERS, the Tier 2 report addresses the applicability of GERS to equipment of older vintage, methods for estimating amplification factors for evaluating devices installed in cabinets and enclosures, and how seismic test data from related studies relate to the GERS approach. 28 refs., 5 figs., 4 tabs.

  17. Generic hierarchical engine for mask data preparation

    NASA Astrophysics Data System (ADS)

    Kalus, Christian K.; Roessl, Wolfgang; Schnitker, Uwe; Simecek, Michal

    2002-07-01

    Electronic layouts are usually flattened on their path from the hierarchical source downstream to the wafer. Mask data preparation has certainly been identified as a severe bottleneck since long. Data volumes are not only doubling every year along the ITRS roadmap. With the advent of optical proximity correction and phase-shifting masks data volumes are escalating up to non-manageable heights. Hierarchical treatment is one of the most powerful means to keep memory and CPU consumption in reasonable ranges. Only recently, however, has this technique acquired more public attention. Mask data preparation is the most critical area calling for a sound infrastructure to reduce the handling problem. Gaining more and more attention though, are other applications such as large area simulation and manufacturing rule checking (MRC). They all would profit from a generic engine capable to efficiently treat hierarchical data. In this paper we will present a generic engine for hierarchical treatment which solves the major problem, steady transitions along cell borders. Several alternatives exist how to walk through the hierarchy tree. They have, to date, not been thoroughly investigated. One is a bottom-up attempt to treat cells starting with the most elementary cells. The other one is a top-down approach which lends itself to creating a new hierarchy tree. In addition, since the variety, degree of hierarchy and quality of layouts extends over a wide range a generic engine has to take intelligent decisions when exploding the hierarchy tree. Several applications will be shown, in particular how far the limits can be pushed with the current hierarchical engine.

  18. Perceptions and attitudes of community pharmacists towards generic medicines.

    PubMed

    Dunne, Suzanne S; Shannon, Bill; Cullen, Walter; Dunne, Colum P

    2014-11-01

    Following the enactment of legislation in June 2013, generic substitution and reference pricing of medicines has been introduced, for the first time, in Ireland. This novel study is the first assessment of the perceptions of community pharmacists in Ireland towards generic medicines completed in the period immediately prior to the introduction of generic substitution and reference pricing.  To determine the perceptions towards generic medicines among community pharmacists. One-to-one semistructured interviews were performed with a convenience sample of 44 community pharmacists (from approximately 4,500 pharmacists in Ireland) recruited from Ireland's Midwest, South, and Southwest regions. Interviews were transcribed and analysed using NVivo (version 9). 98% of pharmacists believed that generics were of a similar quality to the originator, and 96% stated that they were as effective as the originator. However, a small number demonstrated some reticence regarding generics: 9% believed that generics were not manufactured to the same quality as the originator; 7% stated they would prefer to take an originator medicine themselves; and 7% reported having experienced quality issues with generic medicines. 89% of pharmacists reported receiving patient complaints regarding use of generic medicine, although 64% suggested that this was due to a nocebo effect (i.e., a result of patients' preconceived notions that generics were inferior). Only a minority (21%) reported that they had attempted to educate patients as to the equivalency of generics. Although 80% were in favor of Ireland's new legislation promoting the use generic medicines, 46% expressed concerns regarding its practical implementation. This key stakeholder group had positive attitudes towards generics and the legislation that promotes their use. Concerns regarding patient perception and experience, clinical effectiveness, and manufacturing quality were identified. We propose that interventions supporting

  19. Generic drugs--safe, effective, and affordable.

    PubMed

    Peters, John R; Hixon, Dena R; Conner, Dale P; Davit, Barbara M; Catterson, Debra M; Parise, Cecelia M

    2009-01-01

    This article discusses the history and evolution of the process for generic drug evaluation and approval in the United States, with emphasis on locally acting dermatologic products. The requirements for in vivo bioequivalence (BE) testing and the statistical criteria for BE are discussed, and an example of a topical antifungal dermatologic product is used to demonstrate the BE determination for locally acting drugs. Other factors in the dispensing of prescription medications that are not within the Food and Drug Administration regulatory authority are also mentioned.

  20. Generic turbine design study. Final report

    SciTech Connect

    Not Available

    1993-06-01

    The purpose of Task 12, Generic Turbine Design Study was to develop a conceptual design of a combustion turbine system that would perform in a pressurized fluidized bed combustor (PFBC) application. A single inlet/outlet casing design that modifies the W251B12 combustion turbine to provide compressed air to the PFBC and accept clean hot air from the PFBC was developed. Performance calculations show that the net power output expected, at an inlet temperature of 59{degrees}F, is 20,250 kW.

  1. Generic architectures for future flight systems

    NASA Technical Reports Server (NTRS)

    Wood, Richard J.

    1992-01-01

    Generic architecture for future flight systems must be based on open system architectures (OSA). This provides the developer and integrator the flexibility to optimize the hardware and software systems to match diverse and unique applications requirements. When developed properly OSA provides interoperability, commonality, graceful upgradability, survivability and hardware/software transportability to greatly minimize life cycle costs and supportability. Architecture flexibility can be achieved to take advantage of commercial developments by basing these developments on vendor-neutral commercially accepted standards and protocols. Rome Laboratory presently has a program that addresses requirements for OSA.

  2. [Generic and biosimilar drug substitution: a panacea?].

    PubMed

    Daly, M J; Guignard, B; Nendaz, M

    2015-10-14

    Drugs are the third largest source of expenditure under Switzerland's compulsory basic health insurance. Generics, the price of which should be at least 30 per cent less than the cost of the original drugs, can potentially allow substantial savings. Their approval requires bioequivalence studies and their use is safe, although some factors may influence patients' and physicians' acceptance. The increased substitution of biosimilar drugs for more expensive biotech drugs should allow further cost savings. In an attempt to extend the monopoly granted by the original drug patent, some pharmaceutical companies implement "evergreening" strategies including small modifications of the original substance for which the clinical benefit is not always demonstrated.

  3. Holographic entanglement entropy on generic time slices

    NASA Astrophysics Data System (ADS)

    Kusuki, Yuya; Takayanagi, Tadashi; Umemoto, Koji

    2017-06-01

    We study the holographic entanglement entropy and mutual information for Lorentz boosted subsystems. In holographic CFTs at zero and finite temperature, we find that the mutual information gets divergent in a universal way when the end points of two subsystems are light-like separated. In Lifshitz and hyperscaling violating geometries dual to non-relativistic theories, we show that the holographic entanglement entropy is not well-defined for Lorentz boosted subsystems in general. This strongly suggests that in non-relativistic theories, we cannot make a real space factorization of the Hilbert space on a generic time slice except the constant time slice, as opposed to relativistic field theories.

  4. Generic Wing-Body Aerodynamics Data Base

    NASA Technical Reports Server (NTRS)

    Holst, Terry L.; Olsen, Thomas H.; Kwak, Dochan (Technical Monitor)

    2001-01-01

    The wing-body aerodynamics data base consists of a series of CFD (Computational Fluid Dynamics) simulations about a generic wing body configuration consisting of a ogive-circular-cylinder fuselage and a simple symmetric wing mid-mounted on the fuselage. Solutions have been obtained for Nonlinear Potential (P), Euler (E) and Navier-Stokes (N) solvers over a range of subsonic and transonic Mach numbers and angles of attack. In addition, each solution has been computed on a series of grids, coarse, medium and fine to permit an assessment of grid refinement errors.

  5. Speech enhancement using a generic noise codebook.

    PubMed

    Srinivasan, Sriram; Rao Naidu, D Hanumantha

    2012-08-01

    Although single-microphone noise reduction methods perform well in stationary noise environments, their performance in non-stationary conditions remains unsatisfactory. Use of prior knowledge about speech and noise power spectral densities in the form of trained codebooks has been previously shown to address this limitation. While it is possible to use trained speech codebooks in a practical system, the variety of noise types encountered in practice makes the use of trained noise codebooks less practical. This letter presents a method that uses a generic noise codebook for speech enhancement that can be generated on-the-fly and provides good performance.

  6. Generic Conditions for Stable Hybrid Stars

    NASA Astrophysics Data System (ADS)

    Alford, Mark G.; Han, Sophia; Prakash, Madappa

    We study the mass-radius curve of hybrid stars, assuming a single first-order phase transition between nuclear and quark matter with a sharp interface. By using a generic "classical ideal gas" (CIG) parameterization of the quark matter equation of state, which has a density-independent speed of sound we obtain the phase diagram of possible forms of the hybrid star mass-radius relation, where the control parameters are the transition pressure, energy density discontinuity, and the quark matter speed of sound. We find that this diagram is sensitive to the quark matter parameters but fairly insensitive to details of the nuclear matter equation of state.

  7. Generic Wing-Body Aerodynamics Data Base

    NASA Technical Reports Server (NTRS)

    Holst, Terry L.; Olsen, Thomas H.; Kwak, Dochan (Technical Monitor)

    2001-01-01

    The wing-body aerodynamics data base consists of a series of CFD (Computational Fluid Dynamics) simulations about a generic wing body configuration consisting of a ogive-circular-cylinder fuselage and a simple symmetric wing mid-mounted on the fuselage. Solutions have been obtained for Nonlinear Potential (P), Euler (E) and Navier-Stokes (N) solvers over a range of subsonic and transonic Mach numbers and angles of attack. In addition, each solution has been computed on a series of grids, coarse, medium and fine to permit an assessment of grid refinement errors.

  8. Commercial Generic Bioprocessing Apparatus Science Insert - 03

    NASA Technical Reports Server (NTRS)

    Moreno, Nancy; Stodieck, Louis; Cushing, Paula; Stowe, Mark; Hamilton, Mary Ann; Werner, Ken

    2008-01-01

    Commercial Generic Bioprocessing Apparatus Science Insert - 03 (CSI-03) is the third set of investigations in the CSI program series. The CSI program provides the K-12 community opportunities to utilize the unique microgravity environment of the International Space Station as part of the regular classroom to encourage learning and interest in science, technology, engineering and math. CSI-03 will examine the complete life cycle of the painted lady butterfly and the ability of an orb weaving spider to spin a web, eat and remain healthy in space.

  9. 76 FR 54507 - Proposed Generic Communication; Draft NRC Generic Letter 2011-XX: Seismic Risk Evaluations for...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2011-09-01

    ... individual plant examinations of external events (IPEEE) and Generic Issue (GI)-199, ``Implications of.... ML051450456), that the ] issue of increased seismic hazard estimates in the CEUS be examined under the GIP. GI... initial screening analysis for GI-199 suggested that estimates of the seismic hazard for some currently...

  10. Space Generic Open Avionics Architecture (SGOAA) reference model technical guide

    NASA Technical Reports Server (NTRS)

    Wray, Richard B.; Stovall, John R.

    1993-01-01

    This report presents a full description of the Space Generic Open Avionics Architecture (SGOAA). The SGOAA consists of a generic system architecture for the entities in spacecraft avionics, a generic processing architecture, and a six class model of interfaces in a hardware/software system. The purpose of the SGOAA is to provide an umbrella set of requirements for applying the generic architecture interface model to the design of specific avionics hardware/software systems. The SGOAA defines a generic set of system interface points to facilitate identification of critical interfaces and establishes the requirements for applying appropriate low level detailed implementation standards to those interface points. The generic core avionics system and processing architecture models provided herein are robustly tailorable to specific system applications and provide a platform upon which the interface model is to be applied.

  11. Contact Geometry of Hyperbolic Equations of Generic Type

    NASA Astrophysics Data System (ADS)

    The, Dennis

    2008-08-01

    We study the contact geometry of scalar second order hyperbolic equations in the plane of generic type. Following a derivation of parametrized contact-invariants to distinguish Monge-Ampère (class 6-6), Goursat (class 6-7) and generic (class 7-7) hyperbolic equations, we use Cartan's equivalence method to study the generic case. An intriguing feature of this class of equations is that every generic hyperbolic equation admits at most a nine-dimensional contact symmetry algebra. The nine-dimensional bound is sharp: normal forms for the contact-equivalence classes of these maximally symmetric generic hyperbolic equations are derived and explicit symmetry algebras are presented. Moreover, these maximally symmetric equations are Darboux integrable. An enumeration of several submaximally symmetric (eight and seven-dimensional) generic hyperbolic structures is also given.

  12. A Generic Nonlinear Aerodynamic Model for Aircraft

    NASA Technical Reports Server (NTRS)

    Grauer, Jared A.; Morelli, Eugene A.

    2014-01-01

    A generic model of the aerodynamic coefficients was developed using wind tunnel databases for eight different aircraft and multivariate orthogonal functions. For each database and each coefficient, models were determined using polynomials expanded about the state and control variables, and an othgonalization procedure. A predicted squared-error criterion was used to automatically select the model terms. Modeling terms picked in at least half of the analyses, which totalled 45 terms, were retained to form the generic nonlinear aerodynamic (GNA) model. Least squares was then used to estimate the model parameters and associated uncertainty that best fit the GNA model to each database. Nonlinear flight simulations were used to demonstrate that the GNA model produces accurate trim solutions, local behavior (modal frequencies and damping ratios), and global dynamic behavior (91% accurate state histories and 80% accurate aerodynamic coefficient histories) under large-amplitude excitation. This compact aerodynamics model can be used to decrease on-board memory storage requirements, quickly change conceptual aircraft models, provide smooth analytical functions for control and optimization applications, and facilitate real-time parametric system identification.

  13. The generic danger and the idiosyncratic support

    NASA Astrophysics Data System (ADS)

    Temme, Arnaud; Nijp, Jelmer; van der Meij, Marijn; Samia, Jalal; Masselink, Rens

    2016-04-01

    This contribution argues two main points. First, that generic landscapes used in some modelling studies sometimes have properties or cause simulation results that are unrealistic. Such initially flat or straight-sloped landscapes, sometimes with minor random perturbations, e.g. form the backdrop for ecological simulations of vegetation growth and competition that predict catastrophic shifts. Exploratory results for semi-arid systems suggest that the results based on these generic landscapes are end-members from a distribution of results, rather than an unbiased, typical outcome. Apparently, the desire to avoid idiosyncrasy has unintended consequences. Second, we argue and illustrate that in fact new insights often come from close inspection of idiosyncratic case studies. Our examples from landslide systems, connectivity and soil formation show how a central role for the case study - either in empirical work or to provide model targets - has advanced our understanding. Both points contribute to the conclusion that it is dangerous to forget about annoying, small-scale, idiosyncratic and, indeed, perhaps bad-ass case studies in Earth Sciences.

  14. TOGGLE: toolbox for generic NGS analyses.

    PubMed

    Monat, Cécile; Tranchant-Dubreuil, Christine; Kougbeadjo, Ayité; Farcy, Cédric; Ortega-Abboud, Enrique; Amanzougarene, Souhila; Ravel, Sébastien; Agbessi, Mawussé; Orjuela-Bouniol, Julie; Summo, Maryline; Sabot, François

    2015-11-09

    The explosion of NGS (Next Generation Sequencing) sequence data requires a huge effort in Bioinformatics methods and analyses. The creation of dedicated, robust and reliable pipelines able to handle dozens of samples from raw FASTQ data to relevant biological data is a time-consuming task in all projects relying on NGS. To address this, we created a generic and modular toolbox for developing such pipelines. TOGGLE (TOolbox for Generic nGs anaLysEs) is a suite of tools able to design pipelines that manage large sets of NGS softwares and utilities. Moreover, TOGGLE offers an easy way to manipulate the various options of the different softwares through the pipelines in using a single basic configuration file, which can be changed for each assay without having to change the code itself. We also describe one implementation of TOGGLE in a complete analysis pipeline designed for SNP discovery for large sets of genomic data, ready to use in different environments (from a single machine to HPC clusters). TOGGLE speeds up the creation of robust pipelines with reliable log tracking and data flow, for a large range of analyses. Moreover, it enables Biologists to concentrate on the biological relevance of results, and change the experimental conditions easily. The whole code and test data are available at https://github.com/SouthGreenPlatform/TOGGLE .

  15. Generic element processor (application to nonlinear analysis)

    NASA Technical Reports Server (NTRS)

    Stanley, Gary

    1989-01-01

    The focus here is on one aspect of the Computational Structural Mechanics (CSM) Testbed: finite element technology. The approach involves a Generic Element Processor: a command-driven, database-oriented software shell that facilitates introduction of new elements into the testbed. This shell features an element-independent corotational capability that upgrades linear elements to geometrically nonlinear analysis, and corrects the rigid-body errors that plague many contemporary plate and shell elements. Specific elements that have been implemented in the Testbed via this mechanism include the Assumed Natural-Coordinate Strain (ANS) shell elements, developed with Professor K. C. Park (University of Colorado, Boulder), a new class of curved hybrid shell elements, developed by Dr. David Kang of LPARL (formerly a student of Professor T. Pian), other shell and solid hybrid elements developed by NASA personnel, and recently a repackaged version of the workhorse shell element used in the traditional STAGS nonlinear shell analysis code. The presentation covers: (1) user and developer interfaces to the generic element processor, (2) an explanation of the built-in corotational option, (3) a description of some of the shell-elements currently implemented, and (4) application to sample nonlinear shell postbuckling problems.

  16. A developmental analysis of generic nouns in Southern Peruvian Quechua

    PubMed Central

    Mannheim, Bruce; Gelman, Susan A.; Escalante, Carmen; Huayhua, Margarita; Puma, Rosalía

    2010-01-01

    Generic noun phrases (e.g., “Cats like to drink milk”) are a primary means by which adults express generalizations to children, yet they pose a challenging induction puzzle for learners. Although prior research has established that English speakers understand and produce generic noun phrases by preschool age, little is known regarding the cross-cultural generality of generic acquisition. Southern Peruvian Quechua provides a valuable comparison because, unlike English, it is a highly inflected language in which generics are marked by the absence rather than the presence of any linguistic markers. Moreover, Quechua is spoken in a cultural context that differs markedly from the highly educated, middle-class contexts within which earlier research on generics was conducted. We presented participants from 5 age groups (3-6, 7-9, 10-12, 14-35, and 36-90 years of age) with two tasks that examined the ability to distinguish generic from non-generic utterances. In Study 1, even the youngest children understood generics as applying broadly to a category (like “all”) and distinct from indefinite reference (“some”). However, there was a developmental lag before children understood that generics, unlike “all”, can include exceptions. Study 2 revealed that generic interpretations are more frequent for utterances that (a) lack specifying markers and (b) are animate. Altogether, generic interpretations are found among the youngest participants, and may be a default mode of quantification. These data demonstrate the cross-cultural importance of generic information in linguistic expression. PMID:21779154

  17. Impact of generic substitution decision support on electronic prescribing behavior

    PubMed Central

    Chen, Qingxia; Johnson, Kevin B

    2010-01-01

    Objective To evaluate the impact of generic substitution decision support on electronic (e-) prescribing of generic medications. Design The authors analyzed retrospective outpatient e-prescribing data from an academic medical center and affiliated network for July 1, 2005–September 30, 2008 using an interrupted time-series design to assess the rate of generic prescribing before and after implementing generic substitution decision support. To assess background secular trends, e-prescribing was compared with a concurrent random sample of hand-generated prescriptions. Measurements Proportion of generic medications prescribed before and after the intervention, evaluated over time, and compared with a sample of prescriptions generated without e-prescribing. Results The proportion of generic medication prescriptions increased from 32.1% to 54.2% after the intervention (22.1% increase, 95% CI 21.9% to 22.3%), with no diminution in magnitude of improvement post-intervention. In the concurrent control group, increases in proportion of generic prescriptions (29.3% to 31.4% to 37.4% in the pre-intervention, post-intervention, and end-of-study periods, respectively) were not commensurate with the intervention. There was a larger change in generic prescribing rates among authorized prescribers (24.6%) than nurses (18.5%; adjusted OR 1.38, 95% CI 1.17 to 1.63). Two years after the intervention, the proportion of generic prescribing remained significantly higher for e-prescriptions (58.1%; 95% CI 57.5% to 58.7%) than for hand-generated prescriptions ordered at the same time (37.4%; 95% CI 34.9% to 39.9%) (p<0.0001). Generic prescribing increased significantly in every specialty. Conclusion Implementation of generic substitution decision support was associated with dramatic and sustained improvements in the rate of outpatient generic e-prescribing across all specialties. PMID:20962131

  18. Encouraging the use of generic medicines: implications for transition economies.

    PubMed

    King, Derek R; Kanavos, Panos

    2002-08-01

    Generic drugs have a key role to play in the efficient allocation of financial resources for pharmaceutical medicines. Policies implemented in the countries with a high rate of generic drug use, such as Canada, Denmark, Germany, the Netherlands, the United Kingdom, and the United States, are reviewed, with consideration of the market structures that facilitate strong competition. Savings in these countries are realized through increases in the volume of generic drugs used and the frequently significant differences in the price between generic medicines and branded originator medicines. Their policy tools include the mix of supply-side measures and demand-side measures that are relevant for generic promotion and higher generic use. On the supply-side, key policy measures include generic drug marketing regulation that facilitates market entry soon after patent expiration, reference pricing, the pricing of branded originator products, and the degree of price competition in pharmaceutical markets. On the demand-side, measures typically encompass influencing prescribing and dispensing patterns as well as introducing a co-payment structure for consumers/patients that takes into consideration the difference in cost between branded and generic medicines. Quality of generic medicines is a pre-condition for all other measures discussed to take effect. The paper concludes by offering a list of policy options for decision-makers in Central and Eastern European economies in transition.

  19. Pharmacy and generic substitution of antiepileptic drugs: missing in action?

    PubMed

    Welty, Timothy E

    2007-06-01

    Generic substitution of antiepileptic drugs is an issue that is gathering a lot of attention in the neurology community but is not receiving much attention within pharmacy. Several proposals have been drafted that restrict a pharmacist's decision-making in generic substitution. These proposals highlight concerns about the pharmacy community related to generic substitution. Careful consideration needs to be given to these issues by pharmacists and pharmacy professional organizations. Unless pharmacy as a profession takes strong positions in support of a pharmacist's ability to make decisions about pharmacotherapy and addresses many of the pharmacy-related problems of generic substitution, policies that negatively impact pharmacy will be established.

  20. Brand loyalty, patients and limited generic medicines uptake.

    PubMed

    Costa-Font, Joan; Rudisill, Caroline; Tan, Stefanie

    2014-06-01

    The sluggish development of European generic drug markets depends heavily on demand side factors, and more specifically, patients' and doctors' loyalty to branded products. Loyalty to originator drugs, to the point where originator prices rise upon generic entry has been described as the 'generics paradox'. Originator loyalty can emerge for a plethora of reasons; including costs, perceptions about quality and physician advice. We know very little about the behavioural underpinnings of brand loyalty from the consumer or patient standpoint. This paper attempts to test the extent to which patients are brand loyal by drawing upon Spain's 2002 Health Barometer survey as it includes questions about consumer acceptance of generics in a country with exceptionally low generic uptake and substitution at the time of the study. Our findings suggest that at least 13% of the population would not accept generics as substitutes to the originator. These results confirm evidence of brand loyalty for a minority. Alongside high levels of awareness of generics, we find that low cost-sharing levels explain consumer brand loyalty but their impact on acceptance of generic substitution is very small. Higher cost-sharing and exempting fewer patients from cost-sharing have the potential to encourage generic acceptance.

  1. The impact of generic substitution on price competition in Finland.

    PubMed

    Aalto-Setälä, Ville

    2008-05-01

    Generic substitution by pharmacists was introduced in April 2003 in Finnish pharmaceutical markets. This article examines the impact of generic substitution on price development. This study examined all of the 2,100 substitutable drugs in Finland. The impact of generic substitution on price competition was significant. The average price of substitutable drugs decreased by more than 10%. However, the price development was uneven; some prices increased whereas others decreased by more than 50%. The most important factors that influenced the price development were the number of competitors, whether the drug was originator or generic and the width of the price band.

  2. A review of the safety of generic drugs.

    PubMed

    Dighe, S V

    1999-05-01

    Generic drugs have been around for many years. The Drug Price Competition and Patent Term Restoration Act 1984 makes the abbreviated new drug application process available to drugs approved after 1962. It does not lower any standards for generic drugs. FDA's comprehensive drug approval process evaluates information concerning (1) chemistry, manufacturing, and controls, (2) in vivo bioequivalence, (3) labeling, (4) in vitro dissolution data where applicable, and (5) inspection and auditing of all facilities. This stringent and comprehensive approval process ensures the quality of generic drug products marketed in the US and assures the health professionals and patients of the safety and efficacy of generic drug products.

  3. Generics market in Greece: the pharmaceutical industry's beliefs.

    PubMed

    Geitona, Mary; Zavras, Dimitrios; Hatzikou, Magda; Kyriopoulos, John

    2006-11-01

    The aim of this study was to investigate the beliefs and perspectives of the pharmaceutical industry on generic medication in Greece. Questionnaires were mailed to all 58 members of the Hellenic Association of Pharmaceutical Companies from November 2002 to February 2003. The response rate was 52%, namely 30 questionnaires were completed and returned. The questionnaire requested information on companies' involvement in generics, their opinion on generics' characteristics and on public policies affecting the demand and supply of generic medication. A descriptive analysis of the outcomes, that is percentage comparison through binomial tests and Fisher tests, was performed. According to our findings, 43% of the respondents were involved in the production and distribution of generics and the mean period of their involvement was 12 years. The majority of the respondents were in favor of their companies' involvement in generics, despite the relatively small market share of generics in Greece; 9.7% of total pharmaceutical market in 2003. Bearing in mind that in Greece the promotion of generics is not encouraged, pharmaceutical companies believe that the mandatory introduction of bioequivalence studies is an indirect promotional strategy towards generics. Additionally, the majority declared that their main competitive advantages are their safety, efficacy and effectiveness as well as their economic benefit to the society. Finally, the respondents expressed their preference for the introduction of pharmacoeconomic submissions for drugs' reimbursement by social insurance funds.

  4. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.

    PubMed

    Privitera, Michael D; Welty, Timothy E; Gidal, Barry E; Diaz, Francisco J; Krebill, Ron; Szaflarski, Jerzy P; Dworetzky, Barbara A; Pollard, John R; Elder, Edmund J; Jiang, Wenlei; Jiang, Xiaohui; Berg, Michel

    2016-04-01

    Patients and clinicians share concerns that generic drug substitution might lead to loss of efficacy or emergence of adverse events. In this trial, we assessed US Food and Drug Administration (FDA) bioequivalence standards by studying the effects of switching between two disparate generic immediate-release lamotrigine products in patients with epilepsy. The Equivalence among Generic Antiepileptic Drugs (EQUIGEN) chronic-dose study was a randomised, double-blind, crossover study that enrolled adults (aged ≥18 years) with epilepsy from six epilepsy centres at academic institutions across the USA who were receiving immediate-release lamotrigine dosed at 100 mg, 200 mg, 300 mg, or 400 mg twice daily. Eligible patients were randomly allocated (1:1) to one of two treatment sequences (sequence 1 or sequence 2), comprising four study periods of 14 days each. During each 14-day treatment period, patients received balanced doses of an oral generic lamotrigine product every 12 h (200-800 mg total, identical to lamotrigine dose prior to study enrolment); after each 14-day period, patients were crossed over to receive the other generic product. Computer-based randomisation was done using random permuted blocks of size two or four for each site to prevent sequence predictability. Both patients and study personnel were masked to the generic products selected, their predicted exposure (ie, "high" vs "low"), and their group allocation. The primary outcome of this trial was bioequivalence between the generic products, which was assessed at the end of the study through a comparison of maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) for each product in the analysis population (all patients who completed all four treatment periods). Bioequivalence was established if the 90% CIs of the ratios of these two parameters for the two products were within equivalence limits (80-125%) in the analysis population. This study is registered with Clinical

  5. UniBoard: generic hardware for radio astronomy signal processing

    NASA Astrophysics Data System (ADS)

    Hargreaves, J. E.

    2012-09-01

    UniBoard is a generic high-performance computing platform for radio astronomy, developed as a Joint Research Activity in the RadioNet FP7 Programme. The hardware comprises eight Altera Stratix IV Field Programmable Gate Arrays (FPGAs) interconnected by a high speed transceiver mesh. Each FPGA is connected to two DDR3 memory modules and three external 10Gbps ports. In addition, a total of 128 low voltage differential input lines permit connection to external ADC cards. The DSP capability of the board exceeds 644E9 complex multiply-accumulate operations per second. The first production run of eight boards was distributed to partners in The Netherlands, France, Italy, UK, China and Korea in May 2011, with a further production runs completed in December 2011 and early 2012. The function of the board is determined by the firmware loaded into its FPGAs. Current applications include beamformers, correlators, digital receivers, RFI mitigation for pulsar astronomy, and pulsar gating and search machines The new UniBoard based correlator for the European VLBI network (EVN) uses an FX architecture with half the resources of the board devoted to station based processing: delay and phase correction and channelization, and half to the correlation function. A single UniBoard can process a 64MHz band from 32 stations, 2 polarizations, sampled at 8 bit. Adding more UniBoards can expand the total bandwidth of the correlator. The design is able to process both prerecorded and real time (eVLBI) data.

  6. Beliefs, perceptions and behaviours of GPs towards generic medicines.

    PubMed

    Dunne, Suzanne S; Shannon, Bill; Cullen, Walter; Dunne, Colum P

    2014-08-01

    To benefit from cost-savings associated with generic medicine use; in June 2013, Ireland introduced generic substitution and reference pricing. The attitudes and behaviours of health care professionals may influence successful implementation of such changes. To assess perceptions of GPs in Ireland regarding generic medicines in the time leading up to the enactment of the new legislation and for the first time in at least the prior decade. Detailed one-to-one semi-structured interviews performed with a representative cohort of 34 urban- and rural-based GPs in Ireland. Thirty of the participating 34 GPs prescribed generic medicines actively. Predominantly, participants believed that generics worked as effectively, and were of the same quality, as originator medicines. However, 32 GPs reported receiving patient complaints regarding generics; almost a third reported complaints of increased or altered side effects. Thirty-two GPs stated that they would take a generic medicine, although one in seven would choose the originator if offered a choice. A minority of GPs were of the view that generics are manufactured to a poorer quality than originators and may be a risk to patient safety. This study of GPs' attitudes towards generic medicines in Ireland highlights that this key stakeholder group has generally positive attitudes towards both generic medicines and the new legislation. However, variable knowledge about generic medicines and concerns regarding patient experience, clinical effectiveness and manufacturing quality were identified. GPs' opinions could negatively influence patient opinions; enhancing such opinions may prove important in successfully implementing the new legislation. © The Author 2014. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

  7. APIC: A generic interface for sequencing projects

    SciTech Connect

    Bisson, G.; Garreau, A.

    1995-12-31

    In this paper, we describe the APIC graphical interface that aims at displaying the results produced by the genomic sequence analysis methods and at helping a comparison of these results. The major feature of APIC lies in its genericity. As a matter of fact, this interface can obviously be used to visualize genetic or physical maps but it also able to display other kinds of information such as curves or pictures. On the one hand, APIC provides the biologist who builds a new sequence analysis method with a standard interface allowing to display his results. Thus, he can avoid implementing a specific visualization tool. On the other hand, even when the methods already have their own interfaces, using APIC has the advantage of giving a homogeneous way to compare several results coming from different analysis tools. Moreover, it provides some powerful functions for navigating and browsing into the results.

  8. Generic aerocapture atmospheric entry study, volume 1

    NASA Technical Reports Server (NTRS)

    1980-01-01

    An atmospheric entry study to fine a generic aerocapture vehicle capable of missions to Mars, Saturn, and Uranus is reported. A single external geometry was developed through atmospheric entry simulations. Aerocapture is a system design concept which uses an aerodynamically controlled atmospheric entry to provide the necessary velocity depletion to capture payloads into planetary orbit. Design concepts are presented which provide the control accuracy required while giving thermal protection for the mission payload. The system design concepts consist of the following elements: (1) an extendable biconic aerodynamic configuration with lift to drag ratio between 1.0 and 2.0; (2) roll control system concepts to control aerodynamic lift and disturbance torques; (3) aeroshell design concepts capable of meeting dynamic pressure loads during aerocapture; and (4) entry thermal protection system design concepts to meet thermodynamic loads during aerocapture.

  9. [Generics: similarities, bioequivalence but no conformity].

    PubMed

    Even-Adin, D; De Muylder, J A; Sternon, J

    2002-01-01

    The using of generic forms (GF) is presented as a potential source of budgetary "saving of money" in the field of pharmaceutical expenses. Not frequently prescribed in Belgium, they win a new interest thanks to the recent making use of the "reference repayment". Sale's authorization of GF is controlled by european rules, but some questions about their identity to original medications remain. Do similarities based only upon qualitative and quantitative composition in active molecules, pharmaceutical forms and biodisponibility give us all requested guaranties? Several cases of discordances can appear; the major elements of non conformity are the nature of excipients, notice's contents and the value of biodisponibility studies. However, in term of economy, in the drug market, development of GF appears to constitute an unavoidable phenomenon.

  10. Generic Automated Multi-function Finger Design

    NASA Astrophysics Data System (ADS)

    Honarpardaz, M.; Tarkian, M.; Sirkett, D.; Ölvander, J.; Feng, X.; Elf, J.; Sjögren, R.

    2016-11-01

    Multi-function fingers that are able to handle multiple workpieces are crucial in improvement of a robot workcell. Design automation of multi-function fingers is highly demanded by robot industries to overcome the current iterative, time consuming and complex manual design process. However, the existing approaches for the multi-function finger design automation are unable to entirely meet the robot industries’ need. This paper proposes a generic approach for design automation of multi-function fingers. The proposed approach completely automates the design process and requires no expert skill. In addition, this approach executes the design process much faster than the current manual process. To validate the approach, multi-function fingers are successfully designed for two case studies. Further, the results are discussed and benchmarked with existing approaches.

  11. Generic small modular reactor plant design.

    SciTech Connect

    Lewis, Tom Goslee,; Cipiti, Benjamin B.; Jordan, Sabina Erteza; Baum, Gregory A.

    2012-12-01

    This report gives an overview of expected design characteristics, concepts, and procedures for small modular reactors. The purpose of this report is to provide those who are interested in reducing the cost and improving the safety of advanced nuclear power plants with a generic design that possesses enough detail in a non-sensitive manner to give merit to their conclusions. The report is focused on light water reactor technology, but does add details on what could be different in a more advanced design (see Appendix). Numerous reactor and facility concepts were used for inspiration (documented in the bibliography). The final design described here is conceptual and does not reflect any proposed concept or sub-systems, thus any details given here are only relevant within this report. This report does not include any design or engineering calculations.

  12. Preliminary calibration of a generic scramjet combustor

    NASA Technical Reports Server (NTRS)

    Jacobs, P. A.; Morgan, R. G.; Rogers, R. C.; Wendt, M.; Brescianini, C.; Paull, A.; Kelly, G.

    1991-01-01

    The results of a preliminary investigation of the combustion of hydrogen fuel at hypersonic flow conditions are provided. The tests were performed in a generic, constant-area combustor model with test gas supplied by a free-piston-driven reflected-shock tunnel. Static pressure measurements along the combustor wall indicated that burning did occur for combustor inlet conditions of P(static) approximately equal to 19kPa, T(static) approximately equal to 1080 K, and U approximately equal to 3630 m/s with a fuel equivalence ratio approximately equal to 0.9. These inlet conditions were obtained by operating the tunnel with stagnation enthalpy approximately equal to 8.1 MJ/kg, stagnation pressure approximately equal to 52 MPa, and a contoured nozzle with a nominal exit Mach number of 5.5.

  13. Flow establishment in a generic scramjet combustor

    NASA Astrophysics Data System (ADS)

    Jacobs, P. A.; Rogers, R. C.; Weidner, E. H.; Bittner, R. D.

    1990-10-01

    The establishment of a quasi-steady flow in a generic scramjet combustor was studied for the case of a time varying inflow to the combustor. Such transient flow is characteristic of the reflected shock tunnel and expansion tube test facilities. Several numerical simulations of hypervelocity flow through a straight duct combustor with either a side wall step fuel injector or a centrally located strut injector are presented. Comparisons were made between impulsively started but otherwise constant flow conditions (typical of the expansion tube or tailored operations of the reflected shock tunnel) and the relaxing flow produced by the 'undertailored' operations of the reflected shock tunnel. Generally the inviscid flow features, such as the shock pattern and pressure distribution, were unaffected by the time varying inlet conditions and approached steady state in approx. the times indicated by experimental correlations. However, viscous features, such as heat transfer and skin friction, were altered by the relaxing inlet flow conditions.

  14. A generic reaction-based biogeochemical simulator

    SciTech Connect

    Fang, Yilin; Yabusaki, Steven B.; Yeh, Gour T.; C.T. Miller, M.W. Farthing, W.G. Gray, and G.F. Pinder

    2004-06-17

    This paper presents a generic biogeochemical simulator, BIOGEOCHEM. The simulator can read a thermodynamic database based on the EQ3/EQ6 database. It can also read user-specified equilibrium and kinetic reactions (reactions not defined in the format of that in EQ3/EQ6 database) symbolically. BIOGEOCHEM is developed with a general paradigm. It overcomes the requirement in most available reaction-based models that reactions and rate laws be specified in a limited number of canonical forms. The simulator interprets the reactions, and rate laws of virtually any type for input to the MAPLE symbolic mathematical software package. MAPLE then generates Fortran code for the analytical Jacobian matrix used in the Newton-Raphson technique, which are compiled and linked into the BIOGEOCHEM executable. With this feature, the users are exempted from recoding the simulator to accept new equilibrium expressions or kinetic rate laws. Two examples are used to demonstrate the new features of the simulator.

  15. Generic voice interface for cockpit application

    NASA Astrophysics Data System (ADS)

    Williamson, David T.; Feitshans, Gregory L.

    A voice technology interface is proposed that would allow both novice and expert users of voice input and output devices to quickly interface them to their applications while maintaining optimum performance. The objective of this generic voice interface (GVI) is to provide a device-independent interface to existing voice systems. The system will be designed so that any application, not just cockpit applications, can be used with the GVI. Once it has been successfully integrated into a few key applications, the same techniques can be transitioned to other areas. The system will initially be targeted for the rapidly reconfigurable crew-station (RRC) program, which will provide a rapid prototyping environment for advanced crew-station design.

  16. Dream content: Individual and generic aspects.

    PubMed

    Hobson, Allan; Kahn, David

    2007-12-01

    Dream reports were collected from normal subjects in an effort to determine the degree to which dream reports can be used to identify individual dreamers. Judges were asked to group the reports by their authors. The judges scored the reports correctly at chance levels. This finding indicated that dreams may be at least as much like each other as they are the signature of individual dreamers. Our results suggest that dream reports cannot be used to identify the individuals who produced them when identifiers like names and gender of friends and family members are removed from the dream report. In addition to using dreams to learn about an individual, we must look at dreams as telling us about important common or generic aspects of human consciousness.

  17. Generic command interpreter for robot controllers

    SciTech Connect

    Werner, J.

    1991-04-09

    Generic command interpreter programs have been written for robot controllers at Sandia National Laboratories (SNL). Each interpreter program resides on a robot controller and interfaces the controller with a supervisory program on another (host) computer. We call these interpreter programs monitors because they wait, monitoring a communication line, for commands from the supervisory program. These monitors are designed to interface with the object-oriented software structure of the supervisory programs. The functions of the monitor programs are written in each robot controller's native language but reflect the object-oriented functions of the supervisory programs. These functions and other specifics of the monitor programs written for three different robots at SNL will be discussed. 4 refs., 4 figs.

  18. Testing of Advanced Generic Scan Mechanisms (AGSM)

    NASA Astrophysics Data System (ADS)

    Anderson, M. J.; Forshaw, T.; Parzianello, G.

    2013-09-01

    AGSM was envisaged as a generic scan drive mechanism for large across track scanners (e.g. EGPM mission). The two Breadboard Models (BBM's) tested in this programme were foreseen as technology demonstrators and incorporated some novel features, i.e:• Electrical power transfer through the ball bearings• Lead-lubricated bearings with lightweight, ball riding cages for long lifetime (120 million revs) with lead-bronze inserts to replenish lubricant.• A small (< 1 microlitre) drop of Z25 oil added to one bearing to help reduce wear of the lead lubricant film during ground operation.This paper details the results and findings from testing BBM2 and compares them to those from testing carried out on a previous BBM (BBM1) [1].

  19. An object oriented generic controller using CLIPS

    NASA Technical Reports Server (NTRS)

    Nivens, Cody R.

    1990-01-01

    In today's applications, the need for the division of code and data has focused on the growth of object oriented programming. This philosophy gives software engineers greater control over the environment of an application. Yet the use of object oriented design does not exclude the need for greater understanding by the application of what the controller is doing. Such understanding is only possible by using expert systems. Providing a controller that is capable of controlling an object by using rule-based expertise would expedite the use of both object oriented design and expert knowledge of the dynamic of an environment in modern controllers. This project presents a model of a controller that uses the CLIPS expert system and objects in C++ to create a generic controller. The polymorphic abilities of C++ allow for the design of a generic component stored in individual data files. Accompanying the component is a set of rules written in CLIPS which provide the following: the control of individual components, the input of sensory data from components and the ability to find the status of a given component. Along with the data describing the application, a set of inference rules written in CLIPS allows the application to make use of sensory facts and status and control abilities. As a demonstration of this ability, the control of the environment of a house is provided. This demonstration includes the data files describing the rooms and their contents as far as devices, windows and doors. The rules used for the home consist of the flow of people in the house and the control of devices by the home owner.

  20. 40 CFR 721.2825 - Alkyl ester (generic name).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Alkyl ester (generic name). 721.2825... Substances § 721.2825 Alkyl ester (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance alkyl ester (PMN P-84-968) is subject to reporting under this section...

  1. 40 CFR 721.10180 - Trifunctional acrylic ester (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Trifunctional acrylic ester (generic... Specific Chemical Substances § 721.10180 Trifunctional acrylic ester (generic). (a) Chemical substance and... acrylic ester (PMN P-04-692) is subject to reporting under this section for the significant new uses...

  2. Children Expect Generic Knowledge to Be Widely Shared

    ERIC Educational Resources Information Center

    Cimpian, Andrei; Scott, Rose M.

    2012-01-01

    The ability to acquire and store generic information (that is, information about entire categories) is at the core of human cognition. Remarkably, even young children place special value on generic information, often inferring that it holds important insights about the world. Here, we tested whether children's assumptions about the nature of…

  3. Developing competitive and sustainable Polish generic medicines market.

    PubMed

    Simoens, Steven

    2009-10-01

    To descriptively analyze the policy environment surrounding the Polish generic medicines retail market. The policy analysis was based on an international literature review. Also, a simulation exercise was carried out to compute potential savings from substituting generic for originator medicines in Poland using IMS Health pharmaceutical intelligence data. Poland has a mature, high-volume, low-value generic medicines market, primarily driven by the establishment of the reference price at the price of the cheapest medicine in combination with pricing regulation and the low level of medicine prices. The practice of discounting in the distribution chain implies that the National Health Fund and patients do not capture the potential savings from a generic medicines market where companies compete on price. This high-volume market has benefited in the past from the limited availability of originator medicines and a short data exclusivity period, even though there are no incentives for physicians to prescribe generic medicines and a financial disincentive for pharmacists to dispense generic medicines. Increased generic substitution would be expected to reduce public expenditure on originator medicines by 21%. To develop a competitive and sustainable market, Poland needs to consider moving away from competition by discount to competition by price. This could be achieved by replacing maximum distribution margins by fixed margins. Also, Poland may wish to raise reference prices as a temporary measure to boost market entry for medicine classes with few generic medicines.

  4. 40 CFR 721.6097 - Phosphoric acid derivative (generic name).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Phosphoric acid derivative (generic... Specific Chemical Substances § 721.6097 Phosphoric acid derivative (generic name). (a) Chemical substance... phosphoric acid derivative (PMN P-95-284) is subject to reporting under this section for the significant new...

  5. 40 CFR 721.6097 - Phosphoric acid derivative (generic name).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Phosphoric acid derivative (generic... Specific Chemical Substances § 721.6097 Phosphoric acid derivative (generic name). (a) Chemical substance... phosphoric acid derivative (PMN P-95-284) is subject to reporting under this section for the significant new...

  6. When Does an Argument Use a Generic Example?

    ERIC Educational Resources Information Center

    Yopp, David A.; Ely, Rob

    2016-01-01

    We offer criteria that an observer can use to determine whether an argument that uses an example to argue for a general claim appeals to that example generically. We review existing literature on generic example and note the strengths of each contribution, as well as inconsistencies among uses of the term. We offer several examples from the…

  7. Generic ICT Skills Profiles: Future Skills for Tomorrow's World.

    ERIC Educational Resources Information Center

    International Co-operation Europe Ltd. (ICEL), Brussels, Belgium.

    This document describes generic skills profiles relevant to key jobs in information and communications technology (ICT). The profiles cover the main job areas for which the ICT industry is experiencing skills shortages. These types of information are provided for 18 generic job profiles: job description (vision, role, lifestyle); examples of job…

  8. 40 CFR 721.10711 - Alkyl substituted catechol (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Alkyl substituted catechol (generic... Specific Chemical Substances § 721.10711 Alkyl substituted catechol (generic). (a) Chemical substance and... substituted catechol (PMN P-13-197) is subject to reporting under this section for the significant new...

  9. Supporting Synchronous Collaborative Learning: A Generic, Multi-Dimensional Model

    ERIC Educational Resources Information Center

    Lonchamp, Jacques

    2006-01-01

    Future CSCL technologies are described by the community as flexible, tailorable, negotiable, and appropriate for various collaborative settings, conditions and contexts. This paper describes the key design issues of a generic synchronous collaborative learning environment, called Omega+. In this approach, model-based genericity is applied to the…

  10. 40 CFR 721.10582 - Quaternary ammonium compound (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Quaternary ammonium compound (generic... Specific Chemical Substances § 721.10582 Quaternary ammonium compound (generic). (a) Chemical substance and... ammonium compound (PMN P-10-571) is subject to reporting under this section for the significant new...

  11. 40 CFR 721.10591 - Tertiary ammonium compound (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Tertiary ammonium compound (generic... Specific Chemical Substances § 721.10591 Tertiary ammonium compound (generic). (a) Chemical substance and... ammonium compound (PMN P-11-110) is subject to reporting under this section for the significant new...

  12. 40 CFR 721.10582 - Quaternary ammonium compound (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Quaternary ammonium compound (generic... Specific Chemical Substances § 721.10582 Quaternary ammonium compound (generic). (a) Chemical substance and... ammonium compound (PMN P-10-571) is subject to reporting under this section for the significant new...

  13. 40 CFR 721.10591 - Tertiary ammonium compound (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Tertiary ammonium compound (generic... Specific Chemical Substances § 721.10591 Tertiary ammonium compound (generic). (a) Chemical substance and... ammonium compound (PMN P-11-110) is subject to reporting under this section for the significant new...

  14. 40 CFR 721.10706 - Infused carbon nanostructures (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Infused carbon nanostructures (generic... Specific Chemical Substances § 721.10706 Infused carbon nanostructures (generic). (a) Chemical substance... infused carbon nanostructures (PMN P-12-576) is subject to reporting under this section for...

  15. 40 CFR 721.10287 - Infused carbon nanostructures (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Infused carbon nanostructures (generic... Specific Chemical Substances § 721.10287 Infused carbon nanostructures (generic). (a) Chemical substance... infused carbon nanostructures (PMN P-11-188) is subject to reporting under this section for...

  16. 40 CFR 721.10287 - Infused carbon nanostructures (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Infused carbon nanostructures (generic... Specific Chemical Substances § 721.10287 Infused carbon nanostructures (generic). (a) Chemical substance... infused carbon nanostructures (PMN P-11-188) is subject to reporting under this section for...

  17. 40 CFR 721.10287 - Infused carbon nanostructures (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Infused carbon nanostructures (generic... Specific Chemical Substances § 721.10287 Infused carbon nanostructures (generic). (a) Chemical substance... infused carbon nanostructures (PMN P-11-188) is subject to reporting under this section for...

  18. Do All Ducks Lay Eggs? The Generic Overgeneralization Effect

    ERIC Educational Resources Information Center

    Leslie, Sarah-Jane; Khemlani, Sangeet; Glucksberg, Sam

    2011-01-01

    Generics are statements such as "tigers are striped" and "ducks lay eggs". They express general, though not universal or exceptionless, claims about kinds (Carlson & Pelletier, 1995). For example, the generic "ducks lay eggs" seems true even though many ducks (e.g. the males) do not lay eggs. The universally quantified version of the statement…

  19. Expressing Generic Concepts with and without a Language Model

    ERIC Educational Resources Information Center

    Goldin-Meadow, S.; Gelman, S.A.; Mylander, C.

    2005-01-01

    Utterances expressing generic kinds (''birds fly'') highlight qualities of a category that are stable and enduring, and thus provide insight into conceptual organization. To explore the role that linguistic input plays in children's production of generic nouns, we observed American and Chinese deaf children whose hearing losses prevented them from…

  20. 40 CFR 721.7500 - Nitrate polyether polyol (generic name).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Nitrate polyether polyol (generic name... Substances § 721.7500 Nitrate polyether polyol (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance nitrate polyether polyol (PMN P88-2540)...

  1. 40 CFR 721.7500 - Nitrate polyether polyol (generic name).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Nitrate polyether polyol (generic name... Substances § 721.7500 Nitrate polyether polyol (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance nitrate polyether polyol (PMN P88-2540)...

  2. 40 CFR 721.7500 - Nitrate polyether polyol (generic name).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Nitrate polyether polyol (generic name... Substances § 721.7500 Nitrate polyether polyol (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance nitrate polyether polyol (PMN P88-2540)...

  3. 40 CFR 721.7500 - Nitrate polyether polyol (generic name).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Nitrate polyether polyol (generic name... Substances § 721.7500 Nitrate polyether polyol (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance nitrate polyether polyol (PMN P88-2540)...

  4. 40 CFR 721.7500 - Nitrate polyether polyol (generic name).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Nitrate polyether polyol (generic name... Substances § 721.7500 Nitrate polyether polyol (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance nitrate polyether polyol (PMN P88-2540)...

  5. 40 CFR 721.10180 - Trifunctional acrylic ester (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Trifunctional acrylic ester (generic... Specific Chemical Substances § 721.10180 Trifunctional acrylic ester (generic). (a) Chemical substance and... acrylic ester (PMN P-04-692) is subject to reporting under this section for the significant new uses...

  6. 40 CFR 721.2825 - Alkyl ester (generic name).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Alkyl ester (generic name). 721.2825... Substances § 721.2825 Alkyl ester (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance alkyl ester (PMN P-84-968) is subject to reporting under this section...

  7. 40 CFR 721.10511 - Quaternary ammonium salts (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Quaternary ammonium salts (generic... Specific Chemical Substances § 721.10511 Quaternary ammonium salts (generic). (a) Chemical substance and... ammonium salts (PMNs P-07-320, P-07-321, P-07-322, P-07-323, and P-07-324) are subject to reporting...

  8. 40 CFR 721.1648 - Substituted benzenesulfonic acid salt (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Substituted benzenesulfonic acid salt (generic). 721.1648 Section 721.1648 Protection of Environment ENVIRONMENTAL PROTECTION AGENCY (CONTINUED... Specific Chemical Substances § 721.1648 Substituted benzenesulfonic acid salt (generic). (a)...

  9. 40 CFR 721.1648 - Substituted benzenesulfonic acid salt (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Substituted benzenesulfonic acid salt (generic). 721.1648 Section 721.1648 Protection of Environment ENVIRONMENTAL PROTECTION AGENCY (CONTINUED... Specific Chemical Substances § 721.1648 Substituted benzenesulfonic acid salt (generic). (a)...

  10. 40 CFR 721.10114 - Polyhydroxyaminoether salts (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Polyhydroxyaminoether salts (generic... Specific Chemical Substances § 721.10114 Polyhydroxyaminoether salts (generic). (a) Chemical substance and... polyhydroxyaminoether salts (PMNs P-04-578, P-04-579, P-04-580, P-04-581, P-04-582, and-P-04-583) are subject...

  11. 40 CFR 721.10114 - Polyhydroxyaminoether salts (generic).

    Code of Federal Regulations, 2011 CFR

    2011-07-01

    ... 40 Protection of Environment 31 2011-07-01 2011-07-01 false Polyhydroxyaminoether salts (generic... Specific Chemical Substances § 721.10114 Polyhydroxyaminoether salts (generic). (a) Chemical substance and... polyhydroxyaminoether salts (PMNs P-04-578, P-04-579, P-04-580, P-04-581, P-04-582, and-P-04-583) are subject...

  12. 40 CFR 721.6080 - Phosphonium salt (generic name).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Phosphonium salt (generic name). 721... Substances § 721.6080 Phosphonium salt (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance phosphonium salt (PMN Number P-84-820) is subject...

  13. 40 CFR 721.6080 - Phosphonium salt (generic name).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Phosphonium salt (generic name). 721... Substances § 721.6080 Phosphonium salt (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance phosphonium salt (PMN Number P-84-820) is subject...

  14. 40 CFR 721.6080 - Phosphonium salt (generic name).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Phosphonium salt (generic name). 721... Substances § 721.6080 Phosphonium salt (generic name). (a) Chemical substance and significant new uses subject to reporting. (1) The chemical substance phosphonium salt (PMN Number P-84-820) is subject...

  15. 40 CFR 721.1648 - Substituted benzenesulfonic acid salt (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Substituted benzenesulfonic acid salt (generic). 721.1648 Section 721.1648 Protection of Environment ENVIRONMENTAL PROTECTION AGENCY (CONTINUED... Specific Chemical Substances § 721.1648 Substituted benzenesulfonic acid salt (generic). (a)...

  16. 40 CFR 721.1648 - Substituted benzenesulfonic acid salt (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Substituted benzenesulfonic acid salt (generic). 721.1648 Section 721.1648 Protection of Environment ENVIRONMENTAL PROTECTION AGENCY (CONTINUED... Specific Chemical Substances § 721.1648 Substituted benzenesulfonic acid salt (generic). (a)...

  17. 40 CFR 721.10430 - Tetra alkyl ammonium salt (generic).

    Code of Federal Regulations, 2014 CFR

    2014-07-01

    ... 40 Protection of Environment 31 2014-07-01 2014-07-01 false Tetra alkyl ammonium salt (generic... Specific Chemical Substances § 721.10430 Tetra alkyl ammonium salt (generic). (a) Chemical substance and... ammonium salt (PMN P-97-823) is subject to reporting under this section for the significant new...

  18. 40 CFR 721.10114 - Polyhydroxyaminoether salts (generic).

    Code of Federal Regulations, 2010 CFR

    2010-07-01

    ... 40 Protection of Environment 30 2010-07-01 2010-07-01 false Polyhydroxyaminoether salts (generic... Specific Chemical Substances § 721.10114 Polyhydroxyaminoether salts (generic). (a) Chemical substance and... polyhydroxyaminoether salts (PMNs P-04-578, P-04-579, P-04-580, P-04-581, P-04-582, and-P-04-583) are subject...

  19. 40 CFR 721.10114 - Polyhydroxyaminoether salts (generic).

    Code of Federal Regulations, 2013 CFR

    2013-07-01

    ... 40 Protection of Environment 32 2013-07-01 2013-07-01 false Polyhydroxyaminoether salts (generic... Specific Chemical Substances § 721.10114 Polyhydroxyaminoether salts (generic). (a) Chemical substance and... polyhydroxyaminoether salts (PMNs P-04-578, P-04-579, P-04-580, P-04-581, P-04-582, and-P-04-583) are subject...

  20. 40 CFR 721.1648 - Substituted benzenesulfonic acid salt (generic).

    Code of Federal Regulations, 2012 CFR

    2012-07-01

    ... 40 Protection of Environment 32 2012-07-01 2012-07-01 false Substituted benzenesulfonic acid salt (generic). 721.1648 Section 721.1648 Protection of Environment ENVIRONMENTAL PROTECTION AGENCY (CONTINUED... Specific Chemical Substances § 721.1648 Substituted benzenesulfonic acid salt (generic). (a)...